Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
26 "Dae Yong Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Gastrointestinal cancer
One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials
Soo-Yoon Sung, Dae Yong Kim, Hong Seok Jang, Tae Hyun Kim, Hee Chul Park, Eui Kyu Chie, Taek-Keun Nam, Sung Hwan Kim, Jong Hoon Lee
Cancer Res Treat. 2023;55(3):918-926.   Published online February 27, 2023
DOI: https://doi.org/10.4143/crt.2022.1646
AbstractAbstract PDFPubReaderePub
Purpose
The optimal short-course chemotherapeutic regimen for rectal cancer has not been clearly defined until now. KROG 10-01 and KROG 11-02 prospective trials investigated the efficacy and safety of 1- and 2-week chemoradiotherapy (CRT), respectively.
Materials and Methods
Patients eligible for KROG 10-01 and KROG 11-02 involved those with clinical T3-4N0-2M0 rectal cancers. They received preoperative CRT and total mesorectal excision. Patients in KROG 10-01 received radiation of 25 Gy in 5 fractions during 1 week with 5-fluorouracil/leucovorin. Patients in KROG 11-02 received radiation of 33 Gy in 10 fractions for 2 weeks with oral capecitabine.
Results
A total of 150 patients consisting of 70 patients from KROG 10-01 and 80 patients from KROG 11-02 were collectively analyzed. With a median follow-up time of 89.2 months, the 5-year overall survival rate was 86.5% in 1-week CRT and 85.3% in 2-week CRT (p=0.841). The 5-year recurrence-free survival rate was 83.5% in 1-week CRT and 77.1% in 2-week CRT (p=0.448). One patient (1.4%) in 1-week CRT and 11 patients (13.8%) in 2-week CRT exhibited pathologic complete regression (ypT0N0M0) after radiotherapy (p=0.006). One-week CRT had significantly higher acute hematologic (12.8% vs. 3.8%, p=0.040) and nonhematologic (38.6% vs. 16.3%, p=0.002) toxicity than 2-week CRT.
Conclusion
Both 1- and 2-week schedules of CRT showed favorable survival outcomes after 7 years of follow-up. But, 2-week course achieved more increased tumor response and decreased acute toxicity than 1-week course.
  • 2,957 View
  • 152 Download
  • 1 Web of Science
Close layer
Breast cancer
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki Chung, Kyung Su Kim, Ji Ho Nam, Won Sup Yoon, Jin Hee Kim, Jihye Cha, Yoon Kyeong Oh, In Ah Kim
Cancer Res Treat. 2022;54(4):1121-1129.   Published online December 31, 2021
DOI: https://doi.org/10.4143/crt.2021.1083
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to investigate manifestations and patterns of care for patients with brain metastasis (BM) from breast cancer (BC) and compared their overall survival (OS) from 2005 through 2014 in Korea.
Materials and Methods
We retrospectively reviewed 600 BC patients with BM diagnosed between 2005 and 2014. The median follow-up duration was 12.5 months. We categorized the patients into three groups according to the year when BM was initially diagnosed (group I [2005-2008], 98 patients; group II [2009-2011], 200 patients; and group III [2012-2014], 302 patients).
Results
Over time, the median age at BM diagnosis increased by 2.2 years (group I, 49.0 years; group II, 48.3 years; and group III, 51.2 years; p=0.008). The percentage of patients with extracranial metastasis was 73.5%, 83.5%, and 86.4% for group I, II, and III, respectively (p=0.011). The time interval between BC and BM was prolonged in patients with stage III primary BC (median, 2.4 to 3 years; p=0.029). As an initial brain-directed treatment, whole-brain radiotherapy alone decreased from 80.0% in 2005 to 41.1% in 2014. Meanwhile, stereotactic radiosurgery or fractionated stereotactic radiotherapy alone increased from 13.3% to 34.7% during the same period (p=0.005). The median OS for group I, II, and III was 15.6, 17.9, and 15.0 months, respectively, with no statistical significance.
Conclusion
The manifestations of BM from BC and the pattern of care have changed from 2005 to 2014 in Korea. However, the OS has remained relatively unchanged over the 10 years.

Citations

Citations to this article as recorded by  
  • Comparison of initial and sequential salvage brain-directed treatment in patients with 1–4 vs. 5–10 brain metastases from breast cancer (KROG 16–12)
    Jae Sik Kim, Kyubo Kim, Wonguen Jung, Kyung Hwan Shin, Seock-Ah Im, Hee-Jun Kim, Yong Bae Kim, Jee Suk Chang, Jee Hyun Kim, Doo Ho Choi, Yeon Hee Park, Dae Yong Kim, Tae Hyun Kim, Byung Ock Choi, Sea-Won Lee, Suzy Kim, Jeanny Kwon, Ki Mun Kang, Woong-Ki C
    Breast Cancer Research and Treatment.2023; 200(1): 37.     CrossRef
  • 6,455 View
  • 185 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer
Ji Eun Oh, Min Ju Kim, Joohyung Lee, Bo Yun Hur, Bun Kim, Dae Yong Kim, Ji Yeon Baek, Hee Jin Chang, Sung Chan Park, Jae Hwan Oh, Sun Ah Cho, Dae Kyung Sohn
Cancer Res Treat. 2020;52(1):51-59.   Published online May 7, 2019
DOI: https://doi.org/10.4143/crt.2019.050
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Mutation of the Kirsten Ras (KRAS) oncogene is present in 30%-40% of colorectal cancers and has prognostic significance in rectal cancer. In this study, we examined the ability of radiomics features extracted from T2-weighted magnetic resonance (MR) images to differentiate between tumors with mutant KRAS and wild-type KRAS.
Materials and Methods
Sixty patients with primary rectal cancer (25 with mutant KRAS, 35 with wild-type KRAS) were retrospectively enrolled. Texture analysis was performed in all regions of interest on MR images, which were manually segmented by two independent radiologists. We identified potentially useful imaging features using the two-tailed t test and used them to build a discriminant model with a decision tree to estimate whether KRAS mutation had occurred.
Results
Three radiomic features were significantly associated with KRASmutational status (p < 0.05). The mean (and standard deviation) skewness with gradient filter value was significantly higher in the mutant KRAS group than in the wild-type group (2.04±0.94 vs. 1.59±0.69). Higher standard deviations for medium texture (SSF3 and SSF4) were able to differentiate mutant KRAS (139.81±44.19 and 267.12±89.75, respectively) and wild-type KRAS (114.55±29.30 and 224.78±62.20). The final decision tree comprised three decision nodes and four terminal nodes, two of which designated KRAS mutation. The sensitivity, specificity, and accuracy of the decision tree was 84%, 80%, and 81.7%, respectively.
Conclusion
Using MR-based texture analysis, we identified three imaging features that could differentiate mutant from wild-type KRAS. T2-weighted images could be used to predict KRAS mutation status preoperatively in patients with rectal cancer.

Citations

Citations to this article as recorded by  
  • A multicenter study: predicting KRAS mutation and prognosis in colorectal cancer through a CT-based radiomics nomogram
    Manman Li, Yiwen Yuan, Hui Zhou, Feng Feng, Guodong Xu
    Abdominal Radiology.2024; 49(6): 1816.     CrossRef
  • SG-Transunet: A segmentation-guided Transformer U-Net model for KRAS gene mutation status identification in colorectal cancer
    Yulan Ma, Yuzhu Guo, Weigang Cui, Jingyu Liu, Yang Li, Yingsen Wang, Yan Qiang
    Computers in Biology and Medicine.2024; 173: 108293.     CrossRef
  • CHNet: A multi-task global–local Collaborative Hybrid Network for KRAS mutation status prediction in colorectal cancer
    Meiling Cai, Lin Zhao, Yan Qiang, Long Wang, Juanjuan Zhao
    Artificial Intelligence in Medicine.2024; 155: 102931.     CrossRef
  • Assessment of prognostic indicators and KRAS mutations in rectal cancer using a fractional-order calculus MR diffusion model: whole tumor histogram analysis
    Mi Zhou, Hongyun Huang, Deying Bao, Meining Chen, Fulin Lu
    Abdominal Radiology.2024;[Epub]     CrossRef
  • The Role of Predictive and Prognostic MRI-Based Biomarkers in the Era of Total Neoadjuvant Treatment in Rectal Cancer
    Sebastian Curcean, Andra Curcean, Daniela Martin, Zsolt Fekete, Alexandru Irimie, Alina-Simona Muntean, Cosmin Caraiani
    Cancers.2024; 16(17): 3111.     CrossRef
  • A segmentation-based sequence residual attention model for KRAS gene mutation status prediction in colorectal cancer
    Lin Zhao, Kai Song, Yulan Ma, Meiling Cai, Yan Qiang, Jingyu Sun, Juanjuan Zhao
    Applied Intelligence.2023; 53(9): 10232.     CrossRef
  • Rectal MRI Interpretation After Neoadjuvant Therapy
    Natally Horvat, Maria El Homsi, Joao Miranda, Yousef Mazaheri, Marc J. Gollub, Viktoriya Paroder
    Journal of Magnetic Resonance Imaging.2023; 57(2): 353.     CrossRef
  • Association between Dynamic Contrast-Enhanced MRI Parameters and Prognostic Factors in Patients with Primary Rectal Cancer
    Hye Ri Kim, Seung Ho Kim, Kyung Han Nam
    Current Oncology.2023; 30(2): 2543.     CrossRef
  • Virtual biopsy in abdominal pathology: where do we stand?
    Arianna Defeudis, Jovana Panic, Giulia Nicoletti, Simone Mazzetti, Valentina Giannini, Daniele Regge
    BJR|Open.2023;[Epub]     CrossRef
  • Repeatability of radiomics studies in colorectal cancer: a systematic review
    Ying Liu, Xiaoqin Wei, Xu Feng, Yan Liu, Guiling Feng, Yong Du
    BMC Gastroenterology.2023;[Epub]     CrossRef
  • The Role of Radiomics in Rectal Cancer
    Joao Miranda, Natally Horvat, Jose A. B. Araujo-Filho, Kamila S. Albuquerque, Charlotte Charbel, Bruno M. C. Trindade, Daniel L. Cardoso, Lucas de Padua Gomes de Farias, Jayasree Chakraborty, Cesar Higa Nomura
    Journal of Gastrointestinal Cancer.2023; 54(4): 1158.     CrossRef
  • Radiomics and Radiogenomics in Pelvic Oncology: Current Applications and Future Directions
    Niall J. O’Sullivan, Michael E. Kelly
    Current Oncology.2023; 30(5): 4936.     CrossRef
  • Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics
    Yuntai Cao, Jing Zhang, Lele Huang, Zhiyong Zhao, Guojin Zhang, Jialiang Ren, Hailong Li, Hongqian Zhang, Bin Guo, Zhan Wang, Yue Xing, Junlin Zhou
    Japanese Journal of Radiology.2023; 41(11): 1236.     CrossRef
  • Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review
    Giuseppe Di Costanzo, Raffaele Ascione, Andrea Ponsiglione, Anna Giacoma Tucci, Serena Dell’Aversana, Francesca Iasiello, Enrico Cavaglià
    Exploration of Targeted Anti-tumor Therapy.2023; : 406.     CrossRef
  • Investigating the Feasibility of Predicting KRAS Status, Tumor Staging, and Extramural Venous Invasion in Colorectal Cancer Using Inter-Platform Magnetic Resonance Imaging Radiomic Features
    Mohammed S. Alshuhri, Abdulaziz Alduhyyim, Haitham Al-Mubarak, Ahmad A. Alhulail, Othman I. Alomair, Yahia Madkhali, Rakan A. Alghuraybi, Abdullah M. Alotaibi, Abdullalh G. M. Alqahtani
    Diagnostics.2023; 13(23): 3541.     CrossRef
  • Radiogenomics: Contemporary Applications in the Management of Rectal Cancer
    Niall J. O’Sullivan, Hugo C. Temperley, Michelle T. Horan, Alison Corr, Brian J. Mehigan, John O. Larkin, Paul H. McCormick, Dara O. Kavanagh, James F. M. Meaney, Michael E. Kelly
    Cancers.2023; 15(24): 5816.     CrossRef
  • KRAS status predicted by pretreatment MRI radiomics was associated with lung metastasis in locally advanced rectal cancer patients
    Yirong Xiang, Shuai Li, Maxiaowei Song, Hongzhi Wang, Ke Hu, Fengwei Wang, Zhi Wang, Zhiyong Niu, Jin Liu, Yong Cai, Yongheng Li, Xianggao Zhu, Jianhao Geng, Yangzi Zhang, Huajing Teng, Weihu Wang
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Segmentation-based multi-scale attention model for KRAS mutation prediction in rectal cancer
    Kai Song, Zijuan Zhao, Jiawen Wang, Yan Qiang, Juanjuan Zhao, Muhammad Bilal Zia
    International Journal of Machine Learning and Cybernetics.2022; 13(5): 1283.     CrossRef
  • A multitask dual‐stream attention network for the identification of KRAS mutation in colorectal cancer
    Kai Song, Zijuan Zhao, Yulan Ma, JiaWen Wang, Wei Wu, Yan Qiang, Juanjuan Zhao, Suman Chaudhary
    Medical Physics.2022; 49(1): 254.     CrossRef
  • Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data
    Emilia Sardo, Stefania Napolitano, Carminia Maria Della Corte, Davide Ciardiello, Antonio Raucci, Gianluca Arrichiello, Teresa Troiani, Fortunato Ciardiello, Erika Martinelli, Giulia Martini
    Journal of Personalized Medicine.2022; 12(2): 128.     CrossRef
  • The application of radiomics in predicting gene mutations in cancer
    Yana Qi, Tingting Zhao, Mingyong Han
    European Radiology.2022; 32(6): 4014.     CrossRef
  • The prognostic effect of PNN in digestive tract cancers and its correlation with the tumor immune landscape in colon adenocarcinoma
    Hui Zhang, Ming Jin, Meng Ye, Yanping Bei, Shaohui Yang, Kaitai Liu
    Journal of Clinical Laboratory Analysis.2022;[Epub]     CrossRef
  • 18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy
    Giulia Capelli, Cristina Campi, Quoc Riccardo Bao, Francesco Morra, Carmelo Lacognata, Pietro Zucchetta, Diego Cecchin, Salvatore Pucciarelli, Gaya Spolverato, Filippo Crimì
    Nuclear Medicine Communications.2022; 43(7): 815.     CrossRef
  • Radiomics model based on multi-sequence MR images for predicting preoperative immunoscore in rectal cancer
    Kaiming Xue, Lin Liu, Yunxia Liu, Yan Guo, Yuhang Zhu, Mengchao Zhang
    La radiologia medica.2022; 127(7): 702.     CrossRef
  • Heteronemin and Tetrac Induce Anti-Proliferation by Blocking EGFR-Mediated Signaling in Colorectal Cancer Cells
    Sukanya Unson, Tung-Cheng Chang, Yung-Ning Yang, Shwu-Huey Wang, Chi-Hung Huang, Dana R. Crawford, Haw-Ming Huang, Zi-Lin Li, Hung-Yun Lin, Jacqueline Whang-Peng, Kuan Wang, Paul J. Davis, Wen-Shan Li
    Marine Drugs.2022; 20(8): 482.     CrossRef
  • Association between Texture Analysis Parameters and Molecular Biologic KRAS Mutation in Non-Mucinous Rectal Cancer
    Sung Jae Jo, Seung Ho Kim, Sang Joon Park, Yedaun Lee, Jung Hee Son
    Journal of the Korean Society of Radiology.2021; 82(2): 406.     CrossRef
  • Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica
    Samuel Navarro, Miriam Cuatrecasas, Javier Hernández-Losa, Stefania Landolfi, Eva Musulén, Santiago Ramón y Cajal, Rocío García-Carbonero, Jesús García-Foncillas, Pedro Pérez-Segura, Ramón Salazar, Ruth Vera, Pilar García-Alfonso
    Revista Española de Patología.2021; 54(1): 41.     CrossRef
  • Texture analysis using T1-weighted images for muscles in Charcot-Marie-Tooth disease patients and volunteers
    Ji Hyun Lee, Young Cheol Yoon, Hyun Su Kim, Jae-Hun Kim, Byung-Ok Choi
    European Radiology.2021; 31(5): 3508.     CrossRef
  • Radiomics signature of brain metastasis: prediction of EGFR mutation status
    Guangyu Wang, Bomin Wang, Zhou Wang, Wenchao Li, Jianjun Xiu, Zhi Liu, Mingyong Han
    European Radiology.2021; 31(7): 4538.     CrossRef
  • Radiomics and Magnetic Resonance Imaging of Rectal Cancer: From Engineering to Clinical Practice
    Francesca Coppola, Valentina Giannini, Michela Gabelloni, Jovana Panic, Arianna Defeudis, Silvia Lo Monaco, Arrigo Cattabriga, Maria Adriana Cocozza, Luigi Vincenzo Pastore, Michela Polici, Damiano Caruso, Andrea Laghi, Daniele Regge, Emanuele Neri, Rita
    Diagnostics.2021; 11(5): 756.     CrossRef
  • MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients
    ZhiYuan Zhang, LiJun Shen, Yan Wang, Jiazhou Wang, Hui Zhang, Fan Xia, JueFeng Wan, Zhen Zhang
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Differentiating TP53 Mutation Status in Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI-Derived Radiomics
    Jing Gao, Xiahan Chen, Xudong Li, Fei Miao, Weihuan Fang, Biao Li, Xiaohua Qian, Xiaozhu Lin
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Radiomic signature of the FOWARC trial predicts pathological response to neoadjuvant treatment in rectal cancer
    Zhuokai Zhuang, Zongchao Liu, Juan Li, Xiaolin Wang, Peiyi Xie, Fei Xiong, Jiancong Hu, Xiaochun Meng, Meijin Huang, Yanhong Deng, Ping Lan, Huichuan Yu, Yanxin Luo
    Journal of Translational Medicine.2021;[Epub]     CrossRef
  • Systematic Review on the Association of Radiomics with Tumor Biological Endpoints
    Agustina La Greca Saint-Esteven, Diem Vuong, Fabienne Tschanz, Janita E. van Timmeren, Riccardo Dal Bello, Verena Waller, Martin Pruschy, Matthias Guckenberger, Stephanie Tanadini-Lang
    Cancers.2021; 13(12): 3015.     CrossRef
  • Emerging applications of radiomics in rectal cancer: State of the art and future perspectives
    Min Hou, Ji-Hong Sun
    World Journal of Gastroenterology.2021; 27(25): 3802.     CrossRef
  • Spatial-Frequency dual-branch attention model for determining KRAS mutation status in colorectal cancer with T2-weighted MRI
    Yulan Ma, Jiawen Wang, Kai Song, Yan Qiang, Xiong Jiao, Juanjuan Zhao
    Computer Methods and Programs in Biomedicine.2021; 209: 106311.     CrossRef
  • Textural differences based on apparent diffusion coefficient maps for discriminating pT3 subclasses of rectal adenocarcinoma
    Zhi-Hua Lu, Kai-Jian Xia, Heng Jiang, Jian-Long Jiang, Mei Wu
    World Journal of Clinical Cases.2021; 9(24): 6987.     CrossRef
  • 2. Radiomics of MRI
    Koji Sakai
    Japanese Journal of Radiological Technology.2021; 77(8): 866.     CrossRef
  • Radiomics and machine learning applications in rectal cancer: Current update and future perspectives
    Arnaldo Stanzione, Francesco Verde, Valeria Romeo, Francesca Boccadifuoco, Pier Paolo Mainenti, Simone Maurea
    World Journal of Gastroenterology.2021; 27(32): 5306.     CrossRef
  • Role of MRI‑based radiomics in locally advanced rectal cancer (Review)
    Siyu Zhang, Mingrong Yu, Dan Chen, Peidong Li, Bin Tang, Jie Li
    Oncology Reports.2021;[Epub]     CrossRef
  • Development and validation of a MRI-based radiomics signature for prediction of KRAS mutation in rectal cancer
    Yanfen Cui, Huanhuan Liu, Jialiang Ren, Xiaosong Du, Lei Xin, Dandan Li, Xiaotang Yang, Dengbin Wang
    European Radiology.2020; 30(4): 1948.     CrossRef
  • Multi-branch cross attention model for prediction of KRAS mutation in rectal cancer with t2-weighted MRI
    JiaWen Wang, YanFen Cui, GuoHua Shi, JuanJuan Zhao, XiaoTang Yang, Yan Qiang, QianQian Du, Yue Ma, Ntikurako Guy-Fernand Kazihise
    Applied Intelligence.2020; 50(8): 2352.     CrossRef
  • Development and validation of a radiomics model based on T2WI images for preoperative prediction of microsatellite instability status in rectal cancer
    Zixing Huang, Wei Zhang, Du He, Xing Cui, Song Tian, Hongkun Yin, Bin Song
    Medicine.2020; 99(10): e19428.     CrossRef
  • PET/MRI Radiomics in Rectal Cancer: a Pilot Study on the Correlation Between PET- and MRI-Derived Image Features with a Clinical Interpretation
    Barbara Juarez Amorim, Angel Torrado-Carvajal, Shadi A Esfahani, Sara S Marcos, Mark Vangel, Dan Stein, David Groshar, Onofrio A Catalano
    Molecular Imaging and Biology.2020; 22(5): 1438.     CrossRef
  • MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC)
    Filippo Crimì, Giulia Capelli, Gaya Spolverato, Quoc Riccardo Bao, Anna Florio, Sebastiano Milite Rossi, Diego Cecchin, Laura Albertoni, Cristina Campi, Salvatore Pucciarelli, Roberto Stramare
    La radiologia medica.2020; 125(12): 1216.     CrossRef
  • Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
    P. García-Alfonso, R. García-Carbonero, J. García-Foncillas, P. Pérez-Segura, R. Salazar, R. Vera, S. Ramón y Cajal, J. Hernández-Losa, S. Landolfi, E. Musulén, M. Cuatrecasas, S. Navarro
    Clinical and Translational Oncology.2020; 22(11): 1976.     CrossRef
  • MRI-Based Texture Features as Potential Prognostic Biomarkers in Anaplastic Astrocytoma Patients Undergoing Surgical Treatment
    Yang Zhang, Chaoyue Chen, Yangfan Cheng, Danni Cheng, Fumin Zhao, Jianguo Xu
    Contrast Media & Molecular Imaging.2020; 2020: 1.     CrossRef
  • Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning
    Yu Li, Aydin Eresen, Junjie Shangguan, Jia Yang, Al B. Benson, Vahid Yaghmai, Zhuoli Zhang
    Journal of Cancer Research and Clinical Oncology.2020; 146(12): 3165.     CrossRef
  • Diffusion-Weighted MRI and Diffusion Kurtosis Imaging to Detect RAS Mutation in Colorectal Liver Metastasis
    Vincenza Granata, Roberta Fusco, Chiara Risi, Alessandro Ottaiano, Antonio Avallone, Alfonso De Stefano, Robert Grimm, Roberta Grassi, Luca Brunese, Francesco Izzo, Antonella Petrillo
    Cancers.2020; 12(9): 2420.     CrossRef
  • CT Radiomics in Colorectal Cancer: Detection of KRAS Mutation Using Texture Analysis and Machine Learning
    Víctor González-Castro, Eva Cernadas, Emilio Huelga, Manuel Fernández-Delgado, Jacobo Porto, José Ramón Antunez, Miguel Souto-Bayarri
    Applied Sciences.2020; 10(18): 6214.     CrossRef
  • Cancer Genotypes Prediction and Associations Analysis From Imaging Phenotypes: A Survey on Radiogenomics
    Yao Wang, Yan Wang, Chunjie Guo, Xuping Xie, Sen Liang, Ruochi Zhang, Wei Pang, Lan Huang
    Biomarkers in Medicine.2020; 14(12): 1151.     CrossRef
  • Diagnostic performance of multiparametric MRI parameters for Gleason score and cellularity metrics of prostate cancer in different zones: a quantitative comparison
    J. Gao, Q. Zhang, C. Zhang, M. Chen, D. Li, Y. Fu, X. Lv, B. Zhang, H. Guo
    Clinical Radiology.2019; 74(11): 895.e17.     CrossRef
  • Ability of Radiomics in Differentiation of Anaplastic Oligodendroglioma From Atypical Low-Grade Oligodendroglioma Using Machine-Learning Approach
    Yang Zhang, Chaoyue Chen, Yangfan Cheng, Yuen Teng, Wen Guo, Hui Xu, Xuejin Ou, Jian Wang, Hui Li, Xuelei Ma, Jianguo Xu
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • The Diagnostic Value of Radiomics-Based Machine Learning in Predicting the Grade of Meningiomas Using Conventional Magnetic Resonance Imaging: A Preliminary Study
    Chaoyue Chen, Xinyi Guo, Jian Wang, Wen Guo, Xuelei Ma, Jianguo Xu
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • 11,620 View
  • 403 Download
  • 55 Web of Science
  • 54 Crossref
Close layer
Breast Conservation Therapy Versus Mastectomy in Patients with T1-2N1 Triple-Negative Breast Cancer: Pooled Analysis of KROG 14-18 and 14-23
Kyubo Kim, Hae Jin Park, Kyung Hwan Shin, Jin Ho Kim, Doo Ho Choi, Won Park, Seung Do Ahn, Su Ssan Kim, Dae Yong Kim, Tae Hyun Kim, Jin Hee Kim, Jiyoung Kim
Cancer Res Treat. 2018;50(4):1316-1323.   Published online January 8, 2018
DOI: https://doi.org/10.4143/crt.2017.575
AbstractAbstract PDFPubReaderePub
Purpose
The aim of this study is to compare the treatment outcomes of breast conserving surgery (BCS) plus radiotherapy (RT) versus mastectomy for patients with pT1-2N1 triple-negative breast cancer (TNBC).
Materials and Methods
Using two multicenter retrospective studies on breast cancer, a pooled analysis was performed among 320 patients with pT1-2N1 TNBC. All patients who underwent BCS (n=212) receivedwhole breast RTwith orwithoutregional nodal RT,while nonewho underwent mastectomy (n=108)received it. All patients received taxane-based adjuvant chemotherapy. The median follow-up periods were 65 months in the BCS+RT group, and 74 months in the mastectomy group.
Results
The median age of all patients was 48 years (range, 24 to 70 years). Mastectomy group had more patients with multiple tumors (p < 0.001), no lymphovascular invasion (p=0.001), higher number of involved lymph node (p=0.028), and higher nodal ratio ≥ 0.2 (p=0.037). Other characteristics were not significantly different between the two groups. The 5-year locoregionalrecurrence-free, disease-free, and overall survivalrates of BCS+RT group versus mastectomy group were 94.6% versus 87.7%, 89.5% versus 80.4%, and 95.0% versus 87.8%, respectively, and the differences were statistically significant after adjusting for covariates (p=0.010, p=0.006, and p=0.005, respectively).
Conclusion
In pT1-2N1 TNBC, breast conservation therapy achieved better locoregional recurrencefree, disease-free, and overall survival rates compared with mastectomy.

Citations

Citations to this article as recorded by  
  • Breast conserving surgery combined with radiation therapy offers improved survival over mastectomy in early-stage breast cancer
    Elizaveta Vasilyeva, Alan Nichol, Brendan Bakos, Anise Barton, Michelle Goecke, Elaine Lam, Erin Martin, Caroline Lohrisch, Elaine McKevitt
    The American Journal of Surgery.2024; 231: 70.     CrossRef
  • Oncoplastic Breast Conservation for Central Tumors: Definition, Classification, and the Analysis of Single Institution Experience
    Andrii Zhygulin, Artem Fedosov
    Plastic and Reconstructive Surgery - Global Open.2024; 12(5): e5789.     CrossRef
  • Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05)
    Jin Kim, Sang Byun, Myeongsoo Kim, Kyung Shin, Dong Kim, Han Lee, Tae Kim, Yeon Kim, Yong Kim, Jee Chang, Kyubo Kim, Sun Lee
    Journal of Personalized Medicine.2024; 14(9): 941.     CrossRef
  • Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer
    Rajesh Pradhan, Anuradha Dey, Rajeev Taliyan, Anu Puri, Sanskruti Kharavtekar, Sunil Kumar Dubey
    Pharmaceutics.2023; 15(1): 246.     CrossRef
  • Breast-Conserving Therapy is Associated with Improved Survival Without an Increased Risk of Locoregional Recurrence Compared with Mastectomy in Both Clinically Node-Positive and Node-Negative Breast Cancer Patients
    Elizaveta Vasilyeva, Jeremy Hamm, Alan Nichol, Kathryn V. Isaac, Amy Bazzarelli, Carl Brown, Caroline Lohrisch, Elaine McKevitt
    Annals of Surgical Oncology.2023; 30(11): 6413.     CrossRef
  • Postmastectomy Radiation Therapy in Patients With Minimally Involved Lymph Nodes: A Review of the Current Data and Future Directions
    Bum-Sup Jang, Kyung Hwan Shin
    Journal of Breast Cancer.2022; 25(1): 1.     CrossRef
  • A Review of Current treatment for Triple-Negative Breast Cancer (TNBC)
    Wahyuni Wahyuni, Ajeng Diantini, Mohammad Ghozali, Sahidin I
    Research Journal of Pharmacy and Technology.2022; : 409.     CrossRef
  • Long non-coding RNA MRPS30 divergent transcript can be detected in the cytoplasm of triple-negative breast cancer cells and is targeted by microRNA-130b
    Dongtao Wang, Qiang Song, Tianyong Zhao, Fang Wang, Yang Yu, Jing Qi, Pengfei Lyu, Xiangyang Duan
    Bioengineered.2022; 13(3): 5954.     CrossRef
  • Breast-conserving surgery versus mastectomy for older women with triple-negative breast cancer: population-based study
    Waruiru Mburu, Shalini Kulasingam, James S Hodges, Beth A Virnig
    Journal of Comparative Effectiveness Research.2022; 11(13): 953.     CrossRef
  • Determining prognostic factors and optimal surgical intervention for early-onset triple-negative breast cancer
    Yi-Zi Zheng, Yan Liu, Zhen-Han Deng, Guo-Wen Liu, Ni Xie
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy
    Chu-Ying Chen, Si-Yue Zheng, Gang Cai, Cheng Xu, Rong Cai, Min Li, Kun-Wei Shen, Xiao-Song Chen, Dan Ou, Wei-Xiang Qi, Lu Cao, Jia-Yi Chen, Weiren Luo
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • Значення локорегіонарної терапії у хворих на тричі негативний рак грудної залози (огляд літератури)
    M.V. Pavlushenko, R.V. Liubota, R.I. Vereshchako, O.S. Zotov, M.F. Anikusko, I.I. Liubota
    Practical oncology.2022; 5(1): 23.     CrossRef
  • Breast conservation therapy confers survival and distant recurrence advantage over mastectomy for stage II Triple Negative Breast cancer
    Rebekah Macfie, Cynthia Aks, Kathryn Panwala, Nathalie Johnson, Jennifer Garreau
    The American Journal of Surgery.2021; 221(4): 809.     CrossRef
  • Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis
    A Fancellu, N Houssami, V Sanna, A Porcu, C Ninniri, M L Marinovich
    British Journal of Surgery.2021; 108(7): 760.     CrossRef
  • Are the Outcomes of Breast Conservation Surgery Inferior to Those of Mastectomy in Patients with Stage II-IIIA Triple-Negative Breast Cancer?
    Seungju Lee, Hyun Yul Kim, Youn Joo Jung, Hyun-June Paik, Dong-Il Kim, Chang Shin Jung, Seok-Kyung Kang, Jee Yeon Kim, Seokwon Lee, Youngtae Bae
    Journal of Breast Disease.2021; 9(2): 77.     CrossRef
  • Thrombin generation predicts early recurrence in breast cancer patients
    Marina Marchetti, Cinzia Giaccherini, Giovanna Masci, Cristina Verzeroli, Laura Russo, Luigi Celio, Roberta Sarmiento, Sara Gamba, Carmen J. Tartari, Erika Diani, Alfonso Vignoli, Paolo Malighetti, Daniele Spinelli, Nicole M. Kuderer, Federico Nichetti, M
    Journal of Thrombosis and Haemostasis.2020; 18(9): 2220.     CrossRef
  • Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams
    Francesco P. Cammarata, Giusi I. Forte, Giuseppe Broggi, Valentina Bravatà, Luigi Minafra, Pietro Pisciotta, Marco Calvaruso, Roberta Tringali, Barbara Tomasello, Filippo Torrisi, Giada Petringa, Giuseppe A. P. Cirrone, Giacomo Cuttone, Rosaria Acquaviva,
    International Journal of Molecular Sciences.2020; 21(17): 6337.     CrossRef
  • Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions
    Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Jian-Yang Wang, Jiang-Hu Zhang, Yong Yang, Xu-Ran Zhao, Si-Ye Chen, Jing Jin, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Hua Ren, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Shu-Lian Wang, Ye-
    BMC Cancer.2020;[Epub]     CrossRef
  • Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases
    Stefanie Corradini, Daniel Reitz, Montserrat Pazos, Stephan Schönecker, Michael Braun, Nadia Harbeck, Christiane Matuschek, Edwin Bölke, Ute Ganswindt, Filippo Alongi, Maximilian Niyazi, Claus Belka
    Cancers.2019; 11(2): 160.     CrossRef
  • Are breast conservation treatment rates optimized for Asian women with symptomatic malignancies?
    Mona P. C. Tan, Yih Yiow Sitoh
    ANZ Journal of Surgery.2019; 89(5): 529.     CrossRef
  • 9,112 View
  • 221 Download
  • 16 Web of Science
  • 20 Crossref
Close layer
The Impact of Surgical Timing on Pathologic Tumor Response after Short Course and Long Course Preoperative Chemoradiation for Locally Advanced Rectal Adenocarcinoma
Sea-Won Lee, Jong Hoon Lee, In Kyu Lee, Seong Taek Oh, Dae Yong Kim, Tae Hyun Kim, Jae Hwan Oh, Ji Yeon Baek, Hee Jin Chang, Hee Chul Park, Hee Cheol Kim, Eui Kyu Chie, Taek-Keun Nam, Hong Seok Jang
Cancer Res Treat. 2018;50(3):1039-1050.   Published online November 21, 2017
DOI: https://doi.org/10.4143/crt.2017.252
AbstractAbstract PDFPubReaderePub
Purpose
A pooled analysis of multi-institutional trials was performed to analyze the effect of surgical timing on tumor response by comparing short course concurrent chemoradiotherapy (CCRT) with long course CCRT followed by delayed surgery in locally advanced rectal cancer.
Materials and Methods
Three hundred patients with cT3-4N0-2 rectal adenocarcinoma were included. Long course patients from KROG 14-12 (n=150) were matched 1:1 to 150 short course patients from KROG 10-01 (NCT01129700) and KROG 11-02 (NCT01431599) according to stage, age, and other risk factors. The primary endpoint was to determine the interval between surgery and the last day of neoadjuvant CCRT which yields the best tumor response after the short course and long course CCRT. Downstaging was defined as ypT0-2N0M0 and pathologic complete response (ypCR) was defined as ypT0N0M0, respectively.
Results
Both the long and short course groups achieved lowest downstaging rates at < 6 weeks (long 20% vs. short 8%) and highest downstaging rates at 6-7 weeks (long 44% vs. short 40%). The ypCR rates were lowest at < 6 weeks (both long and short 0%) and highest at 6-7 weeks (long 21% vs. short 11%) in both the short and long course arms. The downstaging and ypCR rates of long course group gradually declined after the peak at 6-7 weeks and those of the short course group trend to constantly increase afterwards.
Conclusion
It is optimal to perform surgery at least 6 weeks after both the short course and long course CCRT to obtain maximal tumor regression in locally advanced rectal adenocarcinoma.

Citations

Citations to this article as recorded by  
  • Association between personality types and low anterior resection syndrome in rectal cancer patients following surgery
    Ting‐Yu Chiang, Yu‐Jen Hsu, Yih‐Jong Chern, Chun‐Kai Liao, Wen‐Sy Tsai, Pao‐Shiu Hsieh, Hung‐Chih Hsu, Yu‐Fen Lin, Hsiu‐Lan Lee, Jeng‐Fu You
    Cancer Medicine.2024;[Epub]     CrossRef
  • Lateral Lymph Node Size and Tumor Distance From Anal Verge Accurately Predict Positive Lateral Pelvic Lymph Nodes in Rectal Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Jumyung Song, Ji Hoon Kim, Bong-Hyeon Kye, In Kyu Lee, Hyeon-Min Cho, Yoon Suk Lee
    Diseases of the Colon & Rectum.2023; 66(6): 785.     CrossRef
  • Robotic Lateral Pelvic Lymph Node Dissection Could Harvest More Lateral Pelvic Lymph Nodes over Laparoscopic Approach for Mid-to-Low Rectal Cancer: A Multi-Institutional Retrospective Cohort Study
    Jung Hoon Bae, Jumyung Song, Ri Na Yoo, Ji Hoon Kim, Bong-Hyeon Kye, In Kyu Lee, Hyeon-Min Cho, Yoon Suk Lee
    Biomedicines.2023; 11(6): 1556.     CrossRef
  • Does a long interval between neoadjuvant chemoradiotherapy and surgery benefit the clinical outcomes of locally advanced rectal cancer? A systematic review and meta analyses
    Miao Yu, Deng-Chao Wang, Sheng Li, Li-Yan Huang, Jian Wei
    International Journal of Colorectal Disease.2022; 37(4): 855.     CrossRef
  • Predicting Factors of Complete Pathological Response in Locally Advanced Rectal Cancer
    AmirHossein Latif, Mohammad Shirkhoda, Mohammad Reza Rouhollahi, Saeed Nemati, Seyed Hossein Yahyazadeh, Kazem Zendehdel, Ahmad Reza Soroush, Aidin Yaghoobi Notash
    Middle East Journal of Digestive Diseases.2022; 14(4): 443.     CrossRef
  • Practical recommendation for treatment of patients with colon cancer during covid-19 pandemic
    M. Yu. Fedyanin
    Meditsinskiy sovet = Medical Council.2020; (9): 213.     CrossRef
  • Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer
    É J Ryan, D P O'Sullivan, M E Kelly, A Z Syed, P C Neary, P R O'Connell, D O Kavanagh, D C Winter, J M O'Riordan
    British Journal of Surgery.2019; 106(10): 1298.     CrossRef
  • Preoperative short-course radiotherapy (5 × 5 Gy) with delayed surgery versus preoperative long-course radiotherapy for locally resectable rectal cancer: a meta-analysis
    Wang Qiaoli, Huang Yongping, Xiong Wei, Xu Guoqiang, Ju Yunhe, Liu Qiuyan, Li Cheng, Guo Mengling, Li Jiayi, Xiong Wei, Yang Yi
    International Journal of Colorectal Disease.2019; 34(12): 2171.     CrossRef
  • Comparison of long course and short course preoperative radiotherapy in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis
    Yongjun Yu, Yuwei Li, Chen Xu, Zhao Zhang, Xipeng Zhang
    Revista Española de Enfermedades Digestivas.2018;[Epub]     CrossRef
  • 9,588 View
  • 333 Download
  • 8 Web of Science
  • 9 Crossref
Close layer
Redefining the Positive Circumferential Resection Margin by Incorporating Preoperative Chemoradiotherapy Treatment Response in Locally Advanced Rectal Cancer: A Multicenter Validation Study
Joo Ho Lee, Eui Kyu Chie, Seung-Yong Jeong, Tae-You Kim, Dae Yong Kim, Tae Hyun Kim, Sun Young Kim, Ji Yeon Baek, Hee Jin Chang, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Sung Hwan Kim, Jong Hoon Lee, Doo Ho Choi, Hee Chul Park, Sung-Bum Kang, Jae-Sung Kim
Cancer Res Treat. 2018;50(2):506-517.   Published online May 24, 2017
DOI: https://doi.org/10.4143/crt.2016.607
AbstractAbstract PDFPubReaderePub
Purpose
This study was conducted to validate the prognostic influence of treatment response among patients with positive circumferential resection margin for locally advanced rectal cancer.
Materials and Methods
Clinical data of 197 patientswith positive circumferentialresection margin defined as ≤ 2 mm after preoperative chemoradiotherapy followed by total mesorectal excision between 2004 and 2009were collected forthis multicenter validation study. All patients underwent median 50.4Gy radiationwith concurrentfluoropyrimidine based chemotherapy. Treatmentresponse was dichotomized to good response, including treatmentresponse of grade 2 or 3, and poor response, including grade 0 or 1.
Results
After 52 months median follow-up, 5-year overall survival (OS) for good responders and poor responders was 79.1% and 48.4%, respectively (p < 0.001). In multivariate analysis, circumferential resection margin involvement and treatment response were a prognosticator for OS and locoregional recurrence-free survival. In subgroup analysis, good responders with close margin showed significantly better survival outcomes for survival. Good responders with involved margin and poor responders with close margin shared similar results, whereas poorresponderswith involved margin hadworst survival (5-year OS, 81.2%, 57.0%, 50.0%, and 32.4%, respectively; p < 0.001).
Conclusion
Among patients with positive circumferential resection margin after preoperative chemoradiotherapy, survival of the good responders was significantly better than poor responders. Subgroup analysis revealed that definition of positive circumferential resection margin may be individualized as involvement for good responders, whereas ≤ 2 mm for poor responders.

Citations

Citations to this article as recorded by  
  • Tailored Strategy for Locally Advanced Rectal Carcinoma (GRECCAR 4): Long-term Results From a Multicenter, Randomized, Open-Label, Phase II Trial
    Philippe Rouanet, Eric Rullier, Bernard Lelong, Philippe Maingon, Jean-Jacques Tuech, Denis Pezet, Florence Castan, Stephanie Nougaret
    Diseases of the Colon & Rectum.2022; 65(8): 986.     CrossRef
  • Colorectal Cancer Surgery Quality in Manitoba: A Population-Based Descriptive Analysis
    Iresha Ratnayake, Jason Park, Natalie Biswanger, Allison Feely, Grace Musto, Kathleen Decker
    Current Oncology.2021; 28(3): 2239.     CrossRef
  • 11,109 View
  • 266 Download
  • 4 Web of Science
  • 2 Crossref
Close layer
Clinical Outcomes of Proton Beam Therapy for Choroidal Melanoma at a Single Institute in Korea
Tae Wan Kim, Euncheol Choi, Jeonghoon Park, Dong-ho Shin, Su Kyung Jung, Susie Seok, Kwan Ho Cho, Joo-Young Kim, Dae Yong Kim, Tae Hyun Kim, Yang Kwon Suh, Yeon Joo Kim, Sung Ho Moon
Cancer Res Treat. 2018;50(2):335-344.   Published online April 19, 2017
DOI: https://doi.org/10.4143/crt.2017.070
AbstractAbstract PDFPubReaderePub
Purpose
This study retrospectively evaluated the clinical outcomes and complications of proton beam therapy (PBT) in a single institution in Korea and quantitatively analyzed the change in tumor volume after PBT using magnetic resonance imaging (MRI).
Materials and Methods
Twenty-four treatment-naïve patients who underwent PBT for choroidal melanoma between 2009 and 2015 were reviewed. Dose fractionation was 60-70 cobalt gray equivalents over 5 fractions. Orbital MRIs were taken at baseline and 3, 6, and 12 months after PBT and annually thereafter. The tumor volume was reconstructed and evaluated by stacking the tumor boundary in each thin-sliced axial T1-weighted image using MIM software.
Results
The median follow-up duration was 36.5 months (range, 9 to 82 months). One patient had suspicious local progression and two patients had distant metastasis. The 3-year local progression-free survival, distant metastasis-free survival, and overall survival rates were 95.8%, 95.8%, and 100%,respectively. Five Common Terminology Criteria for Adverse Event ver. 4.03 grade 3-4 toxicities were observed in four patients (16.7%), including one with neovascular glaucoma. The mean tumor volume at the baseline MRI was 0.565±0.084 mL (range, 0.074 to 1.610 mL), and the ratios of the mean volume at 3, 6, and 12 months to that at baseline were 81.8%, 67.3%, and 60.4%, respectively.
Conclusion
The local controlrate and complication profile after PBT in patientswith choroidal melanoma in Korea were comparable with those reported in a previous PBT series. The change in tumor volume after PBT exhibited a gradual regression pattern on MRI.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of proton radiotherapy in treating choroidal melanoma: a systematic review and meta-analysis
    Yuxin Miao, Tingwei Zheng, Qiuning Zhang, Meixuan Li, Qihang Lei, Qin Liu, Hongtao Luo, Huiling Bai
    Radiation Oncology.2025;[Epub]     CrossRef
  • Monte Carlo simulation of polymer phantoms in proton therapy for eye tumor treatment
    Engin Aşlar, Fatih Ekinci
    The European Physical Journal Plus.2025;[Epub]     CrossRef
  • Opportunities and challenges of upright patient positioning in radiotherapy
    Lennart Volz, James Korte, Maria Chiara Martire, Ye Zhang, Nicholas Hardcastle, Marco Durante, Tomas Kron, Christian Graeff
    Physics in Medicine & Biology.2024; 69(18): 18TR02.     CrossRef
  • Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients—A Systematic Review from an Ophthalmic Perspective
    Myriam G. Jaarsma-Coes, Lisa Klaassen, Marina Marinkovic, Gregorius P. M. Luyten, T. H. Khanh Vu, Teresa A. Ferreira, Jan-Willem M. Beenakker
    Cancers.2023; 15(11): 2995.     CrossRef
  • When Is the Optimum Radiological Response to Proton Beam Therapy in Uveal Melanoma?
    Matthew Gillam, Glenn Ace Fenech, Oliver Chadwick, Jonathan Nairn, Vikas Chadha, Julie Connolly, Oliver Cram, Wilma Kincaid, Paul Cauchi
    Ocular Oncology and Pathology.2023; 9(5-6): 130.     CrossRef
  • Optimization of proton therapy eye-treatment systems toward improved clinical performances
    Eustache Gnacadja, Cédric Hernalsteens, Stewart Boogert, Quentin Flandroy, Carolina Fuentes, Laurence J. Nevay, Nicolas Pauly, Eliott Ramoisiaux, William Shields, Robin Tesse, Raphael Van Roermund, Marion Vanwelde
    Physical Review Research.2022;[Epub]     CrossRef
  • Who Will Benefit from Charged-Particle Therapy?
    Kyung Su Kim, Hong-Gyun Wu
    Cancer Research and Treatment.2021; 53(3): 621.     CrossRef
  • Uveal Melanoma: A Review of the Literature and Personal Experiences
    Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee
    Journal of Retina.2021; 6(2): 65.     CrossRef
  • Carbon Fiducial Markers for Tumor Localization in Stereotactic Irradiation of Uveal Melanoma
    Timothy T. Xu, Jose S. Pulido, Ian F. Parney, Cristiane M. Ida, Lauren A. Dalvin, Timothy W. Olsen
    Ocular Oncology and Pathology.2021; 7(5): 368.     CrossRef
  • Uveal Melanoma in Asians: A Review
    Pradeep Manchegowda, Arun D. Singh, Carol Shields, Swathi Kaliki, Parag Shah, Lingam Gopal, Pukhraj Rishi
    Ocular Oncology and Pathology.2021; 7(3): 159.     CrossRef
  • Preliminary Dosimetric Study of Proton Minibeam Radiation Therapy for the Treatment of Choroidal Melanoma
    Myeongsoo Kim, Sang Soo Kim, Haksoo Kim, Sung Ho Moon, Young Kyung Lim, Ui-Jung Hwang, Sang Hyoun Choi
    Journal of the Korean Physical Society.2020; 77(5): 447.     CrossRef
  • Visual outcomes of proton beam therapy for choroidal melanoma at a single institute in the Republic of Korea
    Su-Kyung Jung, Young-Hoon Park, Dong-ho Shin, Hak-Soo Kim, Jong-Hwi Jung, Tae-Hyun Kim, Sung Ho Moon, Vikas Khetan
    PLOS ONE.2020; 15(12): e0242966.     CrossRef
  • 11,959 View
  • 271 Download
  • 12 Web of Science
  • 12 Crossref
Close layer
Effects of Postoperative Radiotherapy on Leptomeningeal Carcinomatosis or Dural Metastasis after Resection of Brain Metastases in Breast Cancer Patients
Boram Ha, Seung Yeun Chung, Yeon-Joo Kim, Ho-Shin Gwak, Jong Hee Chang, Sang Hyun Lee, In Hae Park, Keun Seok Lee, Seeyoun Lee, Tae Hyun Kim, Dae Yong Kim, Seok-Gu Kang, Chang-Ok Suh
Cancer Res Treat. 2017;49(3):748-758.   Published online October 31, 2016
DOI: https://doi.org/10.4143/crt.2016.303
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In this retrospective study, we compared the incidence of leptomeningeal carcinomatosis or dural metastasis (LMCDM) in patients who received whole brain radiotherapy (WBRT), partial radiotherapy (PRT), or no radiotherapy (RT) following resection of brain metastases from breast cancer.
Materials and Methods
Fifty-one patients with breast cancer underwent surgical resection for newly diagnosed brain metastases in two institutions between March 2001 and March 2015. Among these, 34 received postoperative WBRT (n=24) or PRT (n=10) and 17 did not.
Results
With a median follow-up of 12.4 months (range, 2.3 to 83.6 months), 22/51 patients developed LMCDM at a median of 8.6 months (range, 4.8 to 51.2 months) after surgery. The 18-months LMCDM-free survival (LMCDM-FS) rates were 77.5%, 30.0%, and 13.6%, in the WBRT, PRT, and no RT groups, respectively (p=0.013). The presence of a tumor adjacent to cerebrospinal fluid flow and no systemic treatment after treatment for brain metastases were also associated with poor LMCDM-FS rate. Multivariate analysis showed that WBRT compared to PRT (p=0.009) and systemic treatment (p < 0.001) were independently associated with reduced incidence of LMCDM.
Conclusion
WBRT improved LMCDM-FS rate after resection of brain metastases compared to PRT in breast cancer patients.

Citations

Citations to this article as recorded by  
  • Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
    Joshua Mangerel, Andres Rodriguez-Sein, Daniel Masri
    Radiology Case Reports.2025; 20(3): 1620.     CrossRef
  • Revisiting the Role of Surgical Resection for Brain Metastasis
    Joonho Byun, Jong Hyun Kim
    Brain Tumor Research and Treatment.2023; 11(1): 1.     CrossRef
  • Literature Review: Role of Neurosurgery in Leptomeningeal Carcinomatosis
    Thaís Mitie Ogasawara, Thaís Yumi Kobayashi Batista, Rafael Rodrigues Pinheiro dos Santos, Ana Carla Mondek Rampazzo, Caroline Amane Pessoa Badaoui, Igor Ruan de Araújo Caetano, Jonathan Vinícius Martins, Maria Letícia Nogueira, José Ângelo Guarnieri, Car
    Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery.2023; 42(04): e337.     CrossRef
  • Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report
    Brittany M. Stopa, Joshua A. Cuoco, Srijan Adhikari, Douglas J. Grider, Cara M. Rogers, Eric A. Marvin
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • Autocrine GMCSF Signaling Contributes to Growth of HER2+ Breast Leptomeningeal Carcinomatosis
    Khairul I. Ansari, Arunoday Bhan, Mika Saotome, Antariksh Tyagi, Bony De Kumar, Clara Chen, Motoki Takaku, Rahul Jandial
    Cancer Research.2021; 81(18): 4723.     CrossRef
  • Leptomeningeal carcinomatosis in patients with breast cancer
    Maria Alice Franzoi, Gabriel N. Hortobagyi
    Critical Reviews in Oncology/Hematology.2019; 135: 85.     CrossRef
  • Leptomeningeal Metastases
    Jerome J. Graber, Santosh Kesari
    Current Treatment Options in Oncology.2018;[Epub]     CrossRef
  • Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study
    Seung Yeun Chung, Jong Hee Chang, Hye Ryun Kim, Byoung Chul Cho, Chang Geol Lee, Chang-Ok Suh
    Radiation Oncology Journal.2017; 35(2): 153.     CrossRef
  • 13,460 View
  • 286 Download
  • 6 Web of Science
  • 8 Crossref
Close layer
What Is the Ideal Tumor Regression Grading System in Rectal Cancer Patients after Preoperative Chemoradiotherapy?
Soo Hee Kim, Hee Jin Chang, Dae Yong Kim, Ji Won Park, Ji Yeon Baek, Sun Young Kim, Sung Chan Park, Jae Hwan Oh, Ami Yu, Byung-Ho Nam
Cancer Res Treat. 2016;48(3):998-1009.   Published online October 22, 2015
DOI: https://doi.org/10.4143/crt.2015.254
AbstractAbstract PDFPubReaderePub
Purpose
Tumor regression grade (TRG) is predictive of therapeutic response in rectal cancer patients after chemoradiotherapy (CRT) followed by curative resection. However, various TRG systems have been suggested, with subjective categorization, resulting in interobserver variability. This study compared the prognostic validity of four different TRG systems in order to identify the most ideal TRG system. Materials and Methods This study included 933 patients who underwent preoperative CRT and curative resection. Primary tumors alone were graded according to the American Joint Committee on Cancer (AJCC), Dworak, and Ryan TRG systems, and both primary tumors and regional lymph nodes were graded according to a modified Dworak TRG system. The ability of each TRG system to predict recurrence-free survival (RFS) and overall survival (OS) was analyzed using chisquare and C statistics.
Results
All four TRG systems were significantly predictive of both RFS and OS (p < 0.001 each), however none was a better predictor of prognosis than ypStage. Among the four TRGs, the mDworak TRG system was a better predictor of RFS and OS than the AJCC, Dworak, and Ryan TRG systems, and both the chi-square and C statistics were higher for the former, although the differences were not statistically significant. The combination of ypStage and the modified Dworak TRG better predicted RFS and OS than ypStage alone. Conclusion The modified Dworak TRG system for evaluation of entire tumors including regional lymph nodes is a better predictor of survival than current TRG systems for evaluation of the primary tumor alone.

Citations

Citations to this article as recorded by  
  • Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis
    K. van den Berg, I.E.G. van Hellemond, J.M.W.E. Willems, J.W.A. Burger, H.J.T. Rutten, G.J. Creemers
    European Journal of Surgical Oncology.2025; 51(3): 109560.     CrossRef
  • Prognostic Value of Tumor Regression Grade Combined with Pathological Lymph Node Status in Initially Node-Positive Rectal Cancer Treated with Neoadjuvant Chemoradiotherapy
    Dakui Luo, Yajie Chen, Zhouyu Luo, Huangbo Gong, Qingguo Li, Xinxiang Li
    Journal of Investigative Surgery.2025;[Epub]     CrossRef
  • Interpretation of Complete Tumor Response on MRI Following Chemoradiotherapy of Rectal Cancer: Inter-Reader Agreement and Associated Factors in Multi-Center Clinical Practice
    Hae Young Kim, Seung Hyun Cho, Jong Keon Jang, Bohyun Kim, Chul-min Lee, Joon Seok Lim, Sung Kyoung Moon, Soon Nam Oh, Nieun Seo, Seong Ho Park
    Korean Journal of Radiology.2024; 25(4): 351.     CrossRef
  • Evaluating complete response prediction rates in locally advanced rectal cancer with different radiomics segmentation approaches
    Gizem Kaval, Merve Gulbiz Dagoglu Kartal, Sena Azamat, Eda Cingoz, Gokhan Ertas, Sule Karaman, Basak Kurtuldu, Metin Keskin, Neslihan Berker, Senem Karabulut, Ethem Nezih Oral, Nergiz Dagoglu Sakin
    Pathology and Oncology Research.2024;[Epub]     CrossRef
  • Regressionsgrading gastrointestinaler Tumoren
    Doreen Maria Gisder, Andrea Tannapfel, Iris Tischoff
    Die Gastroenterologie.2024; 19(3): 234.     CrossRef
  • Rectal Cancer Survival for Residual Carcinoma In Situ Vs. Pathologic Complete Response After Neoadjuvant Therapy
    Nathan M. Kohrman, Jordan R. Wlodarczyk, Li Ding, Nicholas P. McAndrew, Sandra D. Algaze, Kyle G. Cologne, Sang W. Lee, Sarah E Koller
    Diseases of the Colon & Rectum.2024;[Epub]     CrossRef
  • Predictive value of flexible proctosigmoidoscopy and laboratory findings for complete clinical responses after neoadjuvant chemoradiotherapy in patients with locally advanced primary rectal cancer: a retrospective cohort study
    Alireza Hadizadeh, Hamed Kazemi-Khaledi, Mohammad-Sadegh Fazeli, Seyed-Mohsen Ahmadi-Tafti, Amir Keshvari, Reza Akbari-Asbagh, Mohammad-Reza Keramati, Alireza Kazemeini, Amir-Reza Fazeli, Behnam Behboudi, Mohammadamin Parsaei
    International Journal of Colorectal Disease.2024;[Epub]     CrossRef
  • Are the tumor microenvironment characteristics of pretreatment biopsy specimens of colorectal cancer really effectively predict the efficacy of neoadjuvant therapy: A retrospective multicenter study
    Bingbing Li, Longjiao Chen, Yichun Huang, Meng Wu, Weilan Fang, Xin Zou, Yihong Zheng, Qiuxiang Xiao
    Medicine.2024; 103(35): e39429.     CrossRef
  • Outcomes of rectal cancer treatment in rural Australia and New Zealand: analysis of the bowel cancer outcomes registry
    Ishmam Murshed, Tessa L. Dinger, Duveke P. E. de Gaay Fortman, Luke Traeger, Sergei Bedrikovetski, Andrew Hunter, Hidde M. Kroon, Tarik Sammour
    ANZ Journal of Surgery.2024; 94(10): 1823.     CrossRef
  • Relationship Between Neoadjuvant Chemoradiotherapy Response and Mesorectum Volume in Rectum Cancer
    Ramazan Saygın Kerimoğlu, Ebru Esen, Mustafa Saraçoğlu, İbrahim Babalıoğlu, Bekir Turgut, İlknur Küçükosmanoğlu, Osman Doğru
    Acta Haematologica Oncologica Turcica.2024; : 44.     CrossRef
  • Molecular Mechanism of Radioresponsiveness in Colorectal Cancer: A Systematic Review
    Matthew Lau, Md Islam Khan, Helen Law
    Genes.2024; 15(10): 1257.     CrossRef
  • Tumor Immune Microenvironment Biomarkers for Recurrence Prediction in Locally Advanced Rectal Cancer Patients after Neoadjuvant Chemoradiotherapy
    Jun-Eul Hwang, Sung-Sun Kim, Hyun-Jin Bang, Hyeon-Jong Kim, Hyun-Jeong Shim, Woo-Kyun Bae, Ik-Joo Chung, Eun-Gene Sun, Taebum Lee, Chan-Young Ock, Jeong-Seok Nam, Sang-Hee Cho
    Cancers.2024; 16(19): 3353.     CrossRef
  • A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors
    Kevin Chih-Yang Huang, Chia-Ying Lai, Wei-Ze Hung, Hsin-Yu Chang, Pei-Chun Lin, Shu-Fen Chiang, Tao-Wei Ke, Ji-An Liang, An-Cheng Shiau, Pei-Chen Yang, William Tzu-Liang Chen, K.S. Clifford Chao
    Cancer Immunology Research.2023; 11(1): 123.     CrossRef
  • Does Pathological Complete Response after Neoadjuvant Therapy Influence Postoperative Morbidity in Rectal Cancer after Transanal Total Mesorectal Excision?
    Martin Svoboda, Vladimír Procházka, Tomáš Grolich, Tomáš Pavlík, Monika Mazalová, Zdeněk Kala
    Journal of Gastrointestinal Cancer.2023; 54(2): 528.     CrossRef
  • MRI‐Based Artificial Intelligence in Rectal Cancer
    Chinting Wong, Yu Fu, Mingyang Li, Shengnan Mu, Xiaotong Chu, Jiahui Fu, Chenghe Lin, Huimao Zhang
    Journal of Magnetic Resonance Imaging.2023; 57(1): 45.     CrossRef
  • Pilot proteomic study of locally advanced rectal cancer before and after neoadjuvant chemoradiotherapy indicates high metabolic activity in non‐responders' tumor tissue
    Tamara Babic, Vasiliki Lygirou, Jovana Rosic, Marko Miladinov, Aleksandra Djikic Rom, Eirini Baira, Rafael Stroggilos, Eftychia Pappa, Jerome Zoidakis, Zoran Krivokapic, Aleksandra Nikolic
    PROTEOMICS – Clinical Applications.2023;[Epub]     CrossRef
  • Comparison of the diagnostic performance of changes in signal intensity and volume from multiparametric MRI for assessing response of rectal cancer to neoadjuvant chemoradiotherapy
    Zhengwu Tan, Lan Cheng, Lingling Xie, Lan Zhang, Zhenyu Lin, Ping Han, Xin Li
    Asia-Pacific Journal of Clinical Oncology.2023; 19(3): 327.     CrossRef
  • Carbonic Anhydrase IX Expression and Treatment Response Measured in Rectal Adenocarcinoma Following Neoadjuvant Chemo-Radiotherapy
    Emese Sarolta Bádon, Lívia Beke, Attila Mokánszki, Csilla András, Gábor Méhes
    International Journal of Molecular Sciences.2023; 24(3): 2581.     CrossRef
  • Benefits of Adjuvant Chemotherapy for Clinical T3-4N0 Rectal Cancer After Preoperative Chemoradiotherapy
    Hyun Jin Bang, Hyun Jeong Shim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung, Sang Hee Cho
    Chonnam Medical Journal.2023; 59(1): 76.     CrossRef
  • The prognostic role of tumor budding and tumor-stroma ratio in pulmonary metastasis of colorectal carcinoma
    Topias Karjula, Niko Kemi, Anne Niskakangas, Olli Mustonen, Iiris Puro, Vesa-Matti Pohjanen, Teijo Kuopio, Hanna Elomaa, Maarit Ahtiainen, Jukka-Pekka Mecklin, Toni T. Seppälä, Erkki-Ville Wirta, Eero Sihvo, Juha P. Väyrynen, Fredrik Yannopoulos, Olli Hel
    European Journal of Surgical Oncology.2023; 49(7): 1298.     CrossRef
  • An investigation into tumor regression grade as a parameter for locally advanced rectal cancer and 5-year overall survival rate
    Supparerk Laohawiriyakamol, Wongsakorn Chaochankit, Worawit Wanichsuwan, Kanet Kanjanapradit, Teeranan Laohawiriyakamol
    Annals of Coloproctology.2023; 39(1): 59.     CrossRef
  • Deep learning of endoscopic features for the assessment of neoadjuvant therapy response in locally advanced rectal cancer
    Anqi Wang, Jieli Zhou, Gang Wang, Beibei Zhang, Hongyi Xin, Haiyang Zhou
    Asian Journal of Surgery.2023; 46(9): 3568.     CrossRef
  • Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy alone for patients with locally advanced rectal cancer: a propensity-score-matched analysis combined with SEER validation
    Jingjing Wu, Mingzhe Huang, Yuanhui Wu, Yisong Hong, Linbin Cai, Rongzhao He, Yanxin Luo, Puning Wang, Meijin Huang, Jinxin Lin
    Journal of Cancer Research and Clinical Oncology.2023; 149(11): 8897.     CrossRef
  • A multi-class classification algorithm based on hematoxylin-eosin staining for neoadjuvant therapy in rectal cancer: a retrospective study
    Yihan Wu, Xiaohua Liu, Fang Liu, Yi Li, Xiaomin Xiong, Hao Sun, Bo Lin, Yu Li, Bo Xu
    PeerJ.2023; 11: e15408.     CrossRef
  • Early Age of Onset Is an Independent Predictor for a Worse Response to Neoadjuvant Therapies in Sporadic Rectal Cancer Patients
    Caterina Foppa, Annalisa Maroli, Antonio Luberto, Carlotta La Raja, Paola Spaggiari, Cristiana Bonifacio, Stefano De Zanet, Marco Montorsi, Salvatore Piscuoglio, Luigi Maria Terracciano, Armando Santoro, Antonino Spinelli
    Cancers.2023; 15(14): 3750.     CrossRef
  • Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
    I-Li Lai, Jeng-Fu You, Wen-Sy Tsai, Yu-Jen Hsu, Yih-Jong Chern, Ming-Ying Wu
    World Journal of Surgical Oncology.2023;[Epub]     CrossRef
  • Risk factors for lateral pelvic lymph node metastasis in patients with lower rectal cancer: a systematic review and meta-analysis
    De-xing Zeng, Zhou Yang, Ling Tan, Meng-ni Ran, Zi-lin Liu, Jiang-wei Xiao
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Clinical predictors of rectal cancer response after neo-adjuvant (Chemo)Radiotherapy in Australia and New Zealand: Analysis of the Bi-National Colorectal Cancer Audit (BCCA)
    Jianliang Liu, Justin Y.T. Lee, Sergei Bedrikovetski, Luke Traeger, James W. Moore, Joanne L. Perry, Hidde M. Kroon, Tarik Sammour
    European Journal of Surgical Oncology.2023; 49(11): 107070.     CrossRef
  • Pancreatic ductal adenocarcinoma complete regression after preoperative chemotherapy: Surgical results in a small series
    Domenico Pinelli, Andrea Micalef, Barbara Merelli, Rosangela Trezzi, Annalisa Amaduzzi, Stefano Agnesi, Michela Guizzetti, Stefania Camagni, Veronica Fedele, Michele Colledan
    Cancer Treatment and Research Communications.2023; 37: 100770.     CrossRef
  • The ypT may better predict the efficacy of neoadjuvant chemoradiotherapy than tumor regression grade in locally advanced rectal cancer patients diagnosed ypT1-4N0
    Yujun Cui, Xinzhi Liu, Shuai Li, Hongzhi Wang, Yirong Xiang, Yangzi Zhang, Maxiaowei Song, Jianhao Geng, Zhiyan Liu, Huajing Teng, Xianggao Zhu, Yong Cai, Yongheng Li, Weihu Wang
    Clinical and Translational Oncology.2023; 26(4): 1012.     CrossRef
  • Grading der Tumorregression gastrointestinaler Karzinome nach neoadjuvanter Therapie
    Drolaiz Liu, Rupert Langer
    Der Pathologe.2022; 43(1): 51.     CrossRef
  • Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment
    Lasse Slumstrup, Susanne Eiholm, Astrid Louise Bjørn Bennedsen, Dea Natalie Munch Jepsen, Ismail Gögenur, Anne-Marie Kanstrup Fiehn
    Virchows Archiv.2022; 480(5): 1041.     CrossRef
  • MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy
    Jaeseung Shin, Nieun Seo, Song-Ee Baek, Nak-Hoon Son, Joon Seok Lim, Nam Kyu Kim, Woong Sub Koom, Sungwon Kim
    Radiology.2022; 303(2): 351.     CrossRef
  • Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer
    Laureline Lamy, Jacques Thomas, Agnès Leroux, Jean-François Bisson, Kari Myren, Aslak Godal, Gry Stensrud, Lina Bezdetnaya
    Biomedicines.2022; 10(3): 548.     CrossRef
  • High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates
    Serdar Karakaya, İbrahim Karadağ, Mehmet Emin Yılmaz, Ömür Berna Çakmak Öksüzoğlu
    Cureus.2022;[Epub]     CrossRef
  • Development of a method for digital assessment of tumor regression grade in patients with rectal cancer following neoadjuvant therapy
    Dea Natalie Munch Jepsen, Henrik Høeg, Jeppe Thagaard, Julie Sparholt Walbech, Ismail Gögenur, Anne-Marie Kanstrup Fiehn
    Journal of Pathology Informatics.2022; 13: 100152.     CrossRef
  • The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression
    Fengpeng Wu, Xiaoxiao Zhang, Congrong Yang, Kanghua Wang, Linlin Xiao, Chaoxi Zhou, Xinming Zhao, Guiying Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
    Siwon Jang, Jeong Min Lee, Jeong Hee Yoon, Jae Seok Bae
    Abdominal Radiology.2021; 46(4): 1468.     CrossRef
  • Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer
    Peige Zhou, Paolo Goffredo, Timothy Ginader, Dakota Thompson, Jennifer Hrabe, Irena Gribovskaja‐Rupp, Muneera Kapadia, Imran Hassan
    Journal of Surgical Oncology.2021; 123(1): 278.     CrossRef
  • Clinical predictors of response to chemoradiotherapy for rectal cancer as an aid to organ preservation
    Jesse Fischer, Tim W. Eglinton, Frank A. Frizelle
    ANZ Journal of Surgery.2021; 91(6): 1190.     CrossRef
  • Can the mesorectal fat tissue volume be used as a predictive factor in foreseeing the response to neoadjuvant chemoradiotherapy in rectum cancer? A CT-based preliminary study
    Okan Dilek, Huseyin Akkaya, Cenk Parlatan, Tolga Koseci, Zeynel Abidin Tas, Gökhan Soker, Bozkurt Gulek
    Abdominal Radiology.2021; 46(6): 2415.     CrossRef
  • Pathological response post neoadjuvant therapy for locally advanced rectal cancer is an independent predictor of survival
    Jason On, Joanna Shim, Craig Mackay, Graeme Murray, Leslie Samuel, Craig Parnaby, George Ramsay
    Colorectal Disease.2021; 23(6): 1326.     CrossRef
  • Complete pathological response in rectal cancer utilising novel treatment strategies for neo-adjuvant therapy: A systematic review
    K. Wilson, M. Flood, V. Narasimhan, T. Pham, S. Warrier, R. Ramsay, M. Michael, A. Heriot
    European Journal of Surgical Oncology.2021; 47(8): 1862.     CrossRef
  • Contemporary snapshot of tumor regression grade (TRG) distribution in locally advanced rectal cancer: a cross sectional multicentric experience
    Paola Germani, Francesca Di Candido, Daniel Léonard, Dajana Cuicchi, Ugo Elmore, Marco Ettore Allaix, Vittoria Pia Barbieri, Laura D’Allens, Seraina Faes, Marika Milani, Damiano Caputo, Carmen Martinez, Jan Grosek, Valerio Caracino, Niki Christou, Sapho X
    Updates in Surgery.2021; 73(5): 1795.     CrossRef
  • The value of the tumour-stroma ratio for predicting neoadjuvant chemoradiotherapy response in locally advanced rectal cancer: a case control study
    Yanting Liang, Yaxi Zhu, Huan Lin, Shenyan Zhang, Suyun Li, Yanqi Huang, Chen Liu, Jinrong Qu, Changhong Liang, Ke Zhao, Zhenhui Li, Zaiyi Liu
    BMC Cancer.2021;[Epub]     CrossRef
  • Can histologic features predict neoadjuvant therapy response in rectal adenocarcinoma?
    Yuho Ono, Justin M.M. Cates, Raul S. Gonzalez
    Pathology - Research and Practice.2021; 226: 153608.     CrossRef
  • A 41-Gene Pair Signature for Predicting the Pathological Response of Locally Advanced Rectal Cancer to Neoadjuvant Chemoradiation
    Zhengfa Xue, Shuxin Yang, Yun Luo, Hao Cai, Ming He, Youping Ding, Lei Lei, Wei Peng, Guini Hong, You Guo
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Validation of Gene Expression-Based Predictive Biomarkers for Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
    Tomoyuki Momma, Hirokazu Okayama, Yasuyuki Kanke, Satoshi Fukai, Hisashi Onozawa, Shotaro Fujita, Wataru Sakamoto, Motonobu Saito, Shinji Ohki, Koji Kono
    Cancers.2021; 13(18): 4642.     CrossRef
  • Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey
    Maria Westerhoff, Marek Osecky, Rupert Langer
    Modern Pathology.2020; 33(4): 676.     CrossRef
  • Importance of the neoadjuvant rectal (NAR) score to the outcome of neoadjuvant chemotherapy alone for locally advanced rectal cancer
    Toshiki Mukai, Keisuke Uehara, Toshisada Aiba, Atsushi Ogura, Toyonori Tsuzuki, Aya Tanaka, Masanori Sando, Noriyuki Ohara, Yusuke Sato, Norifumi Hattori, Goro Nakayama, Yasuhiro Kodera, Masato Nagino
    Surgery Today.2020; 50(8): 912.     CrossRef
  • The Effect of Lymph Nodes’ Histologic Response on Survival Outcomes in Moroccan Patients with Rectal Cancer
    Ihsane El Otmani, Fatima El Agy, Mohammed El Abkari, Karim Ibn Majdoub Hassani, Khalid Mazaz, El Bachir Benjelloun, Khalid Ait Taleb, Touria Bouhafa, Zineb Benbrahim, Sidi Adil Ibrahimi, Laila Chbani
    International Journal of Surgical Oncology.2020; 2020: 1.     CrossRef
  • Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus
    Flávio Roberto Takeda, Francisco Tustumi, Carlos de Almeida Obregon, Gustavo Gonçalves Yogolare, Yasmin Peres Navarro, Vanderlei Segatelli, Rubens Antonio Aissar Sallum, Ulysses Ribeiro Junior, Ivan Cecconello
    Annals of Surgical Oncology.2020; 27(4): 1241.     CrossRef
  • Standardized Pathology Report for Colorectal Cancer, 2nd Edition
    Baek-hui Kim, Joon Mee Kim, Gyeong Hoon Kang, Hee Jin Chang, Dong Wook Kang, Jung Ho Kim, Jeong Mo Bae, An Na Seo, Ho Sung Park, Yun Kyung Kang, Kyung-Hwa Lee, Mee Yon Cho, In-Gu Do, Hye Seung Lee, Hee Kyung Chang, Do Youn Park, Hyo Jeong Kang, Jin Hee So
    Journal of Pathology and Translational Medicine.2020; 54(1): 1.     CrossRef
  • Genomic variation as a marker of response to neoadjuvant therapy in locally advanced rectal cancer
    Jason K. Douglas, Rose E. Callahan, Zachary A. Hothem, Craig S. Cousineau, Samer Kawak, Bryan J. Thibodeau, Shelli Bergeron, Wei Li, Claire E. Peeples, Harry J. Wasvary
    Molecular & Cellular Oncology.2020; 7(3): 1716618.     CrossRef
  • 53BP1 expression and immunoscore are associated with the efficacy of neoadjuvant chemoradiotherapy for rectal cancer
    Ai Huang, Yong Xiao, Chunfen Peng, Tao Liu, Zhenyu Lin, Qin Yang, Tao Zhang, Jun Liu, Hong Ma
    Strahlentherapie und Onkologie.2020; 196(5): 465.     CrossRef
  • Predictors of pathological response and clinical outcome following chemoradiation for locally advanced rectal cancer — a systematic review
    Erica Amaral, Maria Bernardes, Sara Ribeiro, Beatriz Rosa, Ana Pereira, Sandra F. Martins
    Journal of Coloproctology.2020; 40(03): 278.     CrossRef
  • The effect of radiotherapy on rectal cancer: a histopathological appraisal and prognostic indicators
    Mohammad AlQudah, Emil Salmo, Najib Haboubi
    Radiation Oncology Journal.2020; 38(2): 77.     CrossRef
  • Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial
    Mahdi Aghili, Nastaran Khalili, Neda Khalili, Mohammad Babaei, Farshid Farhan, Peiman Haddad, Samaneh Salarvand, Amir Keshvari, Mohammad Sadegh Fazeli, Negin Mohammadi, Reza Ghalehtaki
    Radiation Oncology Journal.2020; 38(2): 119.     CrossRef
  • Pre-Treatment T2-WI Based Radiomics Features for Prediction of Locally Advanced Rectal Cancer Non-Response to Neoadjuvant Chemoradiotherapy: A Preliminary Study
    Bianca Petresc, Andrei Lebovici, Cosmin Caraiani, Diana Sorina Feier, Florin Graur, Mircea Marian Buruian
    Cancers.2020; 12(7): 1894.     CrossRef
  • Preoperative Fibrinogen-Albumin Ratio Index (FARI) is a Reliable Prognosis and Chemoradiotherapy Sensitivity Predictor in Locally Advanced Rectal Cancer Patients Undergoing Radical Surgery Following Neoadjuvant Chemoradiotherapy


    Siyi Lu, Zhenzhen Liu, Xin Zhou, Bingyan Wang, Fei Li, Yanpeng Ma, Wendong Wang, Junren Ma, Yuxia Wang, Hao Wang, Wei Fu
    Cancer Management and Research.2020; Volume 12: 8555.     CrossRef
  • Staging of Locally Advanced Rectal Cancer Beyond TME
    Deborah S. Keller
    Clinics in Colon and Rectal Surgery.2020; 33(05): 258.     CrossRef
  • Tumor Regression in Lymph Node Metastases of Esophageal Adenocarcinomas after Neoadjuvant Therapy
    Marek Osecky, Dino Kröll, Marcus Feith, Daniel Reim, Bastian Dislich, Karen Becker, Rupert Langer
    Gastrointestinal Disorders.2020; 2(4): 397.     CrossRef
  • Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer
    Chinock Cheong, Jun Sang Shin, Kwang Wook Suh
    World Journal of Gastroenterology.2020; 26(44): 7022.     CrossRef
  • MicroRNA Profiling in Oesophageal Adenocarcinoma Cell Lines and Patient Serum Samples Reveals a Role for miR-451a in Radiation Resistance
    Frederike Butz, Ann-Kathrin Eichelmann, George C. Mayne, Tingting Wang, Isabell Bastian, Karen Chiam, Shashikanth Marri, Pamela J. Sykes, Bas P. Wijnhoven, Eelke Toxopeus, Michael Z. Michael, Christos S. Karapetis, Richard Hummel, David I. Watson, Damian
    International Journal of Molecular Sciences.2020; 21(23): 8898.     CrossRef
  • Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer
    Heyu Song, Jiping Zeng, Shrabasti Roychoudhury, Pranjal Biswas, Bhopal Mohapatra, Sutapa Ray, Kayvon Dowlatshahi, Jing Wang, Vimla Band, Geoffrey Talmon, Kishor K. Bhakat
    Molecular Cancer Therapeutics.2020; 19(1): 258.     CrossRef
  • Tumor regression grade as a clinically useful outcome predictor in patients with rectal cancer after preoperative chemoradiotherapy
    Jung Wook Huh, Hee Cheol Kim, Seok Hyung Kim, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Woo Yong Lee, Hee Chul Park, Doo Ho Choi, Joon Oh Park, Young Suk Park, Ho-Kyung Chun
    Surgery.2019; 165(3): 579.     CrossRef
  • Tumour regression after radiotherapy for rectal cancer – Results from the randomised Stockholm III trial
    Johan Erlandsson, Ester Lörinc, Madelene Ahlberg, David Pettersson, Torbjörn Holm, Bengt Glimelius, Anna Martling
    Radiotherapy and Oncology.2019; 135: 178.     CrossRef
  • Differences in prognostic relevance of rectal magnetic resonance imaging findings before and after neoadjuvant chemoradiotherapy
    Kwang-Seop Song, Dong Woon Lee, Bun Kim, Bo Yun Hur, Min Jung Kim, Min Ju Kim, Chang Won Hong, Sung Chan Park, Hyoung-Chul Park, Dae Kyung Sohn, Byung Chang Kim, Kyung Su Han, Jae Hwan Oh
    Scientific Reports.2019;[Epub]     CrossRef
  • A prospective feasibility study evaluating the role of multimodality imaging and liquid biopsy for response assessment in locally advanced rectal carcinoma
    Zahra Kassam, Kyle Burgers, Joanna C. Walsh, Ting-Yim Lee, Hon S. Leong, Barbara Fisher
    Abdominal Radiology.2019; 44(11): 3641.     CrossRef
  • Pretreatment Blood Biomarkers Predict Pathologic Responses to Neo-Crt in Patients with Locally Advanced Rectal Cancer
    Aijie Li, Kewen He, Dong Guo, Chao Liu, Duoying Wang, Xiangkui Mu, Jinming Yu
    Future Oncology.2019; 15(28): 3233.     CrossRef
  • Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients’ Prognosis
    Giuseppe N. Fanelli, Fotios Loupakis, Elizabeth Smyth, Marco Scarpa, Sara Lonardi, Salvatore Pucciarelli, Giada Munari, Massimo Rugge, Nicola Valeri, Matteo Fassan
    International Journal of Surgical Pathology.2019; 27(8): 816.     CrossRef
  • Translational Potential of MicroRNAs for Preoperative Staging and Prediction of Chemoradiotherapy Response in Rectal Cancer
    Tana Machackova, Vladimir Prochazka, Zdenek Kala, Ondrej Slaby
    Cancers.2019; 11(10): 1545.     CrossRef
  • Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy
    Qunsheng Huang, Huabo Qin, Jian Xiao, Xiaosheng He, Minghao Xie, Xin He, Qiuqiong Yao, Ping Lan, Lei Lian
    Gastroenterology Report.2019; 7(4): 283.     CrossRef
  • Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma
    M. L. Sánchez de Molina, C. Díaz del Arco, P. Vorwald, D. García-Olmo, L. Estrada, M. J. Fernández-Aceñero
    Clinical and Translational Oncology.2018; 20(2): 253.     CrossRef
  • Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy
    Rupert Langer, Karen Becker
    Virchows Archiv.2018; 472(2): 175.     CrossRef
  • Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)
    Roger von Moos, Dieter Koeberle, Sabina Schacher, Stefanie Hayoz, Ralph C. Winterhalder, Arnaud Roth, György Bodoky, Panagiotis Samaras, Martin D. Berger, Daniel Rauch, Piercarlo Saletti, Ludwig Plasswilm, Daniel Zwahlen, Urs R. Meier, Pu Yan, Paola Izzo,
    European Journal of Cancer.2018; 89: 82.     CrossRef
  • A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers
    You Guo, Weizhong Jiang, Lu Ao, Kai Song, Huxing Chen, Qingzhou Guan, Qiao Gao, Jun Cheng, Huaping Liu, Xianlong Wang, Guoxian Guan, Zheng Guo
    Radiotherapy and Oncology.2018; 129(1): 149.     CrossRef
  • Prediction of lateral pelvic lymph node metastasis in patients with locally advanced rectal cancer with preoperative chemoradiotherapy: Focus on MR imaging findings
    Min Ju Kim, Bo Yun Hur, Eun Sun Lee, Boram Park, Jungnam Joo, Min Jung Kim, Sung Chan Park, Ji Yeon Baek, Hee Jin Chang, Dae Yong Kim, Jae Hwan Oh, Ju-Seog Lee
    PLOS ONE.2018; 13(4): e0195815.     CrossRef
  • Magnetic resonance tumour regression grade and pathological correlates in patients with rectal cancer
    J K Jang, J L Lee, S H Park, H J Park, I J Park, J H Kim, S H Choi, J Kim, C S Yu, J C Kim
    British Journal of Surgery.2018; 105(12): 1671.     CrossRef
  • Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System
    Changhoon Song, Joo-Hyun Chung, Sung-Bum Kang, Duck-Woo Kim, Heung-Kwon Oh, Hye Seung Lee, Jin Won Kim, Keun-Wook Lee, Jee Hyun Kim, Jae-Sung Kim
    Cancers.2018; 10(9): 319.     CrossRef
  • Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer
    Karina Vychnevskaia, Frederic Dumont, Julie Agostini, Catherine Julié, Peggy Dartigues, Thierry Lazure, Valérie Boige, Diane Goéré, Antoine Brouquet, Christophe Penna, Frédérique Peschaud, Stéphane Benoist
    Annals of Surgical Oncology.2017; 24(5): 1304.     CrossRef
  • Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer
    Delphine Dayde, Ichidai Tanaka, Rekha Jain, Mei Tai, Ayumu Taguchi
    International Journal of Molecular Sciences.2017; 18(3): 573.     CrossRef
  • Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy
    Luca Reggiani Bonetti, Simona Lionti, Federica Domati, Giuliana Pagliani, Elisabetta Mattioli, Valeria Barresi
    Histopathology.2017; 71(3): 393.     CrossRef
  • Applicability of American Joint Committee on Cancer and College of American Pathologists Regression Grading System in Rectal Cancer
    Tarkan Jäger, Daniel Neureiter, Romana Urbas, Eckhard Klieser, Wolfgang Hitzl, Klaus Emmanuel, Adam Dinnewitzer
    Diseases of the Colon & Rectum.2017; 60(8): 815.     CrossRef
  • Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer
    Dae Kyung Sohn, Kyung Su Han, Byung Chang Kim, Chang Won Hong, Hee Jin Chang, Ji Yeon Baek, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Dae Yong Kim
    Surgical Oncology.2017; 26(4): 453.     CrossRef
  • Do pathological variables have prognostic significance in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and surgery?
    Luca Reggiani Bonetti, Simona Lionti, Federica Domati, Valeria Barresi
    World Journal of Gastroenterology.2017; 23(8): 1412.     CrossRef
  • Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy
    Ombretta Repetto, Valli De Re, Antonino De Paoli, Claudio Belluco, Lara Alessandrini, Vincenzo Canzonieri, Renato Cannizzaro
    Oncotarget.2017; 8(17): 28328.     CrossRef
  • Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers
    You Guo, Jun Cheng, Lu Ao, Xiangyu Li, Qingzhou Guan, Juan Zhang, Haidan Yan, Hao Cai, Qiao Gao, Weizhong Jiang, Zheng Guo
    Scientific Reports.2016;[Epub]     CrossRef
  • Analysis of long-term outcomes and application of the tumor regression grading system in the therapeutic assessment of resectable limited-disease small cell lung cancer
    Shuonan Xu, Jianfei Zhu, Yawei Dou, Wei Tian, Yun Dai, Xianghui Luo, Hongtao Wang
    Oncology and Translational Medicine.2016; 2(5): 227.     CrossRef
  • 26,263 View
  • 571 Download
  • 94 Web of Science
  • 89 Crossref
Close layer
Endoscopic Criteria for Evaluating Tumor Stage after Preoperative Chemoradiation Therapy in Locally Advanced Rectal Cancer
Kyung Su Han, Dae Kyung Sohn, Dae Yong Kim, Byung Chang Kim, Chang Won Hong, Hee Jin Chang, Sun Young Kim, Ji Yeon Baek, Sung Chan Park, Min Ju Kim, Jae Hwan Oh
Cancer Res Treat. 2016;48(2):567-573.   Published online September 22, 2015
DOI: https://doi.org/10.4143/crt.2015.195
AbstractAbstract PDFPubReaderePub
Purpose
Local excision may be an another option for selected patients with markedly down-staged rectal cancer after preoperative chemoradiation therapy (CRT), and proper evaluation of post-CRT tumor stage (ypT) is essential prior to local excision of these tumors. This study was designed to determine the correlations between endoscopic findings and ypT of rectal cancer.
Materials and Methods
In this study, 481 patients with locally advanced rectal cancer who underwent preoperative CRT followed by surgical resection between 2004 and 2013 at a single institution were evaluated retrospectively. Pathological good response (p-GR) was defined as ypT ≤ 1, and pathological minimal or no response (p-MR) as ypT ≥ 2. The patients were randomly classified according to two groups, a testing (n=193) and a validation (n=288) group. Endoscopic criteria were determined from endoscopic findings and ypT in the testing group and used in classifying patients in the validation group as achieving or not achieving p-GR.
Results
Based on findings in the testing group, the endoscopic criteria for p-GR included scarring, telangiectasia, and erythema, whereas criteria for p-MR included nodules, ulcers, strictures, and remnant tumors. In the validation group, the kappa statistic was 0.965 (p < 0.001), and the sensitivity, specificity, positive predictive value, and negative predictive value were 0.362, 0.963, 0.654, and 0.885, respectively.
Conclusion
The endoscopic criteria presented are easily applicable for evaluation of ypT after preoperative CRT for rectal cancer. These criteria may be used for selection of patients for local excision of down-staged rectal tumors, because patients with p-MR could be easily ruled out.

Citations

Citations to this article as recorded by  
  • The value of multimodality MR in T staging evaluation after neoadjuvant therapy for rectal cancer
    Bin Liu, Chuan Sun, Xinyu Zhao, Lingyu Liu, Shuang Liu, Haichuan Ma
    Technology and Health Care.2024; 32(2): 615.     CrossRef
  • Feasibility of endoscopic techniques in assessing the radicality of chemoradiotherapy in patients with rectal cancer
    A. A. Salimova, M. V. Makarova, M. Yu. Kurdanova, Yu. P. Kuvshinov, I. A. Karasev, T. S. Davydkina
    Surgery and Oncology.2024; 14(2): 48.     CrossRef
  • Clinical predictors of pathological good response in locally advanced rectal cancer
    Kongfeng Shao, Rong Zheng, Anchuan Li, Xiaobo Li, Benhua Xu
    Radiation Oncology.2021;[Epub]     CrossRef
  • A prospective clinical study assessing the presence of exfoliated cancer cells and rectal washout including tumors in patients who receive neoadjuvant chemoradiotherapy for rectal cancer
    Kazutake Okada, Sotaro Sadahiro, Yutaro Kamei, Lin Fung Chan, Takashi Ogimi, Hiroshi Miyakita, Gota Saito, Akira Tanaka, Toshiyuki Suzuki
    Surgery Today.2020; 50(4): 352.     CrossRef
  • Oncologic Risk of Rectal Preservation Against Medical Advice After Chemoradiotherapy for Rectal Cancer: A Multicenter Comparative Cross‐Sectional Study with Rectal Preservation as Supported by Surgeon
    Kwang‐Seop Song, Sung Chan Park, Dae Kyung Sohn, Jae Hwan Oh, Min Jung Kim, Ji Won Park, Seung‐Bum Ryoo, Seung‐Yong Jeong, Kyu Joo Park, Heung‐Kwon Oh, Duck‐Woo Kim, Sung‐Bum Kang
    World Journal of Surgery.2019; 43(12): 3216.     CrossRef
  • Endoscopic assessment of tumor regression after preoperative chemoradiotherapy as a prognostic marker in locally advanced rectal cancer
    Dae Kyung Sohn, Kyung Su Han, Byung Chang Kim, Chang Won Hong, Hee Jin Chang, Ji Yeon Baek, Min Ju Kim, Sung Chan Park, Jae Hwan Oh, Dae Yong Kim
    Surgical Oncology.2017; 26(4): 453.     CrossRef
  • Advances in organ preserving strategies in rectal cancer patients
    Rutger CH. Stijns, Mike-Stephen R. Tromp, Niek Hugen, Johannes HW de Wilt
    European Journal of Surgical Oncology.2017;[Epub]     CrossRef
  • 12,292 View
  • 124 Download
  • 9 Web of Science
  • 7 Crossref
Close layer
Robotic Versus Laparoscopic Surgery for Rectal Cancer after Preoperative Chemoradiotherapy: Case-Matched Study of Short-Term Outcomes
Yong Sok Kim, Min Jung Kim, Sung Chan Park, Dae Kyung Sohn, Dae Yong Kim, Hee Jin Chang, Byung-Ho Nam, Jae Hwan Oh
Cancer Res Treat. 2016;48(1):225-231.   Published online March 11, 2015
DOI: https://doi.org/10.4143/crt.2014.365
AbstractAbstract PDFPubReaderePub
Purpose
Robotic surgery is expected to have advantages over laparoscopic surgery; however, there are limited data regarding the feasibility of robotic surgery for rectal cancer after preoperative chemoradiotherapy (CRT). Therefore, we evaluated the short-term outcomes of robotic surgery for rectal cancer. Materials and Methods Thirty-three patients with cT3N0-2 rectal cancer after preoperative CRT who underwent robotic low anterior resection (R-LAR) between March 2010 and January 2012 were matched with 66 patients undergoing laparoscopic low anterior resection (L-LAR). Perioperative clinical outcomes and pathological data were compared between the two groups.
Results
Patient characteristics did not differ significantly different between groups. The mean operation time was 441 minutes (R-LAR) versus 277 minutes (L-LAR; p < 0.001). The open conversion rate was 6.1% in the R-LAR group and 0% in the L-LAR group (p=0.11). There were no significant differences in the time to flatus passage, length of hospital stay, and postoperative morbidity. In pathological review, the mean number of harvested lymph nodes was 22.3 in R-LAR and 21.6 in L-LAR (p=0.82). Involvement of circumferential resection margin was positive in 16.1% and 6.7%, respectively (p=0.42). Total mesorectal excision (TME) quality was complete in 97.0% in R-LAR and 91.0% in L-LAR (p=0.41). Conclusion In our study, short-term outcomes of robotic surgery for rectal cancer after CRT were similar to those of laparoscopic surgery in respect to bowel function recovery, morbidity, and TME quality. Well-designed clinical trials are needed to evaluate the functional results and longterm outcomes of robotic surgery for rectal cancer.

Citations

Citations to this article as recorded by  
  • Comparison of efficacy and safety between robotic-assisted versus laparoscopic surgery for locally advanced mid-low rectal cancer following neoadjuvant chemoradiotherapy: a systematic review and meta-analysis
    Xin-Mao Zhu, Xiao Bai, Hai-Qi Wang, Dong-Qiu Dai
    International Journal of Surgery.2025; 111(1): 1154.     CrossRef
  • The role of robotic-assisted surgery in the management of rectal cancer: a systematic review and meta-analysis
    Chenxiong Zhang, Hao Tan, Han Xu, Jiaming Ding
    International Journal of Surgery.2024; 110(10): 6282.     CrossRef
  • Robotic-Assisted versus Laparoscopic Surgery for Rectal Cancer: An Analysis of Clinical and Financial Outcomes from a Tertiary Referral Center
    Jasper Max Gebhardt, Neno Werner, Andrea Stroux, Frank Förster, Ioannis Pozios, Claudia Seifarth, Christian Schineis, Benjamin Weixler, Katharina Beyer, Johannes Christian Lauscher
    Journal of Clinical Medicine.2024; 13(6): 1795.     CrossRef
  • Association of Surgical Approaches and Outcomes in Total Mesorectal Excision and Margin Status for Rectal Cancer
    Muhammad Bilal Mirza, Adriana C. Gamboa, Rebecca Irlmeier, Benjamin Hopkins, Scott E. Regenbogen, Katherine A. Hrebinko, Jennifer Holder-Murray, Jason T. Wiseman, Aslam Ejaz, Paul E. Wise, Fei Ye, Kamran Idrees, Alexander T. Hawkins, Glen C. Balch, Aimal
    Journal of Surgical Research.2024; 300: 494.     CrossRef
  • Rapidez y Precisión en la Comunicación en Tiempo Real entre el Laboratorio Clínico y el Médico durante la Cirugía Robótica
    Alfredo Ibarra-Sánchez, Claudia Soto-Félix, Leticia Cano-Barraza, Delia Barraza-Sámano
    Estudios y Perspectivas Revista Científica y Académica .2024; 4(4): 1463.     CrossRef
  • Surgical outcomes of robotic, laparoscopic, and open low anterior resection after preoperative chemoradiotherapy for patients with advanced lower rectal cancer
    Sukchol Lim, Yuzo Nagai, Hiroaki Nozawa, Kazushige Kawai, Kazuhito Sasaki, Koji Murono, Shigenobu Emoto, Yuichiro Yokoyama, Tsuyoshi Ozawa, Shinya Abe, Hiroyuki Anzai, Hirofumi Sonoda, Soichiro Ishihara
    Surgery Today.2023; 53(1): 109.     CrossRef
  • Operative and oncological outcomes after robotic rectal resection compared with laparoscopy: a systematic review and meta‐analysis
    Julie Flynn, Jose T. Larach, Joseph C. H. Kong, Jessica Rahme, Peadar S. Waters, Satish K. Warrier, Alexander Heriot
    ANZ Journal of Surgery.2023; 93(3): 510.     CrossRef
  • Comparison of Operative Time Between Robotic and Laparoscopic Low Anterior Resection for Rectal Cancer:A Systematic Review and Meta-Analysis
    Zhen Chen, Hua Yu, Huaping Wu, Pingxi Wang, Fanwei Zeng
    Surgical Innovation.2023; 30(3): 390.     CrossRef
  • Robotic Rectal Resection for Rectal Cancer in Elderly Patients: A Systematic Review and Meta-Analysis
    Rossella Reddavid, Silvia Sofia, Lucia Puca, Jacopo Moro, Simona Ceraolo, Rosa Jimenez-Rodriguez, Maurizio Degiuli
    Journal of Clinical Medicine.2023; 12(16): 5331.     CrossRef
  • Short-term and long-term efficacy in robot-assisted treatment for mid and low rectal cancer: a systematic review and meta-analysis
    Huiming Wu, Renkai Guo, Huiyu Li
    International Journal of Colorectal Disease.2023;[Epub]     CrossRef
  • Robotic versus laparoscopic surgery for rectal cancer after neoadjuvant chemoradiotherapy: A propensity-score matching analysis
    Tzu-Chun Chen, Jin-Tung Liang
    Journal of the Formosan Medical Association.2022; 121(8): 1532.     CrossRef
  • Short‐term outcomes of robotic‐assisted surgery following neoadjuvant chemotherapy for lower rectal cancer
    Hajime Morohashi, Yoshiyuki Sakamoto, Takuya Miura, Daichi Ichinohe, Shunsuke Kubota, Keisuke Yamazaki, Aika Ichisawa, Yuto Mitsuhashi, Taiichi Wakiya, Kenichi Hakamada
    Asian Journal of Endoscopic Surgery.2022; 15(3): 577.     CrossRef
  • Robotic versus Laparoscopic Low Anterior Resection for Rectal Cancer
    Aba Khaled M. Farid Uddin
    World Journal of Colorectal Surgery.2022; 11(3): 47.     CrossRef
  • Oncological outcomes of robotic-assisted total mesorectal excision after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer
    Po-Jung Chen, Wei-Chih Su, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Tzu-Chieh Yin, Hsiang-Lin Tsai, Cheng-Jen Ma, Ching-Wen Huang, Jaw-Yuan Wang
    Asian Journal of Surgery.2021; 44(7): 957.     CrossRef
  • Difference in surgical outcomes of rectal cancer by study design: meta-analyses of randomized clinical trials, case-matched studies, and cohort studies
    N Hoshino, T Sakamoto, K Hida, Y Takahashi, H Okada, K Obama, T Nakayama
    BJS Open.2021;[Epub]     CrossRef
  • Postoperative complications observed with robotic versus laparoscopic surgery for the treatment of rectal cancer
    Chengkui Liu, Xiaoqing Li, Qingfeng Wang
    Medicine.2021; 100(36): e27158.     CrossRef
  • Robotic and robotic-assisted vs laparoscopic rectal cancer surgery: A meta-analysis of short-term and long-term results
    Guojun Tong, Guiyang Zhang, Zhaozheng Zheng
    Asian Journal of Surgery.2021;[Epub]     CrossRef
  • Robotic-Assisted vs. Standard Laparoscopic Surgery for Rectal Cancer Resection: A Systematic Review and Meta-Analysis of 19,731 Patients
    Kamil Safiejko, Radoslaw Tarkowski, Maciej Koselak, Marcin Juchimiuk, Aleksander Tarasik, Michal Pruc, Jacek Smereka, Lukasz Szarpak
    Cancers.2021; 14(1): 180.     CrossRef
  • Robotic versus Laparoscopic Colorectal Surgeries
    Anil Heroor, Aysha Khan, Kashish Jain, Akshay Patil, Hitesh Rajendra Singhavi
    Indian Journal of Colo-Rectal Surgery.2021; 4(1): 12.     CrossRef
  • Feasibility of robot-assisted surgery in elderly patients with rectal cancer
    Wei-Chih Su, Ching-Wen Huang, Cheng-Jen Ma, Po-Jung Chen, Hsiang-Lin Tsai, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yung-Sung Yeh, Jaw-Yuan Wang
    Journal of Minimal Access Surgery.2021; 17(2): 165.     CrossRef
  • Robotic surgery for colorectal disease: review of current port placement and future perspectives
    Jong Lyul Lee, Hassan A. Alsaleem, Jin Cheon Kim
    Annals of Surgical Treatment and Research.2020; 98(1): 31.     CrossRef
  • Comparison of clinical efficacy between robotic-laparoscopic excision and traditional laparoscopy for rectal cancer
    Zhen Chen, Zhuo Li Zhu, Pingxi Wang, Fanwei Zeng
    Medicine.2020; 99(27): e20704.     CrossRef
  • Oncological Outcomes of Robotic-Assisted Surgery With High Dissection and Selective Ligation Technique for Sigmoid Colon and Rectal Cancer
    Tzu-Chieh Yin, Wei-Chih Su, Po-Jung Chen, Tsung-Kun Chang, Yen-Cheng Chen, Ching-Chun Li, Yi-Chien Hsieh, Hsiang-Lin Tsai, Ching-Wen Huang, Jaw-Yuan Wang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Robotic Total Mesorectal Excision for Rectal Cancer: Current Evidences and Future Perspectives
    Je-Ho Jang, Chang-Nam Kim
    Annals of Coloproctology.2020; 36(5): 293.     CrossRef
  • Systematic review analysis of robotic and transanal approaches in TME surgery- A systematic review of the current literature in regard to challenges in rectal cancer surgery
    Julia K. Grass, Daniel R. Perez, Jakob R. Izbicki, Matthias Reeh
    European Journal of Surgical Oncology.2019; 45(4): 498.     CrossRef
  • Robotic Versus Conventional Laparoscopic Surgery for Colorectal Cancer: A Systematic Review and Meta‐Analysis with Trial Sequential Analysis
    Ka Ting Ng, Azlan Kok Vui Tsia, Vanessa Yu Ling Chong
    World Journal of Surgery.2019; 43(4): 1146.     CrossRef
  • Robotic versus conventional laparoscopic surgery for rectal cancer: systematic review and meta-analysis
    Xi-Yu Sun, Lai Xu, Jun-Yang Lu, Guan-Nan Zhang
    Minimally Invasive Therapy & Allied Technologies.2019; 28(3): 135.     CrossRef
  • Systemic review and network meta‐analysis comparing minimal surgical techniques for rectal cancer: quality of total mesorectum excision, pathological, surgical, and oncological outcomes
    Emanuele Rausa, Federica Bianco, Michael E. Kelly, Alberto Aiolfi, Fausto Petrelli, Gianluca Bonitta, Giovanni Sgroi
    Journal of Surgical Oncology.2019; 119(7): 987.     CrossRef
  • TME for rectal cancer: consecutive 70 patients treated with laparoscopic and robotic technique—cumulative experience in a single centre
    J. L. Mégevand, E. Lillo, M. Amboldi, L. Lenisa, A. Ambrosi, A. Rusconi
    Updates in Surgery.2019; 71(2): 331.     CrossRef
  • Completeness of total mesorectum excision of laparoscopic versus robotic surgery: a review with a meta-analysis
    Marco Milone, Michele Manigrasso, Nunzio Velotti, Stefania Torino, Antonietta Vozza, Giovanni Sarnelli, Giovanni Aprea, Francesco Maione, Nicola Gennarelli, Mario Musella, Giovanni Domenico De Palma
    International Journal of Colorectal Disease.2019; 34(6): 983.     CrossRef
  • Immediate results of robotic-assisted operations in colorectal surgery
    Yu. M. Stojko, A. V. Maksimenkov, A. L. Levchuk, D. A. Kolozyan
    Endoskopicheskaya khirurgiya.2019; 25(2): 5.     CrossRef
  • Short-Term Outcomes of Robotic versus Laparoscopic Total Mesorectal Excision for Rectal Cancer: A Cohort Study
    Wen-Han Liu, Pei-Jing Yan, Dong-Ping Hu, Peng-Hui Jin, Yao-Chun Lv, Rong Liu, Xiong-Fei Yang, Ke-Hu Yang, Tian-Kang Guo
    The American Surgeon™.2019; 85(3): 294.     CrossRef
  • Operative time and length of stay is similar between robotic assisted and laparoscopic colon and rectal resections
    Heather R. Nolan, Betsy E. Smith, Michael D. Honaker
    Journal of Robotic Surgery.2018; 12(4): 659.     CrossRef
  • Does robotic rectal cancer surgery improve the results of experienced laparoscopic surgeons? An observational single institution study comparing 168 robotic assisted with 184 laparoscopic rectal resections
    Rogier M. P. H. Crolla, Paul G. Mulder, George P. van der Schelling
    Surgical Endoscopy.2018; 32(11): 4562.     CrossRef
  • Robotic total meso-rectal excision for rectal cancer: A systematic review following the publication of the ROLARR trial
    Katie Jones, Mohamed G Qassem, Parv Sains, Mirza K Baig, Muhammad S Sajid
    World Journal of Gastrointestinal Oncology.2018; 10(11): 449.     CrossRef
  • Recent surgical advances in colorectal cancer excision: toward optimal outcomes
    Cihangir Akyol, Mehmet Ayhan Kuzu
    Colorectal Cancer.2017; 5(4): 147.     CrossRef
  • The safety and effectiveness of robot-assisted versus laparoscopic TME in patients with rectal cancer
    Xiaofei Li, Tao Wang, Liang Yao, Lidong Hu, Penghui Jin, Tiankang Guo, Kehu Yang
    Medicine.2017; 96(29): e7585.     CrossRef
  • Robotic-assisted total mesorectal excision with the single-docking technique for patients with rectal cancer
    Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Wei-Chih Su, Ming-Yii Huang, Chun-Ming Huang, Yu-Tang Chang, Jaw-Yuan Wang
    BMC Surgery.2017;[Epub]     CrossRef
  • Robotic Surgery for Rectal Cancer: An Update in 2015
    Jung Myun Kwak, Seon Hahn Kim
    Cancer Research and Treatment.2016; 48(2): 427.     CrossRef
  • La chirurgie robotique dans le cancer du rectum
    J. Coget, P. E. Colombo, A. Mourregot, D. Traoré, P. Rouanet
    Oncologie.2016; 18(5): 305.     CrossRef
  • Robot-assisted versus laparoscopic-assisted surgery for colorectal cancer: a meta-analysis
    Xuan Zhang, ZhengQiang Wei, MengJun Bie, XuDong Peng, Cheng Chen
    Surgical Endoscopy.2016; 30(12): 5601.     CrossRef
  • Robotics in Colorectal Surgery
    Allison Weaver, Scott Steele
    F1000Research.2016; 5: 2373.     CrossRef
  • 13,036 View
  • 134 Download
  • 41 Web of Science
  • 42 Crossref
Close layer
Phase I Dose-Escalation Study of Proton Beam Therapy for Inoperable Hepatocellular Carcinoma
Tae Hyun Kim, Joong-Won Park, Yeon-Joo Kim, Bo Hyun Kim, Sang Myung Woo, Sung Ho Moon, Sang Soo Kim, Young-Hwan Koh, Woo Jin Lee, Sang Jae Park, Joo-Young Kim, Dae Yong Kim, Chang-Min Kim
Cancer Res Treat. 2015;47(1):34-45.   Published online September 11, 2014
DOI: https://doi.org/10.4143/crt.2013.218
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to determine the optimal dose of proton beam therapy (PBT) in hepatocellular carcinoma (HCC) patients.
Materials and Methods
Inoperable HCC patients who had naïve, recurrent, or residual tumor to treatment were considered eligible for PBT. Patients received PBT with 60 GyE in 20 fractions (dose level 1; equivalent dose in 2 Gy fractions [EQD2], 65 GyE10); 66 GyE in 22 fractions (dose level 2; EQD2, 71.5 GyE10); or 72 GyE in 24 fractions (dose level 3; EQD2, 78 GyE10). Dose-limiting toxicity was determined by grade ≥ 3 acute toxicity.
Results
Twenty-seven patients were enrolled; eight, seven, and 12 patients were treated with dose levels 1, 2, and 3, respectively. Overall, treatment was well tolerated, with no dose-limiting toxicities. The complete response (CR) rates of primary tumors after PBT for dose levels 1, 2, and 3 were 62.5% (5/8), 57.1% (4/7), and 100% (12/12), respectively (p=0.039). The 3- and 5-year local progression-free survival (LPFS) rates among 26 patients, excluding one patient who underwent liver transplantation after PBT due to its probable significant effect on disease control, were 79.9% and 63.9%, respectively, and the 3- and 5-year overall survival rates were 56.4% and 42.3%, respectively. The 3-year LPFS rate was significantly higher in patients who achieved CR than in those who did not (90% vs. 40%, p=0.003).
Conclusion
PBT is safe and effective and an EQD2 ≥ 78 GyE10 should be delivered for achievement of local tumor control.

Citations

Citations to this article as recorded by  
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Katrin Borucki, Thomas Brunner, Reiner Caspari, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Jamila Gebert, Andreas Geier, Eleni Gkika, M
    Zeitschrift für Gastroenterologie.2025; 63(02): e82.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0
    Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(01): e67.     CrossRef
  • Tumor Response on Diagnostic Imaging after Proton Beam Therapy for Hepatocellular Carcinoma
    Hikaru Niitsu, Masashi Mizumoto, Yinuo Li, Masatoshi Nakamura, Toshiki Ishida, Takashi Iizumi, Takashi Saito, Haruko Numajiri, Hirokazu Makishima, Kei Nakai, Yoshiko Oshiro, Kazushi Maruo, Hideyuki Sakurai
    Cancers.2024; 16(2): 357.     CrossRef
  • S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
    Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho
    Zeitschrift für Gastroenterologie.2024; 62(02): e213.     CrossRef
  • Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
    Sun Hyun Bae, Won Il Jang, Hanna Rahbek Mortensen, Britta Weber, Mi Sook Kim, Morten Høyer
    Journal of Liver Cancer.2024; 24(2): 286.     CrossRef
  • Analytical calculation of proton beam Bragg curve inside heterogeneous media
    Behzad Aminafshar, Hamid Reza Baghani, Ali Asghar Mowlavi
    The European Physical Journal Plus.2024;[Epub]     CrossRef
  • Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma
    Takuto Nosaka, Hidetaka Matsuda, Ryotaro Sugata, Yu Akazawa, Kazuto Takahashi, Tatsushi Naito, Masahiro Ohtani, Kazuyuki Kinoshita, Tetsuya Tsujikawa, Yoshitaka Sato, Yoshikazu Maeda, Hiroyasu Tamamura, Yasunari Nakamoto
    Current Oncology.2023; 30(4): 3915.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
    Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau
    Zeitschrift für Gastroenterologie.2023; 61(04): e92.     CrossRef
  • Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
    Tae Hyun Kim, Bo Hyun Kim, Yu Ri Cho, Young-Hwan Koh, Joong-Won Park
    Journal of Liver Cancer.2023; 23(2): 330.     CrossRef
  • Current evidence and the potential role of proton beam therapy for hepatocellular carcinoma
    Sung Uk Lee, Tae Hyun Kim
    Clinical and Molecular Hepatology.2023; 29(4): 958.     CrossRef
  • S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms
    Voesch Sabrina, Bitzer Michael, Albert Jörg, Bartenstein Peter, Bechstein Wolf, Blödt Susanne, Brunner Thomas, Dombrowski Frank, Evert Matthias, Follmann Markus, La Fougère Christian, Freudenberger Paul, Geier Andreas, Gkika Eleni, Götz Martin, Hammes Elk
    Zeitschrift für Gastroenterologie.2022; 60(01): e56.     CrossRef
  • Proton Therapy in the Management of Hepatocellular Carcinoma
    Jana M. Kobeissi, Lara Hilal, Charles B. Simone, Haibo Lin, Christopher H. Crane, Carla Hajj
    Cancers.2022; 14(12): 2900.     CrossRef
  • Proton Beam Therapy for Treatment-Naïve Hepatocellular Carcinoma and Prognostic Significance of Albumin-Bilirubin (ALBI) Grade
    Tae Hyun Kim, Bo Hyun Kim, Joong-Won Park, Yu Ri Cho, Young-Hwan Koh, Jung Won Chun, Eun Sang Oh, Do Yeul Lee, Sung Uk Lee, Yang-Gun Suh, Sang Myung Woo, Sung Ho Moon, Sang Soo Kim, Woo Jin Lee
    Cancers.2022; 14(18): 4445.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma
    Tae Hyun Kim, Sang Myung Woo, Woo Jin Lee, Jung Won Chun, Yu Ri Cho, Bo Hyun Kim, Young-Hwan Koh, Sang Soo Kim, Eun Sang Oh, Do Yeul Lee, Sung Uk Lee, Yang-Gun Suh, Sung Ho Moon, Joong-Won Park
    Cancers.2022; 14(22): 5561.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • lncRNA MIR22HG-Derived miR-22-5p Enhances the Radiosensitivity of Hepatocellular Carcinoma by Increasing Histone Acetylation Through the Inhibition of HDAC2 Activity
    Qiao Jin, Hao Hu, Siqi Yan, Long Jin, Yuliang Pan, Xiangjun Li, Yayi Peng, Peiguo Cao
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West
    Sang Min Yoon
    Journal of Liver Cancer.2021; 21(1): 25.     CrossRef
  • Role of modern radiotherapy in managing patients with hepatocellular carcinoma
    Liang-Cheng Chen, Hon-Yi Lin, Shih-Kai Hung, Wen-Yen Chiou, Moon-Sing Lee
    World Journal of Gastroenterology.2021; 27(20): 2434.     CrossRef
  • Patterns of Proton Beam Therapy Use in Clinical Practice between 2007 and 2019 in Korea
    Sung Uk Lee, Kyungmi Yang, Sung Ho Moon, Yang-Gun Suh, Gyu Sang Yoo
    Cancer Research and Treatment.2021; 53(4): 935.     CrossRef
  • Current role of proton beam therapy in patients with hepatocellular carcinoma
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
    International Journal of Gastrointestinal Intervention.2021; 10(4): 175.     CrossRef
  • Clinical Effectiveness of Hypofractionated Proton Beam Therapy for Liver Metastasis From Breast Cancer
    Tae Hyun Kim, Keun Seok Lee, Sung Hoon Sim, Yeon-Joo Kim, Dae Yong Kim, Heejung Chae, Eun-Gyeong Lee, Jai Hong Han, So Youn Jung, Seeyoun Lee, Han Sung Kang, Eun Sook Lee
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy
    Won Il Jang, Sun Hyun Bae, Mi‐Sook Kim, Chul Ju Han, Su Cheol Park, Sang Bum Kim, Eung‐Ho Cho, Chul Won Choi, Kyung Su Kim, Sangyoun Hwang, Jin Ho Kim, A Ram Chang, Younghee Park, Eun Seog Kim, Woo Chul Kim, Sunmi Jo, Hae Jin Park
    Cancer.2020; 126(2): 363.     CrossRef
  • Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma
    Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Eun Sang Oh, Sang Hee Youn, Sung Ho Moon, Sang Soo Kim, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Dae Yong Kim
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial
    Tae Hyun Kim, Young Hwan Koh, Bo Hyun Kim, Min Ju Kim, Ju Hee Lee, Boram Park, Joong-Won Park
    Journal of Hepatology.2020;[Epub]     CrossRef
  • Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer
    Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Eun Sang Oh, Sang Hee Youn, Hye Young Jang, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
    Scientific Reports.2020;[Epub]     CrossRef
  • A feasibility study of high-dose hypofractionated carbon ion radiation therapy using four fractions for localized hepatocellular carcinoma measuring 3 cm or larger
    Kei Shibuya, Tatsuya Ohno, Hiroyuki Katoh, Masahiko Okamoto, Shintaro Shiba, Yoshinori Koyama, Satoru Kakizaki, Ken Shirabe, Takashi Nakano
    Radiotherapy and Oncology.2019; 132: 230.     CrossRef
  • Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma?
    Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Hyunjung Kim, Sung Ho Moon, Sang Soo Kim, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Dae Yong Kim, Chang-Min Kim
    Cancers.2019; 11(2): 230.     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
    KLCA Korean Liver Cancer Association, NCC National Cancer Center
    Gut and Liver.2019; 13(3): 227.     CrossRef
  • Rethinking the Role of Radiation Therapy in the Treatment of Unresectable Hepatocellular Carcinoma: A Data Driven Treatment Algorithm for Optimizing Outcomes
    Mutlay Sayan, Nikhil Yegya-Raman, Stephanie H. Greco, Bin Gui, Andrew Zhang, Anupama Chundury, Miral S. Grandhi, Howard S. Hochster, Timothy J. Kennedy, Russell C. Langan, Usha Malhotra, Vinod K. Rustgi, Mihir M. Shah, Kristen R. Spencer, Darren R. Carpiz
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2019; 20(7): 1042.     CrossRef
  • Hypofractionated particle beam therapy for hepatocellular carcinoma–a brief review of clinical effectiveness
    Che-Yu Hsu, Chun-Wei Wang, Ann-Lii Cheng, Sung-Hsin Kuo
    World Journal of Gastrointestinal Oncology.2019; 11(8): 579.     CrossRef
  • Proton therapy: the current status of the clinical evidences
    Dongryul Oh
    Precision and Future Medicine.2019; 3(3): 91.     CrossRef
  • A systematic review of publications on charged particle therapy for hepatocellular carcinoma
    Hiroshi Igaki, Masashi Mizumoto, Toshiyuki Okumura, Kiyoshi Hasegawa, Norihiro Kokudo, Hideyuki Sakurai
    International Journal of Clinical Oncology.2018; 23(3): 423.     CrossRef
  • Strategic application of radiotherapy for hepatocellular carcinoma
    Seo Hee Choi, Jinsil Seong
    Clinical and Molecular Hepatology.2018; 24(2): 114.     CrossRef
  • Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer
    Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo, Hyunjung Kim, Eun Sang Oh, Ju Hee Lee, Sung-Sik Han, Sang-Jae Park, Yang-Gun Suh, Sung Ho Moon, Sang Soo Kim, Dae Yong Kim
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives
    Gyu Sang Yoo, Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2018; 24(28): 3090.     CrossRef
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Current Trends and Controversies
    Stephanie K. Schaub, Pehr E. Hartvigson, Michael I. Lock, Morten Høyer, Thomas B. Brunner, Higinia R. Cardenes, Laura A. Dawson, Edward Y. Kim, Nina A. Mayr, Simon S. Lo, Smith Apisarnthanarax
    Technology in Cancer Research & Treatment.2018;[Epub]     CrossRef
  • Strahlentherapie bei hepatozellulärem Karzinom
    Thomas B. Brunner, Eleni Gkika, Christoph Willich, Maciej Pech, Peter Hass
    Der Onkologe.2018; 24(9): 698.     CrossRef
  • Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma
    Smith Apisarnthanarax, Stephen R. Bowen, Stephanie E. Combs
    Seminars in Radiation Oncology.2018; 28(4): 309.     CrossRef
  • Proton beam therapy for cancer in the era of precision medicine
    Man Hu, Liyang Jiang, Xiangli Cui, Jianguang Zhang, Jinming Yu
    Journal of Hematology & Oncology.2018;[Epub]     CrossRef
  • Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma
    Tae Hyun Kim, Joong-Won Park, Bo Hyun Kim, Dae Yong Kim, Sung Ho Moon, Sang Soo Kim, Ju Hee Lee, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Chang-Min Kim
    Oncotarget.2018; 9(3): 4034.     CrossRef
  • Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis
    Dae Yong Kim, Joong-Won Park, Tae Hyun Kim, Bo Hyun Kim, Sung Ho Moon, Sang Soo Kim, Sang Myung Woo, Young-Hwan Koh, Woo Jin Lee, Chang-Min Kim
    Radiotherapy and Oncology.2017; 122(1): 122.     CrossRef
  • Long‐term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma
    Kuniaki Fukuda, Toshiyuki Okumura, Masato Abei, Nobuyoshi Fukumitsu, Kazunori Ishige, Masashi Mizumoto, Naoyuki Hasegawa, Haruko Numajiri, Kayoko Ohnishi, Hitoshi Ishikawa, Koji Tsuboi, Hideyuki Sakurai, Ichinosuke Hyodo
    Cancer Science.2017; 108(3): 497.     CrossRef
  • Silencing the Girdin gene enhances radio-sensitivity of hepatocellular carcinoma via suppression of glycolytic metabolism
    Li Yu, Yifan Sun, Jingjing Li, Yan Wang, Yuxing Zhu, Yong Shi, Xiaojun Fan, Jianda Zhou, Ying Bao, Jie Xiao, Ke Cao, Peiguo Cao
    Journal of Experimental & Clinical Cancer Research.2017;[Epub]     CrossRef
  • Proton beam therapy for hepatocellular carcinoma
    Rosanna H Yeung, Tobias R Chapman, Stephen R Bowen, Smith Apisarnthanarax
    Expert Review of Anticancer Therapy.2017; 17(10): 911.     CrossRef
  • Strategies to tackle the challenges of external beam radiotherapy for liver tumors
    Michael I Lock, Jonathan Klein, Hans T Chung, Joseph M Herman, Edward Y Kim, William Small, Nina A Mayr, Simon S Lo
    World Journal of Hepatology.2017; 9(14): 645.     CrossRef
  • External beam radiotherapy for unresectable hepatocellular carcinoma
    Omar Abdel-Rahman, Zeinab Elsayed
    Cochrane Database of Systematic Reviews.2017;[Epub]     CrossRef
  • Prognostic group stratification and nomogram for predicting overall survival in patients who received radiotherapy for abdominal lymph node metastasis from hepatocellular carcinoma: a multi-institutional retrospective study (KROG 15-02)
    Youngkyong Kim, Hee Chul Park, Sang Min Yoon, Tae Hyun Kim, Jieun Lee, Jinhyun Choi, Jeong Il Yu, Jin-Hong Park, Jong Hoon Kim, Joong-Won Park, Jinsil Seong
    Oncotarget.2017; 8(55): 94450.     CrossRef
  • Proton Beam Therapy for Hepatocellular Carcinoma: A Review of the University of Tsukuba Experience
    Masashi Mizumoto, Yoshiko Oshiro, Toshiyuki Okumura, Nobuyoshi Fukumitsu, Haruko Numajiri, Kayoko Ohnishi, Teruhito Aihara, Hitoshi Ishikawa, Koji Tsuboi, Hideyuki Sakurai
    International Journal of Particle Therapy.2016; 2(4): 570.     CrossRef
  • Proton Therapy Results in the Treatment of Hepatocellular Carcinoma According to the Barcelona-Clinic Liver Cancer (BCLC) Staging System
    Francesco Dionisi, Maurizio Amichetti
    International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2015; 04(02): 96.     CrossRef
  • Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma
    Doo Yeul Lee, Joong-Won Park, Tae Hyun Kim, Ju Hee Lee, Bo Hyun Kim, Sang Myung Woo, Sang Soo Kim, Woo Jin Lee, Dae Yong Kim, Chang-Min Kim
    Strahlentherapie und Onkologie.2015; 191(11): 835.     CrossRef
  • 14,114 View
  • 130 Download
  • 52 Web of Science
  • 53 Crossref
Close layer
Preclinical Efficacy Testing for Stomach and Liver Cancers
Jun Won Park, Nam Suk Baek, Seok Cheol Lee, Su Jin Oh, Seok Hoon Jang, In Hoo Kim, Dae Yong Kim, Hark Kyun Kim
Cancer Res Treat. 2014;46(2):186-193.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.186
AbstractAbstract PDFPubReaderePub
Purpose

Hollow fiber assays offer an early in vivo method of anticancer drug screening. The assays have been optimized for human cancers originating from the lung, breast, colon, ovary, and brain, but not from the stomach and liver. The current study focused on optimization of hollow fiber assays for gastric and hepatocellular carcinoma cell lines.

Materials and Methods

Gastric (SNU-16, SNU-484, SNU-668) and hepatocellular (HepG2, SK-Hep-1, Hep3B) carcinoma cell lines in hollow fibers were transplanted subcutaneously and intraperitoneally into mice, which were subsequently treated with a standard anticancer agent, paclitaxel. The hollow fiber activity of paclitaxel in each cell line was compared with the xenograft activity.

Results

Using optimized inoculation densities and schedules, treatment with paclitaxel was effective in gastric carcinoma cell lines, SNU-16 and SNU-484, but not in SNU-668. In the hollow fiber assays, paclitaxel was effective in hepatocellular carcinoma cell lines, HepG2 and SK-Hep-1, but not in Hep3B. Consistent with the results of the hollow fiber assay, SNU-16 and SNU-484, but not SNU-668, showed tumor regression, and HepG2 and SK-Hep-1, but not Hep3B, showed effective tumor responses following treatment with paclitaxel in xenograft models. When EW7197, a novel compound, and flavopiridol were tested in SNU-16 cells under optimized conditions, the hollow fiber activity showed good correlation with the xenograft activity of each compound.

Conclusion

Our protocols may be useful for screening candidate small molecules that may exhibit activity against stomach and liver cancers, both of which are common in Korea.

Citations

Citations to this article as recorded by  
  • Synopsis on the Linkage of Alzheimer's and Parkinson's Disease with Chronic Diseases
    Nasimudeen R. Jabir, Chelapram K. Firoz, Saleh S. Baeesa, Ghulam Md Ashraf, Suhail Akhtar, Warda Kamal, Mohammad A. Kamal, Shams Tabrez
    CNS Neuroscience & Therapeutics.2015; 21(1): 1.     CrossRef
  • The Effect of Disintegrin–Metalloproteinase ADAM9 in Gastric Cancer Progression
    Jeong Min Kim, Hei-Cheul Jeung, Sun Young Rha, Eun Jeong Yu, Tae Soo Kim, You Keun Shin, Xianglan Zhang, Kyu Hyun Park, Seung Woo Park, Hyun Cheol Chung, Garth Powis
    Molecular Cancer Therapeutics.2014; 13(12): 3074.     CrossRef
  • 12,416 View
  • 131 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Clinical Outcomes of Local Excision Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer
Nam Kwon Lee, Dae Yong Kim, Sun Young Kim, Jae Hwan Oh, Won Park, Doo Ho Choi, Taek-Keun Nam, Kyung-Ja Lee
Cancer Res Treat. 2014;46(2):158-164.   Published online April 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.2.158
AbstractAbstract PDFPubReaderePub
Purpose

To evaluate the treatment outcomes of local excision following preoperative chemoradiotherapy in patients with locally advanced rectal cancer who have not undergone radical surgery for any reason.

Materials and Methods

The data of 27 patients with locally advanced rectal cancer who underwent preoperative chemoradiotherapy followed by local excision were analyzed retrospectively. The primary endpoint was the 5-year relapse-free survival rate, and the secondary endpoint was the pattern of recurrence.

Results

The median follow-up time was 81.8 months (range, 28.6 to 138.5 months). The 5-year local relapse-free survival (LRFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival (OS) were 88.9%, 81.1%, 77.8%, and 85.0%, respectively. Six (22%) patients developed treatment failure; one (4%) patient had local recurrence only, three (11%) patients had distant recurrence only, and two (7%) patients had both. The 5-year LRFS, DMFS, RFS, and OS for patients with ypT0-1 compared with ypT2-3 were 94.1% vs. 77.8% (p=0.244), 94.1% vs. 55.6% (p=0.016), 88.2% vs. 55.6% (p=0.051), and 94.1% vs. 66.7% (p=0.073), respectively.

Conclusion

Local excision following preoperative chemoradiotherapy may be an alternative treatment for highly selected patients with locally advanced rectal cancer who have achieved ypT0-1 after preoperative chemoradiotherapy.

Citations

Citations to this article as recorded by  
  • Organ‐saving surgery for rectal cancer after neoadjuvant chemoradiation: Analysis of failures and long‐term results
    Maurizio Cosimelli, Pietro Ursi, Raffaello Mancini, Giada Pattaro, Pasquale Perri, Chiara Parrino, Valerio De Peppo, Maria Grazia Diodoro, Andrea Balla, Gian Luca Grazi
    Journal of Surgical Oncology.2020; 121(2): 375.     CrossRef
  • Local excision for ypT2 rectal cancer following preoperative chemoradiation therapy: it should not be justified
    Kwan Mo Yang, Seok-Byung Lim, Jong Lyul Lee, Chan Wook Kim, Yong Sik Yoon, In Ja Park, Chang Sik Yu, Jin Cheon Kim
    International Journal of Colorectal Disease.2018; 33(4): 487.     CrossRef
  • Are We Predicting Disease Progress of the Rectal Cancer Patients without Surgery after Neoadjuvant Chemoradiotherapy?
    Bo Young Oh, Jung Wook Huh, Woo Yong Lee, Yoon Ah Park, Yong Beom Cho, Seong Hyeon Yun, Hee Cheol Kim, Ho-Kyung Chun
    Cancer Research and Treatment.2018; 50(3): 634.     CrossRef
  • Total Mesorectal Excision Versus Local Excision After Favorable Response to Preoperative Chemoradiotherapy in “Early” Clinical T3 Rectal Cancer: A Propensity Score Analysis
    Young Seob Shin, Chang Sik Yu, Jin-hong Park, Jin Cheon Kim, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Kyu-pyo Kim, Sang Min Yoon, Ji Hyeon Joo, Jong Hoon Kim
    International Journal of Radiation Oncology*Biology*Physics.2017; 99(1): 136.     CrossRef
  • Controversial issues in radiotherapy for rectal cancer: a systematic review
    Jong Hoon Kim
    Radiation Oncology Journal.2017; 35(4): 295.     CrossRef
  • Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?
    Clotilde Debove, Nathalie Guedj, Ecoline Tribillon, Léon Maggiori, Magaly Zappa, Yves Panis
    International Journal of Colorectal Disease.2016; 31(4): 853.     CrossRef
  • Seven low-mass ions in pretreatment serum as potential predictive markers of the chemoradiotherapy response of rectal cancer
    Kangsan Roh, Seung-Gu Yeo, Byong Chul Yoo, Kyung-Hee Kim, Sun Young Kim, Min-Jeong Kim
    Anti-Cancer Drugs.2016; 27(8): 787.     CrossRef
  • A Systematic Review of Local Excision After Neoadjuvant Therapy for Rectal Cancer: Are ypT0 Tumors the Limit?
    Sally Hallam, David E. Messenger, Michael G. Thomas
    Diseases of the Colon & Rectum.2016; 59(10): 984.     CrossRef
  • Definitive high-dose radiotherapy with concurrent chemotherapy for locally advanced rectal cancer
    Min-Jeong Kim, Eun Seok Kim, Seung-Gu Yeo
    Medicine.2016; 95(40): e5059.     CrossRef
  • Association of pretreatment serum carcinoembryonic antigen levels with chemoradiation-induced downstaging and downsizing of rectal cancer
    SEUNG-GU YEO
    Molecular and Clinical Oncology.2016; 4(4): 631.     CrossRef
  • The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer
    Jong Hoon Lee, Jong Hee Hyun, Dae Yong Kim, Byong Chul Yoo, Ji Won Park, Sun Young Kim, Hee Jin Chang, Byung Chang Kim, Tae Hyun Kim, Jae Hwan Oh, Dae Kyung Sohn
    Annals of Surgical Oncology.2015; 22(1): 209.     CrossRef
  • Oncologic Outcomes according to the Treatment Strategy in Radiologic Complete Responders after Neoadjuvant Chemoradiation for Rectal Cancer
    Soo Young Lee, Chang Hyun Kim, Young Jin Kim, Hyeong Rok Kim
    Oncology.2015; 89(6): 311.     CrossRef
  • 13,623 View
  • 63 Download
  • 13 Web of Science
  • 12 Crossref
Close layer
Increasing Trend of Colorectal Cancer Incidence in Korea, 1999-2009
Aesun Shin, Kyee-Zu Kim, Kyu-Won Jung, Sohee Park, Young-Joo Won, Jeongseon Kim, Dae Yong Kim, Jae Hwan Oh
Cancer Res Treat. 2012;44(4):219-226.   Published online December 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.4.219
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was conducted in order to demonstrate changing trends in colorectal cancer incidence according to sex, age group, and anatomical location in the Korean population.
MATERIALS AND METHODS
Data from the Korea Central Cancer Registry between 1999 and 2009 were analyzed. Annual percent changes (APCs) of sex- and age-specific incidence rates for cancer of the proximal colon (International Statistical Classification of Diseases and Related Health Problems, 10th revision [ICD-10] code C18.0-18.5), distal colon (C18.6-18.7), and rectum (C19-20), and male-to-female incidence rate ratios (IRR) were calculated.
RESULTS
The age-standardized incidence rate (ASR) of colorectal cancer was 27 (per 100,000) in 1999 and increased to 50.2 in 2009 among men (APC, 6.6%). The ASR for women was 17.2 in 1999 and 26.9 in 2009 (APC, 5.1%). The rectum was the most common site of cancer among both men and women during 1999 and 2009. However, the distal colon had the highest APC (10.8% among men and 8.4% among women), followed by the proximal colon (7.9% among men and 6.6% among women), and rectum (5.2% among men and 2.4% among women). The proportion of rectal cancer decreased from 51.5% in 1999 to 47.1% in 2009 among men, and from 50.5% to 42.8% among women. An increase in the male-to-female IRR was observed for distal colon cancer and rectal cancer, whereas the IRR for proximal colon cancer was stable.
CONCLUSION
The rapid increase in colorectal cancer incidence is mainly attributed to the increase in colon cancer, especially distal colon cancer, and may be explained by a transition of risk factors for subsites or by the effect of colorectal cancer screening.

Citations

Citations to this article as recorded by  
  • Factors influencing advanced colorectal neoplasm anatomic site distribution in China: An epidemiological study based on colorectal cancer screening data
    Kailong Zhao, Hongzhou Li, Baofeng Zhang, Wenwen Pang, Suying Yan, Xinzhu Zhao, Xinyu Liu, Wanting Wang, Qiurong Han, Yao Yao, Tianhao Chu, Zhiqiang Feng, Qinghuai Zhang, Chunze Zhang
    Cancer Medicine.2023; 12(24): 22252.     CrossRef
  • Epidemiology, Risk Factors, and Prevention of Colorectal Cancer-An English Version
    Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
    Journal of the Anus, Rectum and Colon.2022; 6(4): 231.     CrossRef
  • Trends in colorectal cancer incidence in Ho Chi Minh City, Vietnam (1996–2015): Joinpoint regression and age–period–cohort analyses
    Dung X. Pham, An H.T. Phung, Hien D. Nguyen, Tung D. Bui, Linh D. Mai, Bich N.H. Tran, Thach S. Tran, Tuan V. Nguyen, Lan T. Ho-Pham
    Cancer Epidemiology.2022; 77: 102113.     CrossRef
  • The interaction between glycemic index, glycemic load, and the genetic variant ADIPOQ T45G (rs2241766) in the risk of colorectal cancer: a case–control study in a Korean population
    Y-Thanh Lu, Madhawa Gunathilake, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
    European Journal of Nutrition.2022; 61(5): 2601.     CrossRef
  • A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries
    Norah Alsadhan, Alaa Almaiman, Mar Pujades-Rodriguez, Cathy Brennan, Farag Shuweihdi, Sultana A. Alhurishi, Robert M. West
    BMC Medical Research Methodology.2022;[Epub]     CrossRef
  • A comparative analysis of factors influencing colorectal cancer’s age standardized mortality ratio among Korean women in the hot and cold spots
    ChuelWon Lee, SungMin Kim, JaeHyun Woo, Mohammad Asghari Jafarabadi
    PLOS ONE.2022; 17(9): e0273995.     CrossRef
  • Epidemiology, risk factors, and prevention of colorectal cancer
    Kyung Uk Jung, Hyung Ook Kim, Hungdai Kim
    Journal of the Korean Medical Association.2022; 65(9): 549.     CrossRef
  • Statistical methods for measuring trends in colorectal cancer incidence in registries: A systematic review
    Norah Alsadhan, Alaa Almaiman, Mar Pujades-Rodriguez, Cathy Brennan, Farag Shuweihdi, Sultana A. Alhurishi, Robert M. West
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Clinicopathological Characteristics and Outcome of Adolescent and Young Adult-Onset Microsatellite Stable Colorectal Cancer Patients
    Kanjana Sukhokanjanachusak, Ananya Pongpaibul, Akarin Nimmannit, Charuwan Akewanlop, Krittiya Korphaisarn
    Journal of Adolescent and Young Adult Oncology.2021; 10(5): 573.     CrossRef
  • Time trends of colorectal cancer incidence and associated lifestyle factors in South Korea
    Hayeong Khil, Sung Min Kim, SungEun Hong, Hyeon Min Gil, Eugene Cheon, Dong Hoon Lee, Young Ae Kim, NaNa Keum
    Scientific Reports.2021;[Epub]     CrossRef
  • Impact of simethicone on bowel cleansing during colonoscopy in Chinese patients
    Hu Zhang, Jing Liu, Song-Lin Ma, Man-Lin Huang, Yan Fan, Min Song, Jing Yang, Xiao-Xia Zhang, Qi-Long Song, Jing Gong, Ping-Xiao Huang, Heng Zhang
    World Journal of Clinical Cases.2021; 9(10): 2238.     CrossRef
  • Effect of Helicobacter pylori treatment on the long-term mortality in patients with type 2 diabetes
    Young-Il Kim, Young Ae Kim, Hak Jin Kim, Su-Hyun Kim, Yul Hwangbo, Jae Gyu Kim, Jae J. Kim, Il Ju Choi
    The Korean Journal of Internal Medicine.2021; 36(3): 584.     CrossRef
  • Effect of antifoaming agent on benign colorectal tumors in colonoscopy: A meta-analysis
    Hu Zhang, Jing Gong, Lin-Song Ma, Ting Jiang, Heng Zhang
    World Journal of Clinical Cases.2021; 9(15): 3607.     CrossRef
  • Global colorectal cancer burden in 2020 and projections to 2040
    Yue Xi, Pengfei Xu
    Translational Oncology.2021; 14(10): 101174.     CrossRef
  • Clinical characteristics and survival of colorectal cancer patients in Korea stratified by age
    Sun Kyung Baek, Ji Sung Lee, In Gyu Hwang, Jong Gwang Kim, Tae Won Kim, Seung Kook Sohn, Mi Yeon Kang, Sang-Cheol Lee
    The Korean Journal of Internal Medicine.2021; 36(4): 985.     CrossRef
  • Stromal Galectin-1 Promotes Colorectal Cancer Cancer-Initiating Cell Features and Disease Dissemination Through SOX9 and β-Catenin: Development of Niche-Based Biomarkers
    Kai-Yen Peng, Shih-Sheng Jiang, Yu-Wei Lee, Fang-Yu Tsai, Chia-Chi Chang, Li-Tzong Chen, B. Linju Yen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Risk Factors for High-Risk Adenoma on the First Lifetime Colonoscopy Using Decision Tree Method: A Cross-Sectional Study in 6,047 Asymptomatic Koreans
    Kwang Hyun Chung, Min Jung Park, Eun Hyo Jin, Ji Yeon Seo, Ji Hyun Song, Sun Young Yang, Young Sun Kim, Jeong Yoon Yim, Seon Hee Lim, Joo Sung Kim, Su Jin Chung, Joo Kyung Park
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Prognostic Impact of Tumor-Associated Macrophages on Long-Term Oncologic Outcomes in Colorectal Cancer
    Hyeong Chan Shin, Incheol Seo, Hasong Jeong, Sang Jun Byun, Shin Kim, Sung Uk Bae, Sun Young Kwon, Hye Won Lee
    Life.2021; 11(11): 1240.     CrossRef
  • Postoperative Portomesenteric Venous Thrombosis After Colorectal Cancer Surgery
    Myung Jo Kim, Duck-Woo Kim, Jai Young Cho, Il Tae Son, Sung Il Kang, Heung-Kwon Oh, Sung-Bum Kang
    Journal of Gastrointestinal Surgery.2020; 24(2): 396.     CrossRef
  • Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension
    Young-Il Kim, Young Ae Kim, Jang Won Lee, Hak Jin Kim, Su-Hyun Kim, Sang Gyun Kim, Jin Il Kim, Jae J. Kim, Il Ju Choi
    Gut and Liver.2020; 14(1): 47.     CrossRef
  • Histology and its prognostic effect on KRAS‑mutated colorectal carcinomas in Korea
    Hye Lee, Dae Hwang, Hye Han
    Oncology Letters.2020; 20(1): 655.     CrossRef
  • Association between high fatty liver index and development of colorectal cancer: a nationwide cohort study with 21,592,374 Korean
    Yoon Jin Choi, Dong Ho Lee, Kyung-Do Han
    The Korean Journal of Internal Medicine.2020; 35(6): 1354.     CrossRef
  • Clinicopathological Characteristics of TZAP Expression in Colorectal Cancers


    Soo-Jung Jung, Yu-Ri Seo, Won-Jin Park, Yu-Ran Heo, Yun-Han Lee, Shin Kim, Jae-Ho Lee
    OncoTargets and Therapy.2020; Volume 13: 12933.     CrossRef
  • Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer
    In Sub Jung, Cheol Min Shin, Sung Jae Park, Young Soo Park, Hyuk Yoon, Hyun Jin Jo, Nayoung Kim, Dong Ho Lee
    Intestinal Research.2019; 17(3): 404.     CrossRef
  • Opposing Regulation of Cancer Properties via KRT19-Mediated Differential Modulation of Wnt/β-Catenin/Notch Signaling in Breast and Colon Cancers
    Subbroto Kumar Saha, Yingfu Yin, Hee Sung Chae, Ssang-Goo Cho
    Cancers.2019; 11(1): 99.     CrossRef
  • Young-age onset colorectal cancer in Brazil: Analysis of incidence, clinical features, and outcomes in a tertiary cancer center
    Andrea C.B. Silva, Maria Fernanda B. Vicentini, Elizabeth Z. Mendoza, Fernanda K. Fujiki, Leonardo G. da Fonseca, Maria Ignez F.M. Braghiroli, Paulo M. Hoff
    Current Problems in Cancer.2019; 43(5): 477.     CrossRef
  • Prognostic impact of telomeric repeat-containing RNA expression on long-term oncologic outcomes in colorectal cancer
    Sung Uk Bae, Won-Jin Park, Woon Kyung Jeong, Seong Kyu Baek, Hye-Won Lee, Jae-Ho Lee
    Medicine.2019; 98(14): e14932.     CrossRef
  • Novel Germline Mutations ofBRCA1andBRCA2in Korean Familial Breast Cancer Patients
    Hee Nam Kim, Min-Ho Shin, Ran Lee, Min-Ho Park, Sun-Seog Kweon
    Chonnam Medical Journal.2019; 55(2): 99.     CrossRef
  • Effects of an Internet-based informational video on preoperative anxiety in patients with colorectal cancer
    Myung Jo Kim, Heung-Kwon Oh, Keun Chul Lee, Hyun Hui Yang, Bon-Wook Koo, Jebong Lee, Min-Hyun Kim, Sung Il Kang, Duck-Woo Kim, Sung-Bum Kang
    Annals of Surgical Treatment and Research.2019; 96(6): 290.     CrossRef
  • Colorectal cancer epidemiology in Korea
    Aesun Shin, Doeun Jang, Sunho Choe, Young-Joo Won, Kyu-Won Jung, Ji Won Park, Seung-Yong Jeong
    Journal of the Korean Medical Association.2019; 62(8): 407.     CrossRef
  • Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
    NaNa Keum, Edward Giovannucci
    Nature Reviews Gastroenterology & Hepatology.2019; 16(12): 713.     CrossRef
  • Protective Effect of Green Tea Consumption on Colorectal Cancer Varies by Lifestyle Factors
    Hyejin Kim, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
    Nutrients.2019; 11(11): 2612.     CrossRef
  • Colorectal Cancer Risks According to Sex Differences in Patients With Type II Diabetes Mellitus: A Korean Nationwide Population-Based Cohort Study
    Ji Min Lee, Kang-Moon Lee, Dae Bum Kim, Seung-Hyun Ko, Yong Gyu Park
    Clinical and Translational Gastroenterology.2019; 10(10): e00090.     CrossRef
  • Which strategy is better for resectable synchronous liver metastasis from colorectal cancer, simultaneous surgery, or staged surgery? Multicenter retrospective analysis
    Bong-Hyeon Kye, Suk-Hwan Lee, Woon Kyung Jeong, Chang Sik Yu, In Ja Park, Hyeong Rok Kim, Jin Kim, In Kyu Lee, Ki-Jea Park, Hong-Jo Choi, Ho Young Kim, Jeong-Heum Baek, Yoon-Suk Lee
    Annals of Surgical Treatment and Research.2019; 97(4): 184.     CrossRef
  • Green tea extracts for the prevention of metachronous colorectal polyps among patients who underwent endoscopic removal of colorectal adenomas: A randomized clinical trial
    Cheol Min Shin, Dong Ho Lee, A Young Seo, Hyun Joo Lee, Seong Beom Kim, Woo-Chan Son, Young Kyung Kim, Sang Jun Lee, Sung-Hee Park, Nayoung Kim, Young Soo Park, Hyuk Yoon
    Clinical Nutrition.2018; 37(2): 452.     CrossRef
  • Risk and Characteristics of Postcolonoscopy Interval Colorectal Cancer after a Positive Fecal Test: A Nationwide Population-Based Study in Korea
    Chang Kyun Lee, Kui Son Choi, Chang Soo Eun, Dong-Il Park, Dong Soo Han, Minjoo Yoon, Mina Suh, Jae Kwan Jun
    Cancer Research and Treatment.2018; 50(1): 50.     CrossRef
  • Plasma phytoestrogens concentration and risk of colorectal cancer in two different Asian populations
    Kwang-Pil Ko, Yohwan Yeo, Ji-Hye Yoon, Cheong-Sik Kim, Shinkan Tokudome, Le Tran Ngoan, Chihaya Koriyama, Young-Khi Lim, Soung-Hoon Chang, Hai-Rim Shin, Daehee Kang, Sue K. Park, Chul Hwan Kang, Keun-Young Yoo
    Clinical Nutrition.2018; 37(5): 1675.     CrossRef
  • Environmental contributions to gastrointestinal and liver cancer in the Asia–Pacific region
    Kwang‐Pil Ko, Aesun Shin, Sooyoung Cho, Sue K Park, Keun‐Young Yoo
    Journal of Gastroenterology and Hepatology.2018; 33(1): 111.     CrossRef
  • Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae
    Myong Cheol Lim, Young-Joo Won, Jiwon Lim, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Joo-Young Kim, Jae Hwan Oh, Robert E. Bristow, Sang-Yoon Park
    Journal of Cancer Research and Clinical Oncology.2018; 144(5): 845.     CrossRef
  • Resting heart rate is an independent predictor of advanced colorectal adenoma recurrence
    Jihye Park, Jae Hyun Kim, Yehyun Park, Soo Jung Park, Jae Hee Cheon, Won Ho Kim, Ji Soo Park, Justin Y. Jeon, Tae Il Kim, John Green
    PLOS ONE.2018; 13(3): e0193753.     CrossRef
  • Risk of Interval Cancer in Fecal Immunochemical Test Screening Significantly Higher During the Summer Months: Results from the National Cancer Screening Program in Korea
    Jae Myung Cha, Mina Suh, Min Seob Kwak, Na Young Sung, Kui Son Choi, Boyoung Park, Jae Kwan Jun, Sang-Hyun Hwang, Do-Hoon Lee, Byung Chang Kim, You Kyoung Lee, Dong Soo Han
    American Journal of Gastroenterology.2018; 113(4): 611.     CrossRef
  • Long-term outcomes after stenting as a bridge to surgery in patients with obstructing left-sided colorectal cancer
    Jihye Park, Hyun Jung Lee, Soo Jung Park, Hyuk Hur, Byung Soh Min, Jae Hee Cheon, Tae Il Kim, Nam Kyu Kim, Won Ho Kim
    International Journal of Colorectal Disease.2018; 33(6): 799.     CrossRef
  • Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer
    Yuri Choi, Yeo-Jin Won, Sojeong Lee, Ahrong Kim, Younggeum Kim, Won-Young Park, Hong-Jae Jo, Geun Am Song, Chae Hwa Kwon, Do Youn Park
    Translational Oncology.2018; 11(3): 764.     CrossRef
  • Updates on Cancer Epidemiology in Korea, 2018
    Sun-Seog Kweon
    Chonnam Medical Journal.2018; 54(2): 90.     CrossRef
  • Korean physicians’ policies for postoperative surveillance of colorectal cancer
    Sun Kyung Baek, Sang-Cheol Lee, Jong Gwang Kim, Jun Won Um, Suk-Hwan Lee, Byung Ik Jang, Jae Jun Park, Tae Won Kim
    The Korean Journal of Internal Medicine.2018; 33(4): 783.     CrossRef
  • Intestinal microbiota, chronic inflammation, and colorectal cancer
    Chan Hyuk Park, Chang Soo Eun, Dong Soo Han
    Intestinal Research.2018; 16(3): 338.     CrossRef
  • Abdominal obesity, glucose intolerance and decreased high-density lipoprotein cholesterol as components of the metabolic syndrome are associated with the development of colorectal cancer
    Yoon Jin Choi, Dong Ho Lee, Kyung-Do Han, Cheol Min Shin, Nayoung Kim
    European Journal of Epidemiology.2018; 33(11): 1077.     CrossRef
  • Characteristics and Survival of Korean Patients With Colorectal Cancer Based on Data From the Korea Central Cancer Registry Data
    Hyuk Hur, Chang-Mo Oh, Young-Joo Won, Jae Hwan Oh, Nam Kyu Kim
    Annals of Coloproctology.2018; 34(4): 212.     CrossRef
  • Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer
    Sung Uk Bae, Kyoung Sook Won, Bong-Il Song, Woon Kyung Jeong, Seong Kyu Baek, Hae Won Kim
    Cancer Imaging.2018;[Epub]     CrossRef
  • Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea
    Dong Woo Shin, Yoon Jin Choi, Hyun Soo Kim, Kyung-Do Han, Hyuk Yoon, Young Soo Park, Nayoung Kim, Dong Ho Lee
    Diseases of the Colon & Rectum.2018; 61(11): 1250.     CrossRef
  • Prognostic impact of programmed cell death ligand 1 expression on long‑term oncologic outcomes in colorectal cancer
    Sung Bae, Woon Jeong, Seong Baek, Nam Kim, Ilseon Hwang
    Oncology Letters.2018;[Epub]     CrossRef
  • Obstructive sleep apnea is associated with an increased risk of colorectal neoplasia
    Seohui Lee, Byeong Gwan Kim, Ji Won Kim, Kook Lae Lee, Dae Lim Koo, Hyunwoo Nam, Jong Pil Im, Joo Sung Kim, Seong-Joon Koh
    Gastrointestinal Endoscopy.2017; 85(3): 568.     CrossRef
  • Association between dietary fat intake and colorectal adenoma in korean adults
    Jeehyun Kim, Seung-Won Oh, Young-Sun Kim, Hyuktae Kwon, Hee-Kyung Joh, Ji-Eun Lee, Danbee Park, Jae-Hong Park, Ah-Ryoung Ko, Ye-Ji Kim
    Medicine.2017; 96(1): e5759.     CrossRef
  • Dietary Flavonoids, CYP1A1 Genetic Variants, and the Risk of Colorectal Cancer in a Korean population
    Young Ae Cho, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
    Scientific Reports.2017;[Epub]     CrossRef
  • The Incidence and Mortality of Colorectal Cancer and Its Relationship With the Human Development Index in Asia
    Mahshid Ghoncheh, Maryam Mohammadian, Abdollah Mohammadian-Hafshejani, Hamid Salehiniya
    Annals of Global Health.2017; 82(5): 726.     CrossRef
  • The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
    Daeyoun David Won, Jae Im Lee, In Kyu Lee, Seong-Taek Oh, Eun Sun Jung, Sung Hak Lee
    BMC Cancer.2017;[Epub]     CrossRef
  • A Case of Metastatic Rectal Carcinoma to the Frontal Sinus
    Seok Kim, Tae Young Jung, Bo Young Kim, Tae Jung Park
    Korean Journal of Otorhinolaryngology-Head and Neck Surgery.2017; 60(6): 314.     CrossRef
  • Resveratrol analogue, HS-1793, induces apoptotic cell death and cell cycle arrest through downregulation of AKT in human colon cancer cells
    Dong Hwan Kim, Min Jeong Kim, Bokyung Sung, Hongsuk Suh, Jee H. Jung, Hae Young Chung, Nam Deuk Kim
    Oncology Reports.2017; 37(1): 281.     CrossRef
  • Association Among Obesity, Metabolic Health, and the Risk for Colorectal Cancer in the General Population in Korea Using the National Health Insurance Service–National Sample Cohort
    Cheol Min Shin, Kyungdo Han, Dong Ho Lee, Yoon Jin Choi, Nayoung Kim, Young Soo Park, Hyuk Yoon
    Diseases of the Colon & Rectum.2017; 60(11): 1192.     CrossRef
  • Two case reports
    Chang hoon Ahn, Soon Chul Kim
    Medicine.2017; 96(46): e8074.     CrossRef
  • Primary tumor location predicts poor clinical outcome with cetuximab in RAS wild-type metastatic colorectal cancer
    Dalyong Kim, Sun Young Kim, Ji Sung Lee, Yong Sang Hong, Jeong Eun Kim, Kyu-pyo Kim, Jihun Kim, Se Jin Jang, Young-Kwang Yoon, Tae Won Kim
    BMC Gastroenterology.2017;[Epub]     CrossRef
  • The Effects of Physical Activity and Body Fat Mass on Colorectal Polyp Recurrence in Patients with Previous Colorectal Cancer
    Jihye Park, Jae Hyun Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Won Ho Kim, Ji Soo Park, Justin Y. Jeon, Tae Il Kim
    Cancer Prevention Research.2017; 10(8): 478.     CrossRef
  • Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
    Hyun Joo Jang, Eun Mi Hong, Juah Jang, Jung Eun Choi, Se Woo Park, Hyun Woo Byun, Dong Hee Koh, Min Ho Choi, Sea Hyub Kae, Jin Lee
    Gastroenterology Research and Practice.2016; 2016: 1.     CrossRef
  • Dehydroglyasperin D Inhibits the Proliferation of HT-29 Human Colorectal Cancer Cells Through Direct Interaction With Phosphatidylinositol 3-kinase
    Sung Keun Jung, Chul-Ho Jeong
    Journal of Cancer Prevention.2016; 21(1): 26.     CrossRef
  • Colorectal cancer screening of the general population in East Asia
    Yasushi Sano, Jeong‐Sik Byeon, Xiao‐Bo Li, Martin C.S. Wong, Han‐Mo Chiu, Rungsun Rerknimitr, Takahiro Utsumi, Santa Hattori, Wataru Sano, Mineo Iwatate, Philip Chiu, Joseph Sung
    Digestive Endoscopy.2016; 28(3): 243.     CrossRef
  • Cancer Mortality Projections in Korea up to 2032
    Mia Son, Jae-Won Yun
    Journal of Korean Medical Science.2016; 31(6): 892.     CrossRef
  • Molecular Subtypes of Colorectal Cancer and Their Clinicopathologic Features, With an Emphasis on the Serrated Neoplasia Pathway
    Jeong Mo Bae, Jung Ho Kim, Gyeong Hoon Kang
    Archives of Pathology & Laboratory Medicine.2016; 140(5): 406.     CrossRef
  • Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer
    Eunyoung Lee, Sung-Bum Kang, Sang Il Choi, Eun Ju Chun, Min Jeong Kim, Duck-Woo Kim, Heung-Kwon Oh, Myong Hoon Ihn, Jin Won Kim, Soo-Mee Bang, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee
    Cancer Research and Treatment.2016; 48(3): 978.     CrossRef
  • Dietary Inflammatory Index and Risk of Colorectal Cancer: A Case-Control Study in Korea
    Young Cho, Jeonghee Lee, Jae Oh, Aesun Shin, Jeongseon Kim
    Nutrients.2016; 8(8): 469.     CrossRef
  • Colorectal cancer incidence in 5 Asian countries by subsite: An analysis of Cancer Incidence in Five Continents (1998–2007)
    Hye-Min Park, Hyeongtaek Woo, Sun Jae Jung, Kyu-Won Jung, Hai-Rim Shin, Aesun Shin
    Cancer Epidemiology.2016; 45: 65.     CrossRef
  • Association between the TCF7L2 polymorphism and colorectal cancer does not differ by diabetes and obesity statuses
    Hyun-Jeong Shim, Ran Lee, Min-Ho Shin, Hee-Nam Kim, Sun-Seog Kweon
    Cancer Epidemiology.2016; 45: 108.     CrossRef
  • Prevalence of colorectal neoplasms in young, average risk individuals: A turning tide between East and West
    Ari Leshno, Menachem Moshkowitz, Maayan David, Lior Galazan, Alfred I Neugut, Nadir Arber, Erwin Santo
    World Journal of Gastroenterology.2016; 22(32): 7365.     CrossRef
  • Young‐onset colorectal cancer in the Asia–Pacific region
    Moe Kyaw, Joseph JY Sung
    Medical Journal of Australia.2016; 205(10): 450.     CrossRef
  • Predictive microRNAs for lymph node metastasis in endoscopically resectable submucosal colorectal cancer
    Chan Kwon Jung, Seung-Hyun Jung, Seon-Hee Yim, Ji-Han Jung, Hyun Joo Choi, Won-Kyung Kang, Sung-Won Park, Seong-Taek Oh, Jun-Gi Kim, Sug Hyung Lee, Yeun-Jun Chung
    Oncotarget.2016; 7(22): 32902.     CrossRef
  • NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer
    Do Youn Park, Chan Choi, Eunji Shin, Jae Hyuk Lee, Chae Hwa Kwon, Hong-Jae Jo, Hyeong-Rok Kim, Hyun Sung Kim, Nahmgun Oh, Ji Shin Lee, Ok Ku Park, Eok Park, Jonghoon Park, Jong-Yeon Shin, Jong-Il Kim, Jeong-Sun Seo, Hee Dong Park, Joonghoon Park
    Oncotarget.2016; 7(7): 8399.     CrossRef
  • The Role of Fibrinogen as a Predictor in Preoperative Chemoradiation for Rectal Cancer
    Jong Hoon Lee, Jong Hee Hyun, Dae Yong Kim, Byong Chul Yoo, Ji Won Park, Sun Young Kim, Hee Jin Chang, Byung Chang Kim, Tae Hyun Kim, Jae Hwan Oh, Dae Kyung Sohn
    Annals of Surgical Oncology.2015; 22(1): 209.     CrossRef
  • The colorectal cancer mortality‐to‐incidence ratio as an indicator of global cancer screening and care
    Vasu Sunkara, James R. Hébert
    Cancer.2015; 121(10): 1563.     CrossRef
  • Randomized Controlled Trial of Sodium Phosphate Tablets versus 2 L Polyethylene Glycol Solution for Bowel Cleansing prior to Colonoscopy
    Yun Ho Lee, Seong Yeon Jeong, You Sun Kim, Hye Jin Jung, Min Jung Kwon, Cheol Hun Kwak, Song I Bae, Jeong Seop Moon, Ji Won Kim, Su Hwan Kim, Kook Lae Lee
    The Korean Journal of Gastroenterology.2015; 65(1): 27.     CrossRef
  • Difference in Time to Locoregional Recurrence Between Patients With Right-Sided and Left-Sided Colon Cancers
    Jung Hun Park, Min Jung Kim, Sung Chan Park, Min Ju Kim, Chang Won Hong, Dae Kyung Sohn, Kyung Su Han, Jae Hwan Oh
    Diseases of the Colon & Rectum.2015; 58(9): 831.     CrossRef
  • Cost comparison between endoscopic submucosal dissection and transanal endoscopic microsurgery for the treatment of rectal tumors
    Myung Jin Nam, Dae Kyung Sohn, Chang Won Hong, Kyung Su Han, Byung Chang Kim, Hee Jin Chang, Sung Chan Park, Jae Hwan Oh
    Annals of Surgical Treatment and Research.2015; 89(4): 202.     CrossRef
  • Influence of old age on the postoperative outcomes of obstructive colorectal cancer surgery after the insertion of a stent
    Chan Hee Park, Seong Kyu Baek, Ok Suk Bae, Woon Kyung Jeong
    Annals of Surgical Treatment and Research.2015; 89(4): 183.     CrossRef
  • Trends in Colorectal Cancer Incidence in Daejeon and Chungcheongnam-do, South Korea (2000-2012)
    Soon-Young Kim, In-Sun Kweon, Jung-A Kim, Tae-Yong Lee, Hae-Sung Nam
    Journal of agricultural medicine and community health.2015; 40(3): 115.     CrossRef
  • Trends in major cancer mortality in Korea, 1983–2012, with a joinpoint analysis
    Daroh Lim, Mina Ha, Inmyung Song
    Cancer Epidemiology.2015; 39(6): 939.     CrossRef
  • Changing trends in colorectal cancer in the Republic of Korea: contrast with Japan
    Minjoo Yoon, Nicholas Kim, Byungho Nam, Jungnam Joo, Moran Ki
    Epidemiology and Health.2015; 37: e2015038.     CrossRef
  • Temporal Epidemiological Assessment of Colorectal Cancer Incidence and Mortality in East Kazakhstan, 2004-2013
    Kuantkan Zhabagin, Nurbek Igissinov, Zukhra Manambayeva, Tasbolat Adylkhanov, Marat Sandybayev, Murat Nurgazin, Adilzhan Massadykov, Sayat Tanatarov, Daniyar Aldyngurov, Nailya Urazalina, Aizhan Abiltayeva, Ainoor Baissalbayeva, Almagul Zhabagina, Dinara
    Asian Pacific Journal of Cancer Prevention.2015; 16(15): 6413.     CrossRef
  • Isoflavone and Soyfood Intake and Colorectal Cancer Risk: A Case-Control Study in Korea
    Aesun Shin, Jeonghee Lee, Jeeyoo Lee, Moon Sung Park, Ji Won Park, Sung Chan Park, Jae Hwan Oh, Jeongseon Kim, Ajay Goel
    PLOS ONE.2015; 10(11): e0143228.     CrossRef
  • Gender-specific Colorectal Cancer: Epidemiologic Difference and Role of Estrogen
    Hee Man Kim, Hyun-Soo Kim
    The Korean Journal of Gastroenterology.2014; 63(4): 201.     CrossRef
  • A Survey of Colonoscopic Surveillance After Polypectomy
    Dae Kyung Sohn
    Annals of Coloproctology.2014; 30(2): 88.     CrossRef
  • Colonoscopy Quality is the Answer for the Emerging Issue of Interval Cancer
    Jae Myung Cha
    Intestinal Research.2014; 12(2): 110.     CrossRef
  • Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database
    H.‐Y. Yhim, M.‐J. Jang, S.‐M. Bang, K.H. Kim, Y.‐K. Kim, S.‐H. Nam, S.H. Bae, S.‐H. Kim, Y.‐C. Mun, I. Kim, C.W. Jung, D. Oh
    Journal of Thrombosis and Haemostasis.2014; 12(7): 1035.     CrossRef
  • Incidence and risk factors of metachronous colorectal neoplasm after curative resection of colorectal cancer in Korean patients
    Su Young Lee, Byung Chang Kim, Kyung Su Han, Chang Won Hong, Dae Kyung Sohn, Sung Chan Park, Sun Young Kim, Ji‐Yeon Baek, Hee Jin Chang, Dae Yong Kim, Jae Hwan Oh
    Journal of Digestive Diseases.2014; 15(7): 367.     CrossRef
  • Association between fasting serum glucose levels and incidence of colorectal cancer in Korean men: The Korean Cancer Prevention Study-II
    Hyun-Young Shin, Keum Ji Jung, John A. Linton, Sun Ha Jee
    Metabolism.2014; 63(10): 1250.     CrossRef
  • Immune Response, Safety, and Survival and Quality of Life Outcomes for Advanced Colorectal Cancer Patients Treated with Dendritic Cell Vaccine and Cytokine-Induced Killer Cell Therapy
    Hui Zhu, Xuejing Yang, Jiali Li, Yanjie Ren, Tianyu Zhang, Chunze Zhang, Jintai Zhang, Jing Li, Yan Pang
    BioMed Research International.2014; 2014: 1.     CrossRef
  • Tumor SUVmax Normalized to Liver Uptake on 18F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
    Jihyun Park, Kyoung Jin Chang, Young Seok Seo, Byung Hyun Byun, Joon Ho Choi, Hansol Moon, Ilhan Lim, Byung Il Kim, Chang Woon Choi, Sang Moo Lim
    Nuclear Medicine and Molecular Imaging.2014; 48(4): 295.     CrossRef
  • Risk Prediction Model for Colorectal Cancer: National Health Insurance Corporation Study, Korea
    Aesun Shin, Jungnam Joo, Hye-Ryung Yang, Jeongin Bak, Yunjin Park, Jeongseon Kim, Jae Hwan Oh, Byung-Ho Nam, Zhengdong Zhang
    PLoS ONE.2014; 9(2): e88079.     CrossRef
  • Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells
    YUJIN LEE, BOKYUNG SUNG, YONG JUNG KANG, DONG HWAN KIM, JUNG-YOON JANG, SEONG YEON HWANG, MINJUNG KIM, HYUN SOOK LIM, JEONG-HYUN YOON, HAE YOUNG CHUNG, NAM DEUK KIM
    International Journal of Oncology.2014; 44(5): 1599.     CrossRef
  • Overview of Cancer Registration Research in the Asian Pacific from 2008-2013
    Malcolm A. Moore
    Asian Pacific Journal of Cancer Prevention.2013; 14(8): 4461.     CrossRef
  • Clinical Practice of Surveillance Colonoscopy according to the Classification of Colorectal Intraepithelial Neoplasia in Korea: High-grade Dysplasia/CarcinomaIn SituVersus Intramucosal Carcinoma
    Sung Pil Hong, Tae Il Kim, Hyun Gun Kim, Hyun-Soo Kim, Seong-Eun Kim, Kyu Chan Huh, Jeong Eun Shin, Jae Myung Cha, Suck-Ho Lee
    Intestinal Research.2013; 11(4): 276.     CrossRef
  • Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010
    Myong Cheol Lim, Eun-Kyeong Moon, Aesun Shin, Kyu-Won Jung, Young-Joo Won, Sang Soo Seo, Sokbom Kang, Jae-Weon Kim, Joo-Young Kim, Sang-Yoon Park
    Journal of Gynecologic Oncology.2013; 24(4): 298.     CrossRef
  • Short-term and long-term outcome after laparoscopic elective radical rectal cancer resection in octogenarians: is it really a safe procedure?
    Jiae Park, Seok In Seo, Duk-Won Hwang, Ho Suk Lee
    Korean Journal of Clinical Oncology.2013; 9(2): 148.     CrossRef
  • Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options
    Yong Sang Hong, Jee Hyun Kim, Tae Won Kim
    Current Colorectal Cancer Reports.2013; 9(3): 213.     CrossRef
  • Data on the Characteristics and the Survival of Korean Patients With Colorectal Cancer From the Korea Central Cancer Registry
    Hyoung-Chul Park, Aesun Shin, Byung-Woo Kim, Kyu-Won Jung, Young-Joo Won, Jae Hwan Oh, Seung-Yong Jeong, Chang Sik Yu, Bong Hwa Lee
    Annals of Coloproctology.2013; 29(4): 144.     CrossRef
  • 15,718 View
  • 118 Download
  • 102 Crossref
Close layer
The Usefulness of Procalcitonin and C-Reactive Protein as Early Diagnostic Markers of Bacteremia in Cancer Patients with Febrile Neutropenia
Dae Yong Kim, Yoon-Seon Lee, Shin Ahn, Yeon Hee Chun, Kyung Soo Lim
Cancer Res Treat. 2011;43(3):176-180.   Published online September 30, 2011
DOI: https://doi.org/10.4143/crt.2011.43.3.176
AbstractAbstract PDFPubReaderePub
PURPOSE
Procalcitonin (PCT) and C-reactive protein (CRP) are well known inflammatory markers. This study was designed to determine whether PCT and CRP are useful as early diagnostic markers for bacteremia in cancer patients with febrile neutropenia (FN) in the emergency department (ED).
MATERIALS AND METHODS
In this retrospective study, 286 episodes of FN in the ED were consecutively included between June 2009 and August 2010. From medical records, clinical characteristics including PCT and CRP were extracted and analyzed.
RESULTS
Bacteremia was identified in 38 (13.3%) of the 286 episodes. The median values of PCT (2.8 ng/mL vs. 0.0 ng/mL, p=0.000) and CRP (15.9 mg/dL vs. 5.6 mg/dL, p=0.002) were significantly higher in the group with bacteremia compared to the group without bacteremia. In univariate analysis, elevated PCT (>0.5 ng/mL) and CRP (>10 mg/dL) as well as older age, hypotension, tachycardia, tachypnea, and high body temperature were significantly associated with bacteremia. On multivariate analysis, elevated PCT (>0.5 ng/mL) (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.4 to 9.2; p<0.01) and tachypnea (OR, 3.4; 95% CI, 1.4 to 8.5; p<0.01) were independent early diagnostic markers for bacteremia in FN patients. The area under the curve of PCT was 74.8% (95% CI, 65.1 to 84.6%) and that of CRP was 65.5% (95% CI, 54.8 to 76.1%). With a PCT cut-off value of 0.5 ng/mL, sensitivity and specificity were 60.5% and 82.3%, respectively, while the sensitivity and specificity were 57.6% and 67.3%, respectively, with a CRP cutoff of 10 mg/dL.
CONCLUSION
These findings suggest that PCT is a useful early diagnostic marker for the detection of bacteremia in FN at the ED and has better diagnostic value than CRP.

Citations

Citations to this article as recorded by  
  • The utility of procalcitonin for diagnosing bacteremia and bacterial pneumonia in hospitalized oncology patients
    Mary K. Munsell, Temidayo Fadelu, Sherri O. Stuver, Katherine P. Baker, Brett Glotzbecker, Justin L. Simmons, Kerry L. Reynolds, Ami K. Patel
    Journal of Cancer Research and Clinical Oncology.2023; 149(8): 5193.     CrossRef
  • Lycopene: A Natural Arsenal in the War against Oxidative Stress and Cardiovascular Diseases
    May Nasser Bin-Jumah, Muhammad Shahid Nadeem, Sadaf Jamal Gilani, Bismillah Mubeen, Inam Ullah, Sami I. Alzarea, Mohammed M. Ghoneim, Sultan Alshehri, Fahad A. Al-Abbasi, Imran Kazmi
    Antioxidants.2022; 11(2): 232.     CrossRef
  • Current Status of Antibiotic Stewardship and the Role of Biomarkers in Antibiotic Stewardship Programs
    Chung-Jong Kim
    Infection & Chemotherapy.2022; 54(4): 674.     CrossRef
  • Profile of febrile neutropenia in childhood cancer patients and the clinical utility of procalcitonin and C-reactive protein in identifying severe infections
    Latha Sneha, Sunitha Ramasamy, Vidya Krishna, Uma Sekar, Kopula Sathyamoorthy Sridharan, Shruti Krishna Iyengar, Julius Xavier Scott, Dhaarani Jayaraman
    Sri Ramachandra Journal of Health Sciences.2022; 2: 61.     CrossRef
  • Serum procalcitonin in Philadelphia-negative myeloproliferative neoplasms
    Ivan Krečak, Nena Peran, Ivana Lapić, Velka Gverić-Krečak, Filip Krečak, Pavle Rončević, Nadira Duraković
    Wiener klinische Wochenschrift.2021; 133(1-2): 62.     CrossRef
  • Presepsin and Midregional Proadrenomedullin in Pediatric Oncologic Patients with Febrile Neutropenia
    Luisa Agnello, Giulia Bivona, Elisa Parisi, Giuseppe Dejan Lucido, Alessandro Iacona, Anna Maria Ciaccio, Rosaria Vincenza Giglio, Ottavio Ziino, Marcello Ciaccio
    Laboratory Medicine.2020; 51(6): 585.     CrossRef
  • Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India
    Rohan Halder, Tulika Seth, Pradeep K. Chaturvedi, Priyanka Mishra, Manoranjan Mahapatra, Hara P. Pati, Seema Tyagi, Renu Saxena
    Blood Cells, Molecules, and Diseases.2020; 84: 102445.     CrossRef
  • Procalcitonin as a Diagnostic Marker for Bacteremia in Terminal Cancer Patients
    Jungeun Kim, Youn Seon Choi, Juneyoung Lee, In Cheol Hwang
    Korean Journal of Clinical Geriatrics.2020; 21(1): 16.     CrossRef
  • Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients
    Amanda G. Blouin, Meier Hsu, Martin Fleisher, Lakshmi V. Ramanathan, Stephen M. Pastores
    Clinica Chimica Acta.2020; 510: 181.     CrossRef
  • Diagnostic Accuracy of Procalcitonin, Neutrophil-to-Lymphocyte Ratio, and C-Reactive Protein in Detection of Bacterial Infections and Prediction of Outcome in Nonneutropenic Febrile Patients with Lung Malignancy
    Shanshan Ding, Jun Ma, Xingguo Song, Xiaohan Dong, Li Xie, Xianrang Song, Lisheng Liu
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department
    Ignacio Español-Morales, María Dolores Albaladejo-Otón, Ana Hernando-Holgado, Enrique Jiménez-Santos, Patricia Esteban-Torrella, Pablo Cerezuela-Fuentes, Luis García de Guadiana-Romualdo
    Biochemia medica.2019; 29(1): 57.     CrossRef
  • Combination of sepsis biomarkers may indicate an invasive fungal infection in haematological patients
    Igor Stoma, Igor Karpov, Anatoly Uss, Svetlana Krivenko, Igor Iskrov, Natalia Milanovich, Svetlana Vlasenkova, Irina Lendina, Kristina Belyavskaya, Veronika Cherniak
    Biomarkers.2019; 24(4): 401.     CrossRef
  • Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies
    Mina Yang, Seung Jun Choi, Jaewoong Lee, Dong Gun Lee, Yoon-Joo Kim, Yeon-Joon Park, Eun-Jee Oh, Senthilnathan Palaniyandi
    PLOS ONE.2019; 14(12): e0225765.     CrossRef
  • Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies
    Ahmad Baraka, Marwa Zakaria
    International Journal of Hematology.2018; 108(2): 184.     CrossRef
  • Diagnostic value of sepsis biomarkers in hematopoietic stem cell transplant recipients in a condition of high prevalence of gram-negative pathogens
    Igor Stoma, Igor Karpov, Anatoly Uss, Oleg Rummo, Natalia Milanovich, Igor Iskrov
    Hematology/Oncology and Stem Cell Therapy.2017; 10(1): 15.     CrossRef
  • Comparison of diagnostic and prognostic utility of lactate and procalcitonin for sepsis in adult cancer patients presenting to emergency department with systemic inflammatory response syndrome
    Esra Keçe, Elif Yaka, Serkan Yılmaz, Nurettin Özgür Doğan, Cansu Alyeşil, Murat Pekdemir
    Turkish Journal of Emergency Medicine.2016; 16(1): 1.     CrossRef
  • The diagnostic value of soluble urokinase plasminogen activator receptor compared with C-reactive protein and procalcitonin in children with febrile neutropenia
    Melis Sirinoglu, Ahmet Soysal, Ayşe Karaaslan, Eda Kepenekli Kadayifci, Ismail Cinel, Ahmet Koç, Gülnur Tokuç, Ali Yaman, Goncagül Haklar, Önder Şirikçi, Serap Turan, Gülşen Altınkanat Gelmez, Güner Söyletir, Mustafa Bakır
    Pediatric Hematology and Oncology.2016; 33(3): 200.     CrossRef
  • Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia
    Xiao Liu, Dao Feng Wang, Yi Fang, Wen Feng Ye, Shu Liu, Ning Lou
    Leukemia & Lymphoma.2015; 56(1): 85.     CrossRef
  • Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6
    Luis García de Guadiana-Romualdo, Ignacio Español-Morales, Pablo Cerezuela-Fuentes, Luciano Consuegra-Sánchez, Ana Hernando-Holgado, Patricia Esteban-Torrella, Enrique Jiménez-Santos, Monserrat Viqueira-González, África de Béjar-Almira, María Dolores Alba
    Supportive Care in Cancer.2015; 23(7): 2175.     CrossRef
  • Adrenomedullin—A New Marker in Febrile Neutropenia: Comparison With CRP and Procalcitonin
    Metin Demirkaya, Deniz Tugcu, Arzu Akcay, Gönül Aydogan, Ferhan Akıcı, Zafer Salcioglu, Hakan Ekmekci, Betül Sevinir, Ozlem Balci Ekmekci
    Pediatric Hematology and Oncology.2015; 32(7): 482.     CrossRef
  • Utilización de procalcitonina y proteína C reactiva como marcadores de infección en la neutropenia febril de pacientes sometidos a trasplante de progenitores hematopoyéticos
    Marina Sánchez-Yepes, Eduardo Aznar-Oroval, Pablo Lorente-Alegre, Tomás García-Lozano, Isabel Picón-Roig, Pilar Pérez-Ballestero, Blanca Ortiz-Muñoz
    Enfermedades Infecciosas y Microbiología Clínica.2014; 32(7): 418.     CrossRef
  • Predictive factors of bacteremia in patients with febrile urinary tract infection: an experience at a tertiary care center
    H. Lee, Y.-S. Lee, R. Jeong, Y.-J. Kim, S. Ahn
    Infection.2014; 42(4): 669.     CrossRef
  • Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: The role of procalcitonin
    Hiroshi Yaegashi, Kouji Izumi, Yasuhide Kitagawa, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami, Mikio Namiki
    International Journal of Urology.2014; 21(1): 104.     CrossRef
  • Utilidad de la procalcitonina para predecir bacteriemia en pacientes oncológicos con fiebre
    Enrique Jiménez-Santos, Ana Hernando-Holgado, Luis García de Guadiana-Romualdo, Monserrat Viqueira-González, Pablo Cerezuela Fuentes, Ignacio Español Morales
    Revista del Laboratorio Clínico.2014; 7(4): 127.     CrossRef
  • The Utility of Proadrenomedullin and Procalcitonin in Comparison to C-Reactive Protein as Predictors of Sepsis and Bloodstream Infections in Critically Ill Patients With Cancer*
    Labib Debiane, Ray Y. Hachem, Iba Al Wohoush, William Shomali, Ramez R. Bahu, Ying Jiang, Anne-Marie Chaftari, Joseph Jabbour, Munirah Al Shuaibi, Alexander Hanania, S. Egbert Pravinkumar, Philipp Schuetz, Issam Raad
    Critical Care Medicine.2014; 42(12): 2500.     CrossRef
  • Utility of C-Reactive Protein and Procalcitonin for Detecting Bloodstream Infection in Patients with HIV/AIDS
    Arianna Castillo Marshall, Tersilia García Castellanos, Isabel Martínez Motas, Daniel Salazar Rodriguez, María Eugenia Toledo Romaní, Jorge Pérez Ávila
    World Journal of AIDS.2014; 04(03): 287.     CrossRef
  • The Use of Procalcitonin in Clinical Practice
    Clementine YF Yap, Tar Choon Aw
    Proceedings of Singapore Healthcare.2014; 23(1): 33.     CrossRef
  • Is Procalcitonin Reduction Indicative of Immunomodulation in Septic Patients Treated with Hemodialysis with High Cutoff Membrane?
    Gianluca Villa, Paola Di Maggio, A. Raffaele De Gaudio
    Blood Purification.2014; 38(2): 100.     CrossRef
  • Utilidad de la procalcitonina en la detección de bacteriemia en los pacientes con cáncer
    E. Aznar-Oroval, M. Sánchez-Yepes, T. García-Lozano, B. Ortiz-Muñoz, P. Pérez-Ballestero
    Revista Clínica Española.2013; 213(5): 267.     CrossRef
  • The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
    Jean Klastersky, Marianne Paesmans
    Supportive Care in Cancer.2013; 21(5): 1487.     CrossRef
  • Diagnostic Value and Prognostic Significance of Pleural C-Reactive Protein in Lung Cancer Patients with Malignant Pleural Effusions
    Do-Sim Park, Dong Kim, Ki-Eun Hwang, Yu-Ri Hwang, Chul Park, Chang-Hwan Seol, Kyung-Hwa Cho, Byoung-Ryun Kim, Seong-Hoon Park, Eun-Taik Jeong, Hak-Ryul Kim
    Yonsei Medical Journal.2013; 54(2): 396.     CrossRef
  • Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies
    Sebastian Haubitz, Beat Mueller, Philipp Schuetz
    Expert Review of Respiratory Medicine.2013; 7(2): 145.     CrossRef
  • The significance of serum urokinase plasminogen activation receptor (suPAR) in the diagnosis and follow-up of febrile neutropenic patients with hematologic malignancies
    Selçuk Kaya, Iftihar Köksal, Ahmet Menteşe, Mehmet Sönmez, Ayşegül Sümer, Seval Sönmez Yıldırım, Gürdal Yılmaz
    International Journal of Infectious Diseases.2013; 17(11): e1056.     CrossRef
  • Procalcitonin in sepsis and bacterial infections
    Abhijit Chaudhury, G.L. Sachin Sumant, R. Jayaprada, Usha Kalawat, B.V. Ramana
    Journal of Clinical & Scientific Research.2013; 2(4): 216.     CrossRef
  • Procalcitonin as a marker of infection in febrile neutropenia: A systematic review
    Anders K. Boysen, Bettina R. Jensen, Laurids Ø. Poulsen, Paw Jensen, Søren Ladefoged
    Modern Chemotherapy.2013; 02(01): 8.     CrossRef
  • Can procalcitonin distinguish infectious fever from tumor‐related fever in non‐neutropenic cancer patients?
    William Shomali, Ray Hachem, Anne‐Marie Chaftari, Ying Jiang, Ramez Bahu, Joseph Jabbour, Sammy Raad, Munirah Al Shuaibi, Iba Al Wohoush, Issam Raad
    Cancer.2012; 118(23): 5823.     CrossRef
  • Allergic Airway Inflammation Initiates Long-Term Vascular Remodeling of the Pulmonary Circulation
    Kristina Rydell-Törmänen, Lena Uller, Jonas S. Erjefält
    International Archives of Allergy and Immunology.2009; 149(3): 251.     CrossRef
  • 13,280 View
  • 155 Download
  • 37 Crossref
Close layer
Radiation-induced Necrosis Deteriorating Neurological Symptoms and Mimicking Progression of Brain Metastasis after Stereotactic-guided Radiotherapy
Young Zoon Kim, Dae Yong Kim, Heon Yoo, Hee Seok Yang, Sang Hoon Shin, Eun Kyung Hong, Kwan Ho Cho, Seung Hoon Lee
Cancer Res Treat. 2007;39(1):16-21.   Published online March 31, 2007
DOI: https://doi.org/10.4143/crt.2007.39.1.16
AbstractAbstract PDFPubReaderePub
Purpose

Although radiation-induced necrosis (RIN) is not a tumor in itself, the lesion progressively enlarges with mass effects and diffuse peritumoral edema in a way that resembles neoplasm. To identify the RIN that mimics progression of brain metastasis, we performed surgical resections of symptomatic RIN lesions.

Meterials and Methods

From June 2003 to December 2005, 7 patients received stereotactic-guided radiotherapy (SRT) for metastatic brain tumor, and they later underwent craniotomy and tumor resection due to the progressive mass effects and the peritumoral edema that caused focal neurological deficit. On MR imaging, a ring-like enhanced single lesion with massive peritumoral edema could not be distinguished from progression of brain metastasis.

Results

Four patients had non-small cell lung cancer, 2 patients had colorectal cancer and 1 patient had renal cell carcinoma. The mean tumor volume was 8.7 ml (range: 3.0~20.7 ml). The prescribed dose of SRT was 30 Gy with 4 fractions for one patient, 18 Gy for two patients and 20 Gy for the other four patients. The four patients who received SRT with a dose of 20 Gy had RIN with or without microscopic residual tumor cells.

Conclusions

Early detection of recurrent disease after radiotherapy and identifying radiation-induced tissue damage are important for delivering adequate treatment. Therefore, specific diagnostic tools that can distinguish RIN from progression of metastatic brain tumor need to be developed.

Citations

Citations to this article as recorded by  
  • Local radiation enhances systemic CAR T-cell efficacy by augmenting antigen crosspresentation and T-cell infiltration
    Nektarios Kostopoulos, Francesca Costabile, Elisavet Krimitza, Silvia Beghi, Denisa Goia, Renzo Perales-Linares, George Thyfronitis, Michael J. LaRiviere, Elise A. Chong, Stephen J. Schuster, Amit Maity, Constantinos Koumenis, John P. Plastaras, Andrea Fa
    Blood Advances.2024; 8(24): 6308.     CrossRef
  • Salvage craniotomy for treatment-refractory symptomatic cerebral radiation necrosis
    Ashish H Shah, Anil K Mahavadi, Alexis Morell, Daniel G Eichberg, Evan Luther, Christopher A Sarkiss, Alexa Semonche, Michael E Ivan, Ricardo J Komotar
    Neuro-Oncology Practice.2020; 7(1): 94.     CrossRef
  • OAR sparing 3D radiotherapy planning supported by fMRI brain mapping investigations
    Gábor Opposits, Csaba Aranyi, Csaba Glavák, Zsolt Cselik, Lajos Trón, Dávid Sipos, Janaki Hadjiev, Ervin Berényi, Imre Repa, Miklós Emri, Árpád Kovács
    Medical Dosimetry.2020; 45(4): e1.     CrossRef
  • The Role of Navigated Transcranial Magnetic Stimulation Motor Mapping in Adjuvant Radiotherapy Planning in Patients With Supratentorial Brain Metastases
    Maximilian J. Schwendner, Nico Sollmann, Christian D. Diehl, Markus Oechsner, Bernhard Meyer, Sandro M. Krieg, Stephanie E. Combs
    Frontiers in Oncology.2018;[Epub]     CrossRef
  • Impact of the radiosurgery prescription dose on the local control of small (2 cm or smaller) brain metastases
    Alireza M. Mohammadi, Jason L. Schroeder, Lilyana Angelov, Samuel T. Chao, Erin S. Murphy, Jennifer S. Yu, Gennady Neyman, Xuefei Jia, John H. Suh, Gene H. Barnett, Michael A. Vogelbaum
    Journal of Neurosurgery.2017; 126(3): 735.     CrossRef
  • Nonthermal ablation in the rat brain using focused ultrasound and an ultrasound contrast agent: long-term effects
    Nathan McDannold, Yongzhi Zhang, Natalia Vykhodtseva
    Journal of Neurosurgery.2016; 125(6): 1539.     CrossRef
  • Analysis of risk and predictors of brain radiation necrosis after radiosurgery
    Hongqing Zhuang, Yi Zheng, Junjie Wang, Joe Y. Chang, Xiaoguang Wang, Zhiyong Yuan, Ping Wang
    Oncotarget.2016; 7(7): 7773.     CrossRef
  • Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?
    Ashish H. Shah, Brian Snelling, Amade Bregy, Payal R. Patel, Danoushka Tememe, Rita Bhatia, Evelyn Sklar, Ricardo J. Komotar
    Journal of Neuro-Oncology.2013; 112(2): 141.     CrossRef
  • Comparison of Swallowing Functions Between Brain Tumor and Stroke Patients
    Dae Hwan Park, Min Ho Chun, Sook Joung Lee, Yoon Bum Song
    Annals of Rehabilitation Medicine.2013; 37(5): 633.     CrossRef
  • 10,471 View
  • 60 Download
  • 9 Crossref
Close layer
Evaluation of Parotid Gland Function following Intensity Modulated Radiation Therapy for Head and Neck Cancer
Seok Ho Lee, Tae Hyun Kim, Joo Young Kim, Sung Yong Park, Hong Ryull Pyo, Kyung Hwan Shin, Dae Yong Kim, Joo Young Kim, Kwan Ho Cho
Cancer Res Treat. 2006;38(2):84-91.   Published online April 30, 2006
DOI: https://doi.org/10.4143/crt.2006.38.2.84
AbstractAbstract PDFPubReaderePub
Purpose

This study was undertaken to determine the parotid gland tolerance dose levels following intensity modulated radiation therapy (IMRT) for treating patients who suffered with head and neck cancer.

Materials and Methods

From February 2003 through June 2004, 34 head and neck patients with 6 months of follow-up were evaluated for xerostomia after being treated by IMRT. Their median age was 59 years (range: 29~78). Xerostomia was assessed using a 4-question xerostomia questionnaire score (XQS) and a test for the salivary flow rates (unstimulated and stimulated: USFR and SSFR, respectively). The patients were also given a validated LENT SOMA scale (LSS) questionnaire. Evaluations were performed before IMRT and at 1, 3 and 6 months after IMRT.

Results

All 34 patients showed significant changes in the XQS, LSS and Salivary Flow rates (USFR and SSFR) after IMRT. No significant changes in the XQS or LSS were noted in 12 patients who received a total parotid mean dose of ≤3,100 cGy at 1, 3 and 6 months post-IMRT relative to the baseline values. However, for the 22 patients who received >3,100 cGy, significant increases in the XQS and LSS were observed. The USFR and SSFR from the parotid glands in 7 patients who received ≤2,750 cGy were significantly preserved at up to 6 months after IMRT. However, the USFR and SSFR in 27 patients who were treated with >2,750 cGy were significantly lower than the baseline values at all times after IMRT.

Conclusion

We suggest that the total parotid mean dose should be limited to ≤2,750 cGy to preserve the USFR and SSFR and so improve the subsequent quality of life.

Citations

Citations to this article as recorded by  
  • Evaluation of the Effect of Photobiomodulation on Radiation-Induced Xerostomia in Head and Neck Cancer Patients: A Randomized Clinical Trial
    Pegah Mosannen Mozaffari, Zahra Delavarian, Reza Fekrazad, Azar Fani Pakdel, Mahdokht Rashed Mohassel, Mohammad Taghi Shakeri, Ala Ghazi
    Journal of Lasers in Medical Sciences.2024; 15: e4.     CrossRef
  • Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer
    Marcell Costa de Medeiros, Stephanie The, Emily Bellile, Nickole Russo, Ligia Schmitd, Erika Danella, Priyanka Singh, Rajat Banerjee, Christine Bassis, George R. Murphy, Maureen A. Sartor, Isabelle Lombaert, Thomas M. Schmidt, Avi Eisbruch, Carol Anne Mur
    Microbiome.2023;[Epub]     CrossRef
  • Translation and cross-cultural adaption of the Chinese version of the Vanderbilt Head and Neck Symptom Survey version 2.0: a tool for oral symptom assessment in head and neck cancer patients
    Min Jin, Li Sun, Rui Meng, Wenjing Wang, Rui Sun, Jing Huang, You Qin, Bian Wu, Qian Ding, Gang Peng, Tao Zhang, Kunyu Yang
    Health and Quality of Life Outcomes.2021;[Epub]     CrossRef
  • Study of dosimetry and clinical factors for assessment of xerostomia in head and neck squamous cell carcinoma treated by intensity-modulated radiotherapy: A prospective study
    Vrinda Singla, Vipul Nautiyal, Meenu Gupta, Viney Kumar, Shivani Mehra, Mushtaq Ahmad
    Journal of Carcinogenesis.2021; 20(1): 14.     CrossRef
  • Radiotherapy-related quality of life in patients with head and neck cancers: a meta-analysis
    Xiuhong Ge, Zhengluan Liao, Jianhua Yuan, Dewang Mao, Yumei Li, Enyan Yu, Xunheng Wang, Zhongxiang Ding
    Supportive Care in Cancer.2020; 28(6): 2701.     CrossRef
  • Xerostomia, salivary characteristics and gland volumes following intensity‐modulated radiotherapy for nasopharyngeal carcinoma: a two‐year follow up
    CPC Sim, YL Soong, EPP Pang, C Lim, GD Walker, DJ Manton, EC Reynolds, JTS Wee
    Australian Dental Journal.2018; 63(2): 217.     CrossRef
  • Radiotherapy changes salivary properties and impacts quality of life of children with Hodgkin disease
    L. Marangoni-Lopes, L.P. Rodrigues, R.H. Mendonça, M. Nobre-dos Santos
    Archives of Oral Biology.2016; 72: 99.     CrossRef
  • Is linac-based volumetric modulated arc therapy better than helical tomotherapy in the radiotherapy of nasopharyngeal carcinoma?
    Vincent W. C. Wu, Bing-kin Choi, Ho-nam Chan, Ruby Lam, Yu-king Wong, Alan W. L. Mui, George Chiu
    Journal of Radiation Oncology.2015; 4(1): 29.     CrossRef
  • Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers: A Triple-Blind, Randomized, Placebo-Controlled Trial
    Abbas Javadzadeh Bolouri, Atessa Pakfetrat, Arghavan Tonkaboni, Seyed Amir Aledavood, Mohsen Fathi Najafi, Zahra Delavarian, Mohammad Taghi Shakeri, Azade Mohtashami
    Iranian Journal of Cancer Prevention.2015;[Epub]     CrossRef
  • Evaluation of an automated knowledge based treatment planning system for head and neck
    Jerome Krayenbuehl, Ian Norton, Gabriela Studer, Matthias Guckenberger
    Radiation Oncology.2015;[Epub]     CrossRef
  • Translation and validation of the Chinese version of the quality of life radiation therapy instrument and the head & neck module (QOL-RTI/H&N)
    Xin-lin Chen, Zhen-wen Qiu, Mo-fa Gu, Yong Su, Li-zhi Liu, Yan Liu, Chuan-wei Mo, Qian Xu, Juan Sun, Dong-hai Li
    Health and Quality of Life Outcomes.2014;[Epub]     CrossRef
  • Correlation of Parotid Gland Function in Head and Neck Cancer Patients treated with Intensity-modulated Radiotherapy
    Sonal Vahanwala, Sukhjinder Kaur Khosa, Sandeep S Pagare
    International Journal of Head and Neck Surgery.2012; 3(1): 1.     CrossRef
  • Effects of Intensity-modulated Radiotherapy on Human Oral Microflora
    Zi-Yang SHAO, Zi-Sheng TANG, Chao YAN, Yun-Tao JIANG, Rui MA, Zheng LIU, Zheng-Wei HUANG
    Journal of Radiation Research.2011; 52(6): 834.     CrossRef
  • 15,136 View
  • 106 Download
  • 13 Crossref
Close layer
Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Dae Kyung Sohn, Seung-Yong Jeong, Hyo Seong Choi, Seok-Byung Lim, Jin Myeong Huh, Dae-Hyun Kim, Dae Yong Kim, Young Hoon Kim, Hee Jin Chang, Kyung Hae Jung, Joong-Bae Ahn, Hyun Kyung Kim, Jae-Gahb Park
Cancer Res Treat. 2005;37(1):20-23.   Published online February 28, 2005
DOI: https://doi.org/10.4143/crt.2005.37.1.20
AbstractAbstract PDFPubReaderePub
Purpose

This study was designed to investigate the validity of a single immunochemical fecal occult blood test (FOBT) for detection of colorectal neoplasia.

Materials and Methods

A total of 3,794 average-risk screenees and 304 colorectal cancer patients admitted to the National Cancer Center, Korea, between May 2001 and November 2002, were studied prospectively. All screenees and admitted patients underwent FOBT and total colonoscopic examinations. Stools were self-collected, and examined using an immunochemical fecal occult blood test (OC-hemodia®, Eiken Chemical Co. Tokyo, Japan) and an OC-sensor analyzer® (Eiken Chemical Co. Tokyo, Japan).

Results

Of the 3,794 asymptomatic screenees, the colonoscopy identified colorectal adenomas and cancers in 613 (16.2%) and 12 (0.3%) subjects, respectively. The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The false positive rate of FOBT for colorectal cancer in screenees was 1.19%. For the total 316 colorectal cancer cases (including 12 cases from screenees), the FOBT sensitivities according to the T-stage were 38.5, 75.0%, 78.9 and 79.2% for T1, 2, 3 and 4 cancers, respectively. The sensitivities according to the Dukes stages A, B and C were 63.4, 79.3 and 78.6%, respectively.

Conclusion

The sensitivities of a single immunochemical FOBT for detecting colorectal cancers and adenomas in screenees were 25.0 and 2.4%, respectively. The sensitivities of FOBT were about 80% for Dukes B or C colorectal cancers and 63.4% for Dukes A.

Citations

Citations to this article as recorded by  
  • Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test
    Kyle S. Liu, Rollin George, Caleb Shin, Jia Q. Xiong, Taher Jamali, Yan Liu, Priya Roy, Sonia Singh, Samuel Ma, Hashem B. El-Serag, Mimi C. Tan
    Digestive Diseases and Sciences.2025; 70(1): 350.     CrossRef
  • Findings in the distal and proximal colon in colonoscopy screening after positive FIT and related pre-procedure factors
    M.� Henar Núñez Rodríguez, Pilar Díez Redondo, Fausto Riu Pons, Marta Cimavilla, Andrea Loza, Manuel Perez-Miranda
    Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
  • Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals
    Esmée J Grobbee, Pieter HA Wisse, Eline H Schreuders, Aafke van Roon, Leonie van Dam, Ann G Zauber, Iris Lansdorp-Vogelaar, Wichor Bramer, Sarah Berhane, Jonathan J Deeks, Ewout W Steyerberg, Monique E van Leerdam, Manon CW Spaander, Ernst J Kuipers
    Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
  • Potential Modifiers and Different Cut-offs in Diagnostic Accuracy of Fecal Immunochemical Test in Detecting Advanced Colon Neoplasia: A Diagnostic Test Accuracy Meta-analysis
    Mohammad Yaghoobi, Parsa Mehraban Far, Lawrence Mbuagbaw, Yuhong Yuan, David Armstrong, Lehana Thabane, Paul Moayyedi
    Middle East Journal of Digestive Diseases.2022; 14(4): 382.     CrossRef
  • Guidelines for accreditation of endoscopy units: quality measures from the Korean Society of Coloproctology
    Rumi Shin, Seongdae Lee, Kyung-Su Han, Dae Kyung Sohn, Sang Hui Moon, Dong Hyun Choi, Bong-Hyeon Kye, Hae-Jung Son, Sun Il Lee, Sumin Si, Won-Kyung Kang
    Annals of Surgical Treatment and Research.2021; 100(3): 154.     CrossRef
  • Screening for Colorectal Cancer
    Jennifer S. Lin, Leslie A. Perdue, Nora B. Henrikson, Sarah I. Bean, Paula R. Blasi
    JAMA.2021; 325(19): 1978.     CrossRef
  • Colorectal Cancer Screening Outcomes of 2412 Prostate Cancer Patients Considered for Carbon Ion Radiotherapy
    Nao Kobayashi, Takahiro Oike, Nobuteru Kubo, Yuhei Miyasaka, Tatsuji Mizukami, Hiro Sato, Akiko Adachi, Hiroyuki Katoh, Hidemasa Kawamura, Tatsuya Ohno
    Cancers.2021; 13(17): 4481.     CrossRef
  • Evaluation of the Cut-Off Value of Fecal Immunochemical Test for Colorectal Cancer Screening during Health Checkups
    Hye-Ran Park, Eun-Hee Nah, Jong-Seon Lee, Seon Cho
    Journal of Laboratory Medicine and Quality Assurance.2021; 43(4): 190.     CrossRef
  • Stage-Specific Sensitivity of Fecal Immunochemical Tests for Detecting Colorectal Cancer: Systematic Review and Meta-Analysis
    Tobias Niedermaier, Yesilda Balavarca, Hermann Brenner
    American Journal of Gastroenterology.2020; 115(1): 56.     CrossRef
  • Sensitivity of Fecal Immunochemical Test for Colorectal Cancer Detection Differs According to Stage and Location
    Tobias Niedermaier, Kaja Tikk, Anton Gies, Stefanie Bieck, Hermann Brenner
    Clinical Gastroenterology and Hepatology.2020; 18(13): 2920.     CrossRef
  • Performance Characteristics of Fecal Immunochemical Tests for Colorectal Cancer and Advanced Adenomatous Polyps
    Thomas F. Imperiale, Rachel N. Gruber, Timothy E. Stump, Thomas W. Emmett, Patrick O. Monahan
    Annals of Internal Medicine.2019; 170(5): 319.     CrossRef
  • Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis
    Kevin Selby, Emma H. Levine, Cecilia Doan, Anton Gies, Hermann Brenner, Charles Quesenberry, Jeffrey K. Lee, Douglas A. Corley
    Gastroenterology.2019; 157(6): 1494.     CrossRef
  • Quantitative fecal immunochemical tests for colorectal cancer screening
    Anton Gies, Megha Bhardwaj, Christian Stock, Petra Schrotz‐King, Hermann Brenner
    International Journal of Cancer.2018; 143(2): 234.     CrossRef
  • Prevalence of functional gastrointestinal disorders in adults with systemic lupus erythematosus
    M García-Carrasco, C Mendoza-Pinto, M A Autrán-Limón, E Herrera Robles, S Méndez Martínez, I Etchegaray Morales, Á Montiel Jarquín, J L Gálvez Romero, P Soto-Santillán, J Galindo-Herrera, A López-Colombo
    Lupus.2018; 27(5): 788.     CrossRef
  • Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea
    Dae Ho Kim, Jae Myung Cha, Min Seob Kwak, Jin Young Yoon, Young-Hak Cho, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
    Gut and Liver.2018; 12(2): 183.     CrossRef
  • Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
    Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
    Gastroenterology.2017; 152(5): 1217.     CrossRef
  • Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer
    Douglas J. Robertson, Jeffrey K. Lee, C. Richard Boland, Jason A. Dominitz, Francis M. Giardiello, David A. Johnson, Tonya Kaltenbach, David Lieberman, Theodore R. Levin, Douglas K. Rex
    Gastrointestinal Endoscopy.2017; 85(1): 2.     CrossRef
  • Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer
    Douglas J Robertson, Jeffrey K Lee, Richard C Boland, Jason A Dominitz, Francis M Giardiello, David A Johnson, Tonya Kaltenbach, David Lieberman, Theodore R Levin, Douglas K Rex
    American Journal of Gastroenterology.2017; 112(1): 37.     CrossRef
  • Risk Factors for False Fecal Immunochemical Test Results in Colorectal Cancer Screening
    Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn, Kyuyong Choi, Yoon Suk Jung
    Journal of Clinical Gastroenterology.2017; 51(2): 151.     CrossRef
  • Which Fecal Immunochemical Test Should I Choose?
    Jeanette M. Daly, Yinghui Xu, Barcey T. Levy
    Journal of Primary Care & Community Health.2017; 8(4): 264.     CrossRef
  • Cancer-Type Oatp1B3 mRNA Has the Potential to Become a Detection and Prognostic Biomarker for Human Colorectal Cancer
    Yuchen Sun, Manami Harada, Osamu Shimozato, Hiroaki Souda, Nobuhiro Takiguchi, Yoshihiro Nabeya, Takehiko Kamijo, Hidetaka Akita, Naohiko Anzai, Kan Chiba, Tomomi Furihata
    Biomarkers in Medicine.2017; 11(8): 629.     CrossRef
  • Screening of colorectal cancer: present and future
    Marcello Maida, Fabio Salvatore Macaluso, Gianluca Ianiro, Francesca Mangiola, Emanuele Sinagra, Georgina Hold, Carlo Maida, Giovanni Cammarota, Antonio Gasbarrini, Giuseppe Scarpulla
    Expert Review of Anticancer Therapy.2017; 17(12): 1131.     CrossRef
  • Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance
    Min Seob Kwak, Jae Myung Cha, Jin Young Yoon, Jung Won Jeon, Hyun Phil Shin, Kwang Ro Joo, Joung Il Lee
    Journal of Clinical Gastroenterology.2017; 51(9): 825.     CrossRef
  • Use of a Low Cut-Off Value for the Fecal Immunochemical Test Enables Better Detection of Proximal Neoplasia
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jung Won Jeun, Jun Uk Lim
    Digestive Diseases and Sciences.2013; 58(11): 3256.     CrossRef
  • Performance of the Fecal Immunochemical Test Is Not Decreased by High Ambient Temperature in the Rapid Return System
    Jae Myung Cha, Joung Il Lee, Kwang Ro Joo, Hyun Phil Shin, Jae Jun Park, Jung Won Jeun, Jun Uk Lim, Sang-Hyun Hwang
    Digestive Diseases and Sciences.2012; 57(8): 2178.     CrossRef
  • A comparison of qualitative and quantitative fecal immunochemical tests in the Korean national colorectal cancer screening program
    Mi Jin Park, Kui Son Choi, You Kyoung Lee, Jae Kwan Jun, Hoo-Yeon Lee
    Scandinavian Journal of Gastroenterology.2012; 47(4): 461.     CrossRef
  • Clinical Features of Colorectal Cancer Detected by the National Cancer Screening Program
    Dae-Do Park, Rumi Shin, Ji-Sun Kim, Heung-Kwon Oh, Seung-Yong Jeong, Kyu Joo Park, Jae-Gahb Park
    Journal of the Korean Society of Coloproctology.2010; 26(6): 420.     CrossRef
  • The Significance of Fecal Immunochemical Test to Screen for Colorectal Cancer in National Cancer Screening Program
    Jun Uk Lim, Na Young Bae, Won Koung Song, Jae Myung Cha, Joung Il Lee
    Intestinal Research.2010; 8(2): 126.     CrossRef
  • False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening
    Leo G.M. van Rossum, Anne F. van Rijn, Martijn G.H. van Oijen, Paul Fockens, Robert J.F. Laheij, Andre L.M. Verbeek, Jan B.M.J. Jansen, Evelien Dekker
    International Journal of Cancer.2009; 125(4): 746.     CrossRef
  • Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme
    L G M van Rossum, A F van Rijn, R J F Laheij, M G H van Oijen, P Fockens, J B M J Jansen, A L M Verbeek, E Dekker
    British Journal of Cancer.2009; 101(8): 1274.     CrossRef
  • Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for Colorectal Cancer in a Screening Population
    Leo G. van Rossum, Anne F. van Rijn, Robert J. Laheij, Martijn G. van Oijen, Paul Fockens, Han H. van Krieken, Andre L. Verbeek, Jan B. Jansen, Evelien Dekker
    Gastroenterology.2008; 135(1): 82.     CrossRef
  • 11,059 View
  • 89 Download
  • 31 Crossref
Close layer
Combined Chemotherapy and Radiotherapy for Primary CNS Lymphoma
Jeong Eun Lee, Dae Yong Kim, Yong Chan Ahn, Do Hoon Lim, Seung Jae Huh, Seong Soo Shin, Won Seok Kim, Won Ki Kang, Do Hyun Nam, Jung Il Lee, Jong Hyun Kim
Cancer Res Treat. 2001;33(5):398-403.   Published online October 31, 2001
DOI: https://doi.org/10.4143/crt.2001.33.5.398
AbstractAbstract PDF
PURPOSE
This study was performed in order to evaluate the effectiveness of combined chemotherapy and radiotherapy (RT) in primary central nervous system lymphoma (PCNSL).
MATERIALS AND METHODS
From January 1995 to August 1999, 21 patients with a diagnosis of PCNSL were treated with combined chemotherapy and radiotherapy. Their median age was 47 years with range of 19 to 78 years. Twelve patients were male and nine patients were female. All patients were immunocompetent and they had no evidence of systemic lymphoma. All patients underwent placement of an Ommaya reservoir and recieved a combination regimen using pre-RT systemic and intra-Ommaya methotrexate (MTX), 40 Gy whole-brain RT with a 14.4 Gy boost, and 2 courses of post-RT high-dose cytarabine. The median follow-up period of all patients and survived patients were 22 months and 36 months, respectively.
RESULTS
The median overall survival duration was 21 months and the overall two- and four-year survival rates were 51% and 43%, respectively. Complete response (CR), partial response, stable disease, and progressive disease were achieved in 12, 3, 1, and 5 patients, respectively. All nine patients without CR expired within 1-31 months (median 6 months). Two patients among the patients with CR developed recurrence after 13 and 14 months, respectively. The location of recurrent disease was within the port of radiation boost. Survival was influenced by age, performance status, and CR. There was one episode of MTX neurotoxicity and hepatotoxicity,respectively.
CONCLUSION
Combined chemotherapy and radiotherapy was an effective treatment for PCNSL, and was associated with a minimum toxicity. However, we must pay attention to the recurrence and late toxicity, particularly within two years following treatment.
  • 4,675 View
  • 38 Download
Close layer
Stereotactic Radiosurgery and Fractionated Stereotactic Radiotherapy for Intracranial Schwannoma
Dae Yong Kim, Yong Chan Ahn, Jung Il Lee, Do Hyun Nam, Jeong Eun Lee, Do Hoon Lim, Inhwan J Yeo, Seung Jae Huh, Young Joo Noh, Hyung Jin Shin, Kwan Park, Jong Hyun Kim
J Korean Cancer Assoc. 2001;33(1):27-33.
AbstractAbstract PDF
PURPOSE
To assess the radiologic response and cranial nerve morbidity in intracranial schwannoma patients treated with stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT).
MATERIALS AND METHODS
Twenty-six patients with intracranial schwannoma were treated with linear accelerator- based SRS or FSRT between February 1995 and October 1999. The origin of schwannoma was acoustic nerve in twenty-one patients, facial nerve in two, trigeminal nerve in two, and glossopharyngeal nerve in one. SRS were performed with the median peripheral dose of 14 Gy (range 12-16), and FSRT were done with the median peripheral dose of 25 2 Gy (range 50-60).
RESULTS
With a median follow-up period of 33 months (range 12-67), the local control rate was 100%. Tumorregression was noted in eleven patients, and tumor stabilization was found in the remaining fifteen. Useful hearing preservation was achieved in two of three patients. Facial nerve neuropathy was shown in two patients and one patients developed trigeminal nerve neuropathy.
CONCLUSION
Stereotactic radiotherapy including SRS and FSRT provided excellent local control in intracranial schwannoma. It shows the possibility of a high rate of hearing preservation and an acceptable neurotoxicity, although the number of patients are small and follow-up is relatively short.
  • 3,478 View
  • 23 Download
Close layer
Dose-Response Relationship of Radiotherapy for Locally Advanced Hepatocellular Carcinoma
Dae Yong Kim, Joon Hyoek Lee, Kwang Cheol Koh, Seung Woon Paik, Yong Chan Ahn, Seung Jae Huh, Inhwan J Yeo, Suk Won Park, Seung Hee Chang
J Korean Cancer Assoc. 2000;32(5):918-924.
AbstractAbstract PDF
PURPOSE
Recently radiotherapy is applied alone or in conjunction with transcatheter arterial chemoembolizaion (TACE) or percutaneous ethanol injection therapy (PEIT) for locally advanced hepatocellular carcinoma (HCC). The purpose of this study was to evaluate dose-response relationship of radiotherapy for local control and toxicity in inoperable HCC.
MATERIALS AND METHODS
Twenty-eight patients who were not eligible for TACE and PEIT or had showed no response to these treatment were treated with a total dose of 40 Gy with 2 Gy per fraction or 30 Gy with 3 Gy per fraction (low dose group, 18 patients) or 45 Gy with 3 Gy per fraction (high dose group, 10 patients).
RESULTS
The median survival duration was 8 months and 1-year survival rate was 37%. The treatment results were as follows; partial response in 11% and 70% (p=0.001), stable disease in 56% and 30%, and progressive disease in 33% and 0% in low dose group and high dose group, respectively. The incidence of gastrointestinal (G-I) toxicity by the criteria of Southwest Oncology Group was as follows; grade 1 in 22% and 40%, grade 2 in 17% and 10%, respectively (p=0.56). There was no patient with severe G-I toxicity above grade 3. The incidence of G-I toxicity by site was as follows; grade 1 in 24% and 29%, and grade 2 in 0% and 57% in patients with right lobe and left lobe lesion, respectively (p=0.001).
CONCLUSION
This study indicates that there is clear dose-response relationship in local control. The G-I toxicity does not increase significantly with increment of radiation dose within the dose range tested in this study. And careful attention should be paid for G-I toxicity when the tumor is located in left lobe.
  • 2,837 View
  • 15 Download
Close layer
Preliminary Results of Postoperative Radiotherapy after Breast Conserving Surgery in Early Breast Cancer
Seung Hee Chang, Seung Jae Huh, Jung Hyun Yang, Do Hoon Lim, Seok Jin Nam, Sung Soo Yoon, Yong Chan Ahn, Dae Yong Kim, Suk Won Park, Moon Kyung Kim
J Korean Cancer Assoc. 2000;32(4):775-782.
AbstractAbstract PDF
PURPOSE
To evaluate treatment results of breast conserving surgery and radiation therapy including survival rates, patterns of failure, and complication and to analyze prognostic factors.
MATERIALS AND METHODS
Retrospective analysis was carried out for 111 (112 cases) consecutive patients with breast cancer treated by radiation therapy after breast conserving surgery from October 1994 to April 1997. The median follow up was 45 months (range 10~66). AJCC staging was as follows: 16 cases (14%) for ductal carcinoma in situ, 46 cases (41%) for stage I, 33 cases (30%) for stage IIa, and 17 cases (15%) for stage IIb. Radiation therapy after breast conserving surgery was delivered to whole breast with 50.4 Gy and additional 10 Gy electron beam boost to tumor bed. Adjuvant CMF or CAF chemotherapy was performed in 61 patients.
RESULTS
Overall three- and five-year survivals were 99% and 95%, and progression-free survival were 93%, 87%, respectively. Treatment failure occurred in 11 cases (10%); loco-regional recur rence in six; distant metastasis in five. Univariate analysis showed prognostic factor affecting survival was only T-stage. Acute radiation dermatitis were found in five cases (4%), and chronic complications were found in five (4%); one case with amputation of nipple, two cases with lymphedema requiring rehabilitation therapy and two cases with symptomatic radiation pneu monitis requiring steroid therapy.
CONCLUSION
Breast conserving therapy of early breast cancer including ductal carcinoma in situ showed high survival rates and low complications, and T stage was prognostic factor for survival. But further follow-up should be needed.
  • 3,095 View
  • 15 Download
Close layer
Stereotactic Radiotherapy for the Treatment of Brain Metastases
Dae Yong Kim, Yong Chan Ahn, Seung Jae Huh, Jung Il Lee, Do Hyun Nam, Seung Chyul Hong, Hyung Jin Shin, Kwan Park, Jong Hyun Kim
J Korean Cancer Assoc. 2000;32(1):148-155.
AbstractAbstract PDF
PURPOSE
To evaluate the clinical results of stereotactic radiosurgery (SRS) and frac- tionated stereotactic radiotherapy (FSRT) for metastatic brain tumors.
MATERIALS AND METHODS
Nineteen patients with brain metastases (34 lesions) were treated with LINAC-based SRS or FSRT with or without whole brain radiotherapy between October 1995 and February 1998. SRS was preferred to FSRT in cases with three or more lesions and poor performance status. FSRT was preferred to SRS in cases with lesions larger than 3 cm and lesions located near or at the eloquent areas such as thalamus, brain stem, and optic apparatus. Single isocenter was used both in SRS and FSRT, and the median peripheral dose in SRS was 15 Gy (range 13~20 Gy), while that in FSRT was 21 Gy (range 15~24 Gy) by 3 Gy per fraction.
RESULTS
Local control was achieved in 79% (27/34 treated lesions) and 1-year over- all survival rate was 58% with the median survival of 12 months. Lethal progressive brain metastases, both local and regional, were in four patients (27% of all deaths). No significant differences in local control and survival was observed with histology, age, sex, performance status, tumor volume, number of lesions, or treatment modality. Unacceptable acute or late complications did not occur.
CONCLUSION
Stereotactic radiotherapy including SRS and FSRT is effective, non-invasive therapy for brain metastases. This study suggests that stereotactic radiotherapy might be an alternative to surgical resection in selected patients of brain metastases.
  • 3,863 View
  • 24 Download
Close layer
p 53 Expression in Non - Small Cell Lung Cancer: Its relationship to the clinical prognostic factor and smoking history
Moon Kyung Kim, Han Kyeom Kim, In Sun Kim, Joung Ho Han, Seung Jae Huh, Yong Chan Ahn, Dae Yong Kim, Young Mok Shim
J Korean Cancer Assoc. 1999;31(6):1219-1226.
AbstractAbstract PDF
PURPOSE
p53 mutations are one of the most common genetic alterations in human lung cancer. Although the prognostic value of mutant p53 is still debated, it is widely accepted as a relatively early genetic event in the development and progression of lung cancer. Moreover, there are growing reports about an association between smoking and p53 mutation, suggesting that the p53 gene could be a target of the smoking associated carcino- genesis in the lung cancer.
MATERIALS AND METHODS
Surgically resected 89 primary non-small cell lung cancers were obtained from May of 1995 to May of 1997. p53 expression and Ki-67 expression were measured by immunohistochemistry, and each p53 expression and smoking amount were compared with Ki-67 expression and other clinical prognostic factors.
RESULTS
Positive p53 expressions were found in 52 (58%) specimens, including 38 (69%) squamous cell carcinomas, 11 (39%) adenocarcinomas, and 3 (50%) large cell carcinomas, and closely associated with male and squamous cell carcinoma. Also close correlation was observed between smoking amount and p53 expression by the regression analysis. But p53 and Ki-67 expression showed no associations in pathologic stage and survival, and there was no association between p53 expression and survival after adjuvant radiotherapy.
CONCLUSION
Smoking seems to affect p53 mutations in non-small cell lung cancer, and additional efforts are needed to evaluate the carcinogesis of lung cancer.
  • 2,949 View
  • 12 Download
Close layer
Antitumor Effect of Methotrexate in SCID Mice with Human Leukemia CCRF-CEM Cell Line
Yang Kyu Choi, Jae Yoon Choi, Byung Hwa Hyun, Yong Joon Kim, Chul Ho Lee, Won Kee Yoon, Kyu Shik Jeong, Dae Yong Kim
J Korean Cancer Assoc. 1997;29(1):19-28.
AbstractAbstract PDF
No abstract available
  • 2,147 View
  • 19 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP